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1. Circulatory microRNAs hold great promise as biomarker for metabolic
and cardiovascular diseases in the general population - this thesis
2. Epigenetic research must go beyond DNA methylation by studying the
essential role of other epigenetic markers in particular microRNAs
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CHAPTER 1  
Nothing in biology makes sense except in the light of evolution  
- Theodosius Dobzhansky
The history of the Homo Sapiens goes far beyond the hundreds of thousands of years 
we are walking on planet Earth. As our origin may be relatively novel, the evolutionary 
timeline, represented as scientific theory goes millions of years back in time. In 
biology, evolution describes any changes across successive generations in the heritable 
characteristics of biological populations1. This has resulted in diversity at every level 
of biological organization, from differences in species, to individual organisms, to 
cellular biology. In this context, we used to think that our genes are the controlling 
factor that makes each of us unique, both from a physical and health perspective. The 
human genome consists of approximately 20,000 genes, which are only a tiny part (< 
2%) of our DNA2, 3. Until recently, the remaining 98% of our DNA was thought to be 
“Junk DNA”, a term coined by Ohno in 19724. This term turned out to be outdated, 
as scientists soon realized that there are factors within this “Junk DNA”, that have 
major influence on the way genes are controlled. This mechanism was introduced 
as “epigenetics” 5-7. Nowadays, epigenetics is considered as at least equivalent, and 
perhaps more important than our genes themselves. 
Epigenetics is the study of heritable changes in organisms caused by modification 
of gene expression rather than alteration of the DNA itself. In 1969, Griffith and 
Mahler were the first suggesting that covalent modifications to the DNA may affect 
the expression of genes8. The most studied modification is a methylated cytosine 
next to a guanine at a 5’-position. This dinucleotide is called a CpG, short for cytosine 
phosphate guanine. Evidence suggests that cytosines are frequently methylated in 
promoter regions of silenced genes in comparison to actively transcribed genes9. In 
general, DNA methylation within promoter regions of genes prevents the binding of 
transcription factors or acts as mediator of gene expression repressors10, 11. Besides 
covalent modifications to the DNA, histone modifications, including acetylation and 
methylation of histones, affect chromatin structures and thereby transcription of 
genes12, 13. Another phenomena within the epigenetics are non-coding RNAs, which 
can be characterized into several classes based on their transcript size into small non-
coding RNAs (<200 nucleotide) and long non-coding RNAs (>200 nucleotide). In 
recent years, increasing research has shed light on the potential of non-coding RNAs 





A mighty flame could begin as a faraway spark  
- Dante Alighieri
The most studied small non-coding RNA class are microRNAs (miRNAs), consisting of 
20-24 nucleotides. In 1993, miRNAs were first described in Caenorhabditis elegans by 
Ambros and Ruvkun14, 15. It was actually during their work on genetic regulation in the 
roundworm, that they noticed an intriguing complementary relationship between two 
genes: lin-4 and lin-14. Contrary to their expectations that lin-4 encodes a regulatory 
gene, they found that lin-4 produces a non-coding string of RNA, with a length of 
only 22 nucleotides. When they read off the sequences of nucleotides of lin-4 and lin-
14, they observed that parts of lin-4 and lin-14 were complementary to each other. 
Notably, they determined that lin-4 is capable of downregulating the expression of lin-
14. In 2000 the second miRNA, let-7, was characterized by Reinhart et al.16. Soon after, 
many more miRNAs were discovered and shown to be conserved throughout different 
species, indicating that miRNAs are widely used as regulatory mechanism and proved 
the significant evolutionary importance of these small molecules. From 2000 onwards, 
miRNAs rapidly became an exciting topic of research, reporting the implications of 
miRNAs in human diseases. According to the miRBase database (v.22), a total number 
of 2,656 miRNAs have been identified in human17.
Biogenesis of microRNAs 
The genomic location of miRNAs can be discriminated among intergenic and intragenic. 
Roughly half of the known miRNAs are found to be transcribed from intergenic regions 
of the genome, suggesting that these miRNAs are transcribed under independent 
control of regulatory elements of coding genes18. The intragenic miRNAs are embedded 
within sequences of protein-coding genes (host gene), including intronic and exonic 
regions. If the intragenic miRNA and its host gene share the same promoter, the 
miRNA is likely to be under control of regulatory elements of the host gene and thus to 
be co-expressed with the host gene19. The maturation process of miRNAs is a complex 
mechanism that starts in the nucleus, where primary miRNAs (pri-miRNAs) are 
transcribed from DNA (Figure 1.1). These long stem loop-like structures have single-
stranded RNA extensions at both ends and are cleaved by enzymes Drosha and DGCR8, 
yielding precursor miRNAs (pre-miRNAs). These hairpin structure pre-miRNAs are 
transported to the cytoplasm by Exportin-5 protein. Here, an enzyme called Dicer 
cleaves the pre-miRNA into a mature miRNA. Subsequently, mature miRNAs can be 
cleaved by helicase into strands, including 3’-strand and 5’-strand. For clarification of 
mature miRNAs a nomenclature has been used. MiRNAs originating from the 3′ end 
or 5′ end of the microRNA gene are denoted with a ‘-3p’ or ‘-5p’ suffix, respectively. 
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One of the miRNA strands is active and binds to an Ago protein which can then be 
loaded into a RNA-induced silencing complex (RISC). The miR-RISC complex 
facilitates base-pairing interaction between miRNAs and 3' untranslated regions 
(3’UTRs) of target messenger RNA (mRNA). The thermodynamically stable 5' end 
of a mature miRNA (nucleotides 2-7/8), known as the “seed region”, is the essential 
part in target recognition and interaction. A perfect complementary binding between 
miRNA and target mRNA can lead to a degradation of the target transcript. If the 
complementary binding is imperfect, the miRNA can repress the target transcript20, 21.
Figure 1.1. The biogenesis of miRNAs. The maturation process of miRNAs begins in the nucleus, where 
primary miRNAs (pri-miRNAs) are transcribed from double-stranded DNA. Pri-miRNAs have single-stranded 
RNA extensions at both ends that are cleaved by enzymes Drosha and DGCR8, resulting in precursor miRNAs 
(pre-miRNAs). These pre-miRNAs are transported to the cytoplasm by Exportin-5 protein. In the cytoplasm, the 
Dicer enzyme cleaves the pre-miRNA into a mature miRNA. Mature miRNAs can then be cleaved by helicase into 
strands, including 3 'strand and 5' strand. One of the miRNA strands is active and binds to an Ago protein which 
can then be loaded into an RNA-induced silencing complex (RISC). The miR-RISC complex facilitates the base 
pairing interaction between miRNAs and 3 'untranslated regions (3'UTRs) of target messenger RNA (mRNA). 
Perfect complementary binding between miRNA and target mRNA can lead to degradation of the target transcript. 





MiRNAs have been proposed as instrumental in regulating the interaction of thousands 
of coding-genes and are involved in a variety of developmental functions, such as cell 
proliferation and differentiation, as well as pathological conditions22-24. Many miRNAs 
are expressed in a tissue-specific manner25, 26. For example, miR-1, miR-133 and miR-
208 have cardiac-specific expression patterns and are involved in heart development 
and disease, including myocardial infarction27-30. Another highly tissue-specific miRNA 
is miR-122, the most abundant hepatic miRNA important for cholesterol and fatty acid 
synthesis31 and recognized as marker for hepatocellular carcinoma (HCC)32, hepatitis 
C virus (HCV)33, 34. Although miRNAs primarily function within cells, previous studies 
discovered miRNAs circulating in body fluid, including blood35, saliva36, serum37 and 
urine38. Because aberrant expression of miRNAs often results from a pathological 
process in a specific tissue, miRNAs secreted from these tissues and released into the 
circulation represent a potentially ongoing pathological process. Indeed, circulatory 
miRNA profiles differ between healthy donors and individuals with underlying diseases, 
such as cancer24, 39 or type 2 diabetes40. In addition, given the fact that these miRNAs 
are easy accessible and remain in a very stable state in the circulation, the interest in 
using miRNAs as biomarker for disease has grown in recent years41. However, miRNAs 
derived from different types of body fluids were observed to show discrepancy42. For 
example, the levels of miRNAs measured in blood and CSF of Alzheimer’s disease 
patients might be different43. In addition, plasma derived miRNAs can show different 
expression levels as compared to whole blood derived miRNAs. Because whole-blood 
is cellular, miRNAs are more likely to reflect blood-based features than those caused 
by disease44. This is much less the case with cell-free miRNAs, such as miRNAs derived 
from plasma. In this thesis, we specially focus on circulatory miRNAs in plasma.
Over the past decade, increasing research has explored the potential of miRNAs as 
biomarker for common diseases, such as coronary artery disease45, type 2 diabetes40 
and stroke46. To date, the clinical application of the identified biomarkers has not been 
successful. One of the main reasons for the lack of success is the inability to replicate47. 
Studies are often subject to a small sample size, which is prone to many false positives 
with inflated effect estimates. Furthermore, miRNAs quantification methods are 
different, such as qPCR, RNA sequencing and microarray-based hybridization. These 
methods have all their advantages and disadvantages with regard to sensitivity in 
identification, quantification, timing and price48. Of all methods, next-generation 
sequencing (NGS)-based RNA sequencing is the most sensitive method that can 
identify novel miRNAs48. In this thesis, we used NGS-RNA sequencing to measure the 
expression levels of human miRNAs. 
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Systems biology 
Great knowlegde sees all in one. Small knowledge breaks down into the 
many – Chuang Tzu
Systems biology aims to understand the whole biological system working as a unit, rather 
than investigating their individual components. This holistic approach deciphers the 
complexity of biological systems and focuses on the network between different –omics 
layers, including genomics, epigenomics, transcriptomics, proteomics and metabolomics. 
The complex interplay between genotype and phenotype is essential for the optimal 
characterization of diseases. By integrating different omics layers, observed variations 
in each of these layers can lead to a better understanding of the functional consequences 
of the pathology of disease. Similar to protein-coding genes, the function of non-coding 
elements, including miRNAs can be affected by variations on different omics levels.   
Genomics: An organism’s complete set of DNA is called its genome. The field of genetic 
epidemiology seeks to define statistical and quantitative analysis of how genetics work 
in large groups, with as main goal to discover genes involved in diseases. The concept 
of finding genes for disease by comparing genetic variants between patients and 
healthy individuals was promising. In genome-wide association studies (GWAS), the 
observed associations between single nucleotide polymorphisms (SNPs) in, especially 
common diseases, have led to many novel insights into genetic determinants. Since the 
first GWAS study published in 200549, which was conducted on just over a hundred 
individuals, the sample sizes of GWAS studies has tremendously increased to over 
a million individuals in recent studies50-52. It has become more usual to combine 
GWAS results from different studies in order to increase the sample size. These meta-
analyses are a collaborative genomic research consortium, often targeting specific 
characteristics, such as cardiovascular (CARDIoGRAM)53, diabetic (DIAGRAM)54 or 
anthropometrics (GIANT)55 domains. 
As with protein-coding genes, genetic variants can have profound effects on the miRNA 
expression and function at different levels, from the regulatory regions such as promoter 
to (pre)-mature sequences56. For example, SNPs located in the promoter region of 
miRNAs can affect the transcription of miRNAs and thus the expression levels57. In 
addition, SNPs in pri- or pre-miRNA sequences can influence the miRNA maturation 
process, such as the binding affinity between miRNA and proteins (Drosha, Dicer, 
RISC)56. Overall, this can affect the ability to target mRNAs. Given the fact that a single 
miRNA can target a plethora of mRNAs, it is not surprising that genetic variants in 
miRNA genes have been linked to a variety of diseases, such as obesity58 and Alzheimer’s 
disease57. Although the number of disease-associated loci has increased over the years, 
the identified loci explain only a small proportion of the estimated heritability. In fact, for 




Epigenomics: Unlike genetics, epigenetics can be influenced by a variety of factors 
such as the environment, diet, and medication use, making epigenetics a dynamic 
phenomenon. Epigenetics is therefore recognized as an important link between 
environment and disease risk. An epigenome-wide association study (EWAS) is an 
approach to examine the association between changes in DNA methylation patterns 
and complex traits and diseases59-62. Also, factors such as smoking can induce changes 
in DNA methylation, which in turn can affect risk of diseases such as cancer63. DNA 
methylation at CpG sites in promoter regions of miRNA genes are associated with 
reductions in miRNA expression. Also, DNA methylation in pre-miRNA coding 
sequences is reported to affect the miRNA biogenesis64. A recent EWAS on a subset of 
miRNAs found that DNA methylation on CpGs was associated with expression levels 
of miRNAs that are subsequently causal for disease development65. In the latter study, 
about half of the miRNAs identified were located in intragenic regions, and, more 
interestingly, whose epigenetic regulation of DNA methylation on miRNA expression 
was independent of host gene expression. This indicates that DNA methylation is an 
important regulator of miRNA expression and suggests that underlying mechanisms of 
diseases can be epigenetically driven. 
Transcriptomics: The study of genome-wide levels of gene expression, also known 
as RNA transcripts, is known as transcriptomics. Both genetic variants and DNA 
methylation can change the expression of genes. These SNPs are indicated as expression 
quantitative trait loci (eQTL)66 and CpGs as methylation expression quantitative trait 
loci (meQTL)67. Gene expression is often tissue specific and to study specific diseases 
one must focus on the tissue of interest. For example, pancreas and liver are most 
relevant tissues to diabetes, while the brain is most relevant for studying stroke 
and Alzheimer’s disease. However, tissue availability is a major concern, especially 
in large observational studies. For that reason, less invasive tissue such as blood is 
often used68. Recent large-scale transcriptome-wide association studies (TWAS) can 
prioritize genes, that were previously been localized by GWAS, and increase the power 
in detecting functionally relevant loci69-71. In addition to eQTLs, a relative new concept 
studying the association between genetic variants and expression levels of miRNAs, 
called miR-eQTLs, added a dimension to the transcriptomics72, 73. 
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Objectives 
The overall aim of this thesis was to investigate the role of miRNAs in aging and 
age-related diseases, including various metabolic and cardiovascular diseases, using 
population-based omics data. In this epidemiological approach, I aimed to better 
understand the role of miRNAs in pathophysiology and identify circulatory miRNAs as 
potential biomarkers for these diseases.
Study population 
The Rotterdam Study 
The studies described in this thesis are performed within a large population based 
cohort study, the Rotterdam Study, also known as the “Erasmus Rotterdam 
Gezondheid Onderzoek (ERGO)”74. In 1990, residents aged 55 years and older residing 
in Ommoord, a district of Rotterdam, the Netherlands, were invited to participate in 
the study. Of 10,215 invited inhabitants, 7,983 agreed to participate in the baseline 
examinations, forming the Rotterdam cohort I (RS-I). In 2000, the Rotterdam Study 
was extended by including 3,011 participants who had reached 55 years of age or moved 
into the study district, forming the Rotterdam Study II (RS-II). In 2006, a further 
extension of the cohort was started in which 3,932 participants, aged at least 45 years 
living in Ommoord were included to form the Rotterdam Study III (RS-III). In June 
2016, recruitment of the Rotterdam cohort IV (RS-IV) began to enroll participants 
aged 40 years and over, and is ongoing with a target size of around 3,000 participants. 
All participants were examined in detail at baseline. Briefly, a home interview was 
conducted and the participants had an extensive set of examinations in the research 
center in Ommoord. Participants have been re-examined every 3-4 years and have been 
followed for multiple diseases and determinants. MiRNA profiling has been conducted 
in 2,000 randomly selected individuals from the fourth round of Rotterdam Study I 
(RS-I-4) and the second round of Rotterdam Study II (RS-II-2) between January 2002 
and December 2005. In addition, the miRNA expression was profiled in 754 randomly 
selected individuals from Rotterdam Study IV. DNA methylation was measured in a 
random sample of 1,454 participants from the third round of Rotterdam Study II and 
first round of Rotterdam Study III. Genotyping was performed in 11,496 individuals 
from Rotterdam Study I, II and III.  Figure 1.2 illustrates omics layers across different 




































































































































































CHAPTER 1  
Thesis outline 
In Part I, I focused on elucidating the role of miRNAs on biological aging. In chapter 
2, the current knowledge of miRNA regulatory roles in cell cycle progression in 
different types of stem cells is discussed. Chapter 3 presents a microRNA aging 
signature describing the ability to predict lifespan. 
In Part II, I aimed to investigate miRNAs as potential diagnostic or prognostic 
biomarkers, and elaborated on possible underlying mechanisms to link the identified 
miRNAs to the diseases of interest. In chapter 4, a genome-wide profiling of plasma 
miRNA levels was performed and the causal association of miRNAs with type 2 diabetes 
was studied. In chapter 5, I have described the association between circulatory 
miRNAs and liver enzymes, hepatic steatosis and liver fibrosis at the population level. 
In chapter 6, I conducted a multi-omics analysis to identify miRNAs associated with 
cardiometabolic risk factors and diseases. To do that, I used genetic (GWAS), epigenetic 
(EWAS), and miRNA expression data. In chapter 7, I investigated the association of 
plasma levels of miRNAs with incident stroke and their potential as biomarker for the 
disease. Finally, Chapter 8 presents the association and sex-specific role of miRNAs 
in atrial fibrillation.  
In Chapter 9 the main findings of the studies described in this thesis, their applications 
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MicroRNAs (miRNAs) are a class of small non-coding RNA molecules involved in the 
regulation of gene expression. They are involved in the fine-tuning of fundamental 
biological processes such as proliferation, differentiation, survival and apop- tosis 
in many cell types. Emerging evidence suggests that miRNAs regulate critical 
pathways involved in stem cell function. Several miRNAs have been suggested to 
target transcripts that directly or indirectly coordinate the cell cycle progression of 
stem cells. Moreover, previous studies have shown that altered expression levels of 
miRNAs can contribute to pathological conditions, such as cancer, due to the loss of 
cell cycle regulation. However, the precise mechanism underlying miRNA- mediated 
regulation of cell cycle in stem cells is still incompletely understood. In this review, we 
discuss current knowledge of miRNAs regulatory role in cell cycle progression of stem 
cells. We describe how specific miRNAs may control cell cycle associated molecules 
and checkpoints in embryonic, somatic and cancer stem cells. We further outline how 
these miRNAs could be regulated to influence cell cycle progression in stem cells as a 
potential clinical application.
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Introduction
Stem cells and cell cycle regulation
Stem cells are characterized by their unlimited ability to self-renew and capability to 
differentiate into multiple cell lineages 1. In this end, stem cells undergo an asymmetric 
cell division during which only one of the two daughter cells differentiates. This is a 
complex mechanism in which different transcription factors, epigenetic modifications 
and hormones are involved. There are two broad types of stem cells including embryonic 
stem cells (ESCs), which are solely present at the earliest stages of development, and 
various types of somatic (or adult) stem cells, which appear during fetal development 
and remain throughout life. ESCs are pluripotent and therefore have the capacity to 
differentiate into all the possible cell types of the three germ layers. Somatic stem cells, 
however, are multipotent and can only differentiate into cell types of the specific tissue 
or organ from which they originate. It is also suggested that a certain type of stem-like 
cells is responsible for the initiation of cancer, so-called cancer stem cells (CSCs). It is 
thought that CSCs arise from either differentiated cancer cells or somatic stem cells 2. 
In eukaryotes, the cell division cycle includes four discrete phases: Gap 1 (G1), 
Synthesis (S), Gap 2 (G2) and Mitosis (M). During the G1 phase, which is known as the 
first interphase, the cell synthesizes proteins that are needed for DNA replication and 
continuous growth. DNA replication takes place during the S phase and is followed by 
the G2 phase, which is known as the second interphase, where the DNA integrity is 
checked. At this point, the cell is growing and preparing for cell division. During the 
M phase, the cell divides into two daughter cells. After the mitotic phase, the daughter 
cells re-enter the G1 phase or go into the quiescent state. This is defined as a state 
of reversible cell cycle arrest and is known as the G0 phase 3. The quiescent state 
is important for cellular homeostasis, meaning that it has the ability to either stop 
proliferating or to re-enter the cell cycle and self-renew when needed 4, 5. 
The duration of the cell cycle and the transition from one phase to the next is highly 
variable between different cell types. For example, while the cell cycle duration in 
murine somatic cells is relatively long ( >16h), the duration in murine ESCs (mESCs) 
is much faster (8-10h). A reduced G1 phase and prolonged S phase in ESCs are causes 
of this difference. In addition, human ESCs (hESCs) spend only 3h in the G1 phase, 
compared to human somatic cells that spend 10h in this phase 6. The difference in 
cell cycle duration between ESCs and somatic stem cells is remarkable, an explanation 
could be that somatic stem cells are predominantly in a quiescent state compared to 
the fast dividing ESCs. Previous studies have indicated that the G1 phase is the most 
variable phase and that its duration contributes to cell fate determination 7-9. 
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When a cell enters the G1 phase, a protein called cyclin D increases in response to 
mitogenic stimuli. Cyclin D proteins bind to enzymes called CDK4/6 and together 
they form heterodimers. These complexes subsequently phosphorylate proteins of 
the retinoblastoma (RB) family. The E2F family is a group of genes encoding for 
transcription factors E2F-1, E2F-2 and E2F-3, which are downstream targets of the RB 
family. The central member of the RB family, the RB tumor suppressor protein (pRb), is 
a negative regulator of the E2F genes. When pRb is hypophosphorylated, it inactivates 
E2F transcription factors, which results in the inhibition of transition from G1 to S phase. 
Hyperphosphorylation of pRb leads to dissociation of E2F from the E2F/pRb complex 
and contributes to the G1/S transition from. Recent findings show the importance of the 
E2F/pRb activity in relation to ESCs self-renewal and differentiation 10-12.
Cyclin dependent kinase proteins (CDK) tightly regulate the progression of the cell 
cycle. A CDK binds to its regulatory cyclin protein partner to control the different cell 
cycle phases. Progression through S phase is regulated by the cyclin E-CDK2 complex, 
while the G2/M transition is under control of cyclin A and cyclin B-CDK1 complexes. 
Cyclin dependent kinase inhibitor (CDKI) proteins including p21/Cip1, p27/Kip1 and 
p57/Kip2, block the activity of cyclin E-CDK2 and cyclin A-CDK1 13. Furthermore, 
proteins of the INK4 family, including p16/INK4A, p15/INK4B, p18/INK4C and 
p19/INK4D inhibit the cyclin D-CDK4/6 activity. These mechanisms can lead to cell 
cycle arrest and are of major importance to regulate tissue homeostasis and prevent 
tumorigenesis. The p53-p21 signaling pathway is also involved in the transition of 
G1 to S phase and G2 to M phase. It is well established that loss of p53 is the main 
reason for genomic instability as the p53-null cells have disrupted the G1/S checkpoint 
14-17. In addition, the expression levels of p53 and p21 in ESCs are important for the 
maintenance of pluripotency 18. 
Biogenesis of microRNAs
Epigenetic features, such as the activity of microRNAs (miRNAs), modulate the 
expression of cell cycle-associated genes 19-23. MiRNAs are a conserved class of 
endogenously expressed small non-coding RNAs (spanning 20-24 nucleotides), that 
have been widely implicated in fine-tuning various biological processes. Since the 
discovery of the first miRNA in 1993 24, the knowledge on miRNAs has been rapidly 
increased. MiRNAs are ubiquitously expressed in plants, animals and viruses, 
indicating the evolutionary importance of these small molecules. According to the 
miRBase database (v.21), 1881 miRNAs have been identified with confidence in human 
25. These miRNAs are suggested to regulate the expression of more than 60% of all 
protein-coding genes. Previous research has investigated the functional role of miRNAs 
in diverse mechanisms including cell proliferation, apoptosis, and differentiation. 
Additionally, alteration in the expression of miRNAs contribute to human diseases 
such as cancer and cardiovascular disease 26-33. 
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MiRNA maturation is a complex biological process that is subjected to tight molecular 
regulation. In the nucleus, miRNAs are initially transcribed as 800-3000nt long 
primary transcripts (pri-miRNA). These pri-miRNAs are subsequently cleaved by 
Drosha, RNaseII, endonuclease III, and Pasha/DGCR8 proteins to generate ~70nt 
hairpin precursor miRNAs (pre-miRNAs). Following this initial process, pre-miRNAs 
are transported to the cytoplasm by Exportin 5. Subsequently, the hairpin precursor 
is cleaved in a ~22nt double-stranded miRNA by the ribonuclease III enzyme called 
Dicer together with TRBP/ PACT proteins. The guide strand (5’ end) then associates 
with members of the Argonaute family and is been incorporated into the RNA-induced 
silencing complex (RISC). The miR-RISC complex facilitates base-pairing interaction 
between miRNA and the 3' untranslated region (3’UTR) of target mRNA. The core of a 
mature miRNA, called the ‘seed’ region, includes nucleotides 2-7/8 from the 5’ end of 
the miRNA and plays a critical role in target recognition and interaction.  Binding of the 
miRNA seed region to the complementary site in target mRNA leads to translational 
repression or degradation of the target transcript. 
The first studies investigating miRNA function in cell cycle regulation were published 
two decades ago, where two independent studies revealed that miRNAs lin-4 and let-
7 induce cell cycle arrest in the nematode, C. elegans 24, 34. Since then, several studies 
have demonstrated the importance of miRNAs in cell cycle regulation in different cell 
types including stem cells 21, 35, 36. The role of miRNAs in stem cell proliferation was 
initially observed in knockout mice lacking Dicer and Dgcr8, which are key components 
of the miRNA biogenesis 37. Dicer knockout mice were embryonic lethal and ESCs 
from Dicer-deficient mice exhibited defects in cell cycle progression 38. Similarly, ESCs 
derived from Dgcr8-deficient mice exhibited delay in the cell cycle progression due to 
downregulation of genes involved in regulation of self-renewal 37. These initial studies 
indicated that miRNAs are crucial for cell cycle regulation of stem cells. Then, other 
studies demonstrated that miRNAs are involved in the cell cycle progression of stem 
cells by direct or indirect targeting of different cell cycle-associated genes (e.g. Cyclins, 
CDKs and CDKIs). Understanding the tightly regulated networks of the cell cycle in 
which miRNAs are interacting, will enhance our knowledge in the development of 
both healthy and disease state of the human body. In the following, we will discuss 
the recent advances on the functions of miRNAs in cell cycle regulation of stem cells. 
In addition, a promising therapeutic potential of miRNAs in controlling somatic and 
cancer stem cells self-renewal and proliferation will be discussed. 
34
CHAPTER 2
MiRNAs and cell cycle regulation of stem cells
Embryonic Stem Cells (ESCs)
The duration of the cell cycle is variable between different types of stem cells. ESCs 
have a shorter cell cycle compared to somatic stem cells, which is due to a significantly 
abbreviated G1 phase and a prolonged S phase 39-41. Previous studies have explored 
on the phosphorylation status of pRb as a regulator for the length of G1 phase. Since 
mESCs lack cyclin D-CDK4-as well as cyclin E-CDK2, pRb will not be phosphorylated 
and therefore not stimulating the cyclin E-CDK2 activity 42.  Therefore, the time spent 
in G1 phase compared to S phase may be a key feature of the pluripotency fate 12. 
Moreover, DNA damage response pathways, which are activated in the G1 phase, are 
reduced or absent in both hESCs and mESCs 43. Several negative regulators of cell cycle 
progression, including p53, p16/INK4A, p19/ARF and p21/Cip1, are expressed at low 
levels in ESCs, while DNA repair and replication regulators are expressed at high levels 
6, 43. 
Previous studies have shown the distinct expression pattern of miRNAs in ESCs. These 
studies demonstrate that ESCs express a set of miRNAs, of which a few are abundantly 
expressed at 60,000 or more copies per cell. The most abundantly expressed miRNAs 
in ESCs are miR-290-295, miR-302, miR-17-92, miR-106b-25 and miR-106a-363 
clusters, which provide approximately 70% of the total miRNA molecules in ESCs 20, 
44-46. These miRNAs are expressed in homologous clusters, so-called polycistronic loci, 
which contribute to the same cis-regulatory elements 47. The miR-290-295 cluster and 
miR-302 share a highly conserved seed-sequence ‘AAGUGCU’, while miR-17-92, miR-
106b-25 and miR-106a-363 clusters share the seed-sequence ‘AAAGUGC’ 20. These 
miRNAs are called the regulators of the embryonic stem cell cycle (ESCC), because 
of the ability in rescuing cell cycle progression in Dgcr8 knockout ESCs 20, 44, 48-50. A 
schematic overview of the functionality of ESCC miRNAs is illustrated in Figure 2.1. 
In general, ESCC miRNAs facilitate the G1/S transition mainly through suppressing 
the expression of RB proteins 44. In addition, these miRNAs have been demonstrated to 
directly regulate the expression of p21/Cip1 and cyclin E-CDK2 regulatory molecules 
in mESCs, including RB, RBL1, RBL2, and LATS2,21, 48-50. 
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D, cyclin E). Several cluster and single miRNAs are involved in the regulation of cell cycle in ESCs, among them 
miR-17-92, miR-290-295, miR-302, miR-106b-25 and miR-106a-363 are abundantly expressed in ESCs. For 
example, through inhibition of E2F by miR-92 and miR-195, transcription of multiple transcription factors and 
proteins (e.g. E2F1, E2F2, E2F3, CDK2, CDC25A) will decrease, resulting in a reduction of G1 duration. Further, 
the expression of main G1/S and G2/M checkpoint regulator p53 is decreased via indirect targeting of miR-290-
295 and miR-302 in ESCs. This contributes to facilitating the transition to S phase, which duration is prolonged. 
Moreover, p21 expression is reduced via miR-290-295, miR-372a, miR-302 and miR-106b-25 in a direct manner. 
This will inhibit cyclin E-CDK2 activity and therefore facilitating the G1/S transition. Additionally, pro-apoptotic 
gene BIM will not be activated, resulting in a reduced fraction of cells going into apoptosis. 
The miR-290 cluster, consisting of miR-291a-3p, miR-291b-3p, miR-294, and miR-
295, is upregulated in undifferentiated ESCs, but is rapidly downregulated during 
differentiation 21, 50, 51. It has been shown that members of this miRNA cluster promote 
the G1/S transition. Cells can relatively quick enter the S phase, because members of 
the miR-290-295 cluster directly target cyclin D-CDK4/6 and indirectly downregulate 
the cyclin E-CDK2 complex (Figure 2.1). MiR-290-295 downregulates diverse 
inhibitors of the cell cycle, including RB, RBL1, RBL2, p21 and LATS2,which change the 
distribution of ECS in each cell cycle phase 47. Furthermore, the miR-290-295 cluster 
enhances the somatic reprogramming by increasing the expression of pluripotent 
transcription factors OCT4, SOX2, KLF4, LIN28, MYC and NANOG 47, 52. Also, miR-
290-295 is shown to be directly involved to suppress apoptosis by targeting Caspase 2 
53. This leads to a reduced percentage of ESCs in G1 phase and an increased fraction of 
cells in S or G2/M phases. Due to the enhanced proliferation, the metabolism of ESCs 
rather rely on glycolysis than aerobic respiration. This metabolism is similar to the 
Warburg effect that is known in cancer cells 44, 47, 48. Therefore, glycolysis-associated 
genes, such as MYC, LIN28 and HIF1, have been promoted by the miR-290-295 cluster 
44, 47. Moreover, members of this miRNA cluster could affect epigenetic pathways 
including DNA methylation, histone acetylation and activation of Polycomb proteins, 
which inactivates genes involved in differentiation 54, 55. 
The miR-17-92 cluster consists of miR-17, miR-18a, miR-19a, miR-19b, miR-20a and 
miR-92a. This miRNA cluster is crucial in early mammalian development by supporting 
cellular reprogramming and tumorigenesis 44. In particular, miR-17-92 is a regulator 
of the MYC oncogene 56, 57. MYC inhibits the expression of chromatin regulatory genes 
including SIN3B, HBP1, and BTG1, via miR-17-92. Through epigenetic mechanisms 
including reduced recruitment of histone deacetylase (HADC) via HBP1, miR-17-92 
controls the chromatin stage of cell cycle related genes (Figure 2.1) 56. MYC through 
miR-17-92 contributes to the euchromatin formation of specific gene expression 
involved in DNA replication and repair mechanisms that goes along with a shift in the 
percentage of cells in a proliferating state 56. Likewise, miR-106b, which share a similar 
seed sequence, has been reported to promote G1/S transition by directly targeting p21, 
which results in a higher portion of cells in S phase compared to G1 phase 58. 
37
Cell cycle regulation of stem cells by microRNAs
2
The miR-302-367 cluster, consisting of miR-302a, b, c, d, and miR-367, has also been 
shown to play a crucial role in the proliferation of ESCs. Members of the miR-302-367 
cluster are highly expressed in early stages of embryonic development 59. This miRNA 
cluster targets genes that are involved in epigenetic mechanisms. For example, the miRNA 
cluster downregulates lysine demethylases and CpG binding proteins MECP1-p66 and 
MECP2 59. This facilitates the transcription of pluripotent genes and thereby contributes 
to the sustenance of pluripotency in mammalian ESCs 59. Furthermore, it has been 
demonstrated that the promoter of miR-302-367 is activated when bound by OCT4, 
SOX2, which are core transcription factors directly involved in the maintenance of 
ESCs 59, 60. It has been also shown that this cluster promotes pluripotency in ESCs by 
targeting the SMAD signaling pathway and the PI3K/PKB signaling molecules. MiR-
302 inhibits the expression of transforming growth factor beta-receptor 2 (TGFBR2) and 
RAS homolog gene family member C (RHOC), which leads to a reduction of epithelial-
mesenchymal transition 59, 61, 62. In addition, the miR-302 cluster has been suggested 
to negatively regulate p21 and LATS2 activity in both hESCs and mESCs 63, 64. These 
described molecular mechanisms enlighten the important role of the miR-302-367 
cluster with respect to pluripotency and cell cycle modulations. 
Another well-known miRNA family that is involved in the regulation of cell cycle 
progression is the let-7 family, which consist of let-7a-1, a-2, a-3, b, c, d, e, f-1, f-2, 
g, i and miR-98. Members of this miRNA family affect the G1/S transition of ESCs 
differently than the above-described ESCC miRNAs. While most of the ESCC miRNAs 
are related to promote self-renewal, the let-7 miRNAs suppress self-renewal 35, 51. The 
mechanism underlying this antagonistic effect remains unclear. However, it has been 
suggested that the ESCC miRNAs positively regulate the expression of LIN28, which 
through a negative feedback loop suppress the let-7 maturation 65, 66. 
Two other miRNAs known to affect the regulation of ESCs are miR-195 and miR-372a. 
Both miRNAs are highly enriched in hESCs compared to differentiated cells and their 
function also relies on maintaining the proliferative capacity of hESCs 67. For example, 
ectopic expression of miR-195 results in reduced expression of the G2/M cell cycle 
checkpoint kinase WEE1 and an enhancement of BrdU incorporation 67, 68. Ectopic 
expression of miR-372 has been shown to reduce the p21 expression levels in Dicer-
knockdown hESCs 67.
Human ESCs have the therapeutic potential to treat a myriad of disorders by cell 
replacement. In theory, ESCs could be used in regenerative medicine, drugs discovery 
and disease modeling. However, the usage of ESCs as clinical application is limited 
because of high tumorigenicity and ethical restrictions. A miRNA-based therapy that 
use induced pluripotent stem cells (iPSC) might overcome these limitations. In this 
regard, ectopic expression of ESCC miRNAs may contribute to expansion of stem cells 




An extensive body of research has revealed the role of miRNAs in the cell cycle 
regulation of somatic stem cells 45, 69, 70. In particular, studies with tissue specific Dicer-
knockout or Dgcr8-deficient mice have demonstrated that miRNAs are essential 
regulators of proliferation, survival and differentiation in somatic stem cells 71. In the 
following paragraphs, the role of miRNAs in the cell cycle regulation of hematopoietic 
and mesenchymal stem cells, which are two commonly investigated somatic stem 
cells, will be discussed. The associations of miRNAs with other somatic stem cells are 
summarized in Table 2.1.
Table 2.1. miRNAs associated with the cell cycle regulation in somatic stem cells 
Stem cell miRNA ID Potential target gene(s) Reference
Epidermal miR-205 PI3K-AKT [148]
miR-203 SNAI2, p63, SNAP2 [149]
miR-34 p63 [150]
miR-184 NOTCH, p63, FIH1 [151]
miR-214 WNT/β-catenin [152]




miR-124 SOX-2, PTBP1, SCP1 [157-159]
miR-302 p53, OCT4, SOX2, NANOG [160]
miR-148b WNT/β-catenin [161]
miR-138 TRIP6 [162]
Muscle miR-27 PAX3 [163]
miR-322 CDC25A [164]
miR-206 HDAC4, PAX7 [165, 166]
miR-1 HDAC4, PAX7 [166]
miR-133 SRF, MALAT1 [167]
miR-221 PI3K-AKT [168]
miR-143 IGFBP5, ERK1/2 [169]
miR-486 PAX7 [170]
Hematopoietic stem cell (HSC) development has been characterized by several 
mechanisms leading to generate multiple cell lineages. Adult HSCs are predominantly 
quiescent (in the G0 phase) compared to fetal HSCs 4. Well established is the self-
renewal function of the LIN28 gene, which is highly expressed in fetal HSCs compared 
39
Cell cycle regulation of stem cells by microRNAs
2
to adult HSCs (Figure 2.2b) 72, 73. This process based on a form-feedback loop includes 
the downregulation of let-7 through LIN28, which subsequently  downregulates 
HMGA2. Given that HMGA2 enhances the self-renewal capacity, the LIN28-HMGA2 
pathway is crucial in stem cell development 74. Most of the previous research has focused 
on determining the expression of miRNAs in hematopoietic stem and progenitor 
cells during lineage differentiation 75. Several studies have also reported differential 
miRNA expressions between HSCs, hematopoietic progenitor cells and both myeloid 
and lymphoid linages (e.g. T cell, B cell, Granulocyte, Monocyte, Erythrocyte), 
demonstrating that miRNAs are involved in the differentiation of specific hematopoietic 
lineages 72, 76-78. Although the conventional model suggests that hematopoietic lineages 
are derived from a common HSC, more recent research revealed that a rather  large 
number of progenitor cells are the main drivers behind steady-state hematopoiesis and 
clonal diversity 79. In this regards, short-term HSC could support the heterogeneous 
range of progeny 79. Taken the functional role of miRNAs into consideration, both 
progenitor cells and diverse miRNAs may be equally important for clonal expansion 
and hematopoiesis. 
For example, miRNAs are differentially expressed between long term hematopoietic 
stem cells (LT-HSCs) and short term HSCs, which are defined by a combination of cell 
surface markers such as c-Kit+/Sca-1+/Lin- (KSL). Based on the expression levels of cell 
surface markers includingCD34, Flk-2, CD150, CD48, CD224, c-Kit, Sca-1, and Lin the 
heterogeneous population of HSCs differ in proliferation and differentiation capacity 
80. The transition of HSCs into progenitor cells is related with a switch from quiescent 




Figure 2.2. miRNA mediated regulation of cell cycle in HSCs. A) The schematic describes the miRNAs 
that have critical roles in the cell cycle regulation in adult HSC by directly targeting one of the cell cycle 
components, including miR-125, miR-126, miR-33, miR-146 and let-7. Furthermore, miR-29 and miR-124 
target components involved in DNA methylation, whereby the chromatin architecture has been affected and 
thereby indirectly influences the expression of genes involved in cell cycle. B) The LIN28-HMGA2 feed-forward 
loop is among the most important mechanisms that drive fetal HSC self-renewal. LIN28 is highly expressed in 
fetal HSC compared to adult HSC. This indicates the important role of let-7 upon stem cell differentiation, as 
LIN28 directly inhibits let-7 expression. Decreased level of let-7 has resulted in higher expression of HMGA2, 
which induces self-renewal. Additionally, LIN28 independently of let-7, contributes to self-renewal [73, 74]. C) 
Adult HSCs are a heterogeneous population that differs in self-renewal and differentiation capacity based on 
surface markers. Long term HSC (LT-HSC) are predominantly quiescent (c-kit+ Sca-1+ Lin-Flk-2-CD34-)[147]. 
However, a large fraction of short term-HSC (c-kit+ Sca-1+ Lin-Flk-2- CD34+) gives rise to the differentiated 
progeny, and also shows greater cell proliferation capacity than LT-HSCs [80, 147]. Progenitor cells are 
associated with proliferation and differentiation into hematopoietic lineages. KSL (c-kit+ Sca-1+ Lin-) with 
high CD150+ expression may give predominant rise to myeloid linages, whereas KSL-CD150- are more likely 
to a lymphoid outcome [81]. Moreover, several studies demonstrated that specific miRNAs are differentially 
expressed among HSC and progenitor cells.
Therefore, the expression of cell cycle related miRNAs in exclusively progenitor cells 
is likely to be involved in the alteration of cell cycle duration 70. One of the enhanced 
expressed miRNAs in LT-HSC is the miR-125 cluster (miR-125a, miR-125b1, miR-
125b2). The expression of miR-125 has been shown to be associated with self-renewal 
and expansion of the stem cell population in vivo 81-83. Furthermore, miR-29a has been 
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revealed to regulate the G1/S transition in hematopoietic progenitor stem cells. MiR-
29a promotes the self-renewal capacity by targeting a subset of genes that are involved 
in cell cycle progression, including CDC42EP2 and HBP1 84. Recently, Lechman et 
al. demonstrated that miR-126 can control the cell cycle progression by targeting the 
PI3K/AKT/MTOR pathway 85. They showed that overexpression of miR-126 results in 
an increased percentage of quiescent cells, whereas a knockdown of miR-126 lead to 
enhanced proliferation and differentiation of HSCs 85-87. 
Additionally, previous studies have suggested miR-125 and miR-126 as potential target 
treatment for acute myeloid leukemia (AML) 88, 89. An indication for the potential 
therapeutic function is based on the alternated expression of these miRNAs between 
CD34+ CD38- HSC and CD34+ CD38- leukemic stem cells. A reduction of miR-126 
stimulates the PI3K/AKT/MTOR pathway in HSCs and will result in an increased 
number of HSCs, while this effect decreases the self-renewal capacity in CD34+ 
CD38- leukemic stem cells 88. However, this miRNA-based treatment holds promising 
capacity in vivo experiments, issues with respect to toxicity and delivery need to be 
solved before application in AML patients 88. 
Mesenchymal stem cells (MSCs) are multipotent cells that originate from bone marrow 
stroma, but are present in various tissues such as adipose tissue, bone, skeletal muscle, 
cartilage and tendon 90. Evidence suggests that miRNAs are closely involved in the 
regulation of MSC differentiation into specific cell lineages 78, 91-93. The role of miRNAs 
in proliferation and cell cycle regulation of human MSCs has been investigated through 
Drosha and Dicer knockdown studies 94. These studies have shown a significant 
increase in the number of cells in G1 phase and a reduced proliferation rate of MSCs 
94. In the same study, Drosha knockdown in MSCs resulted in a decrease of pRb and 
an increase in p16 and p15 levels 94. Other studies have been implicated miR-16 and 
miR-143 in the regulation of MSC proliferation and differentiation. In this regard, 
miR-16 has been shown to inhibit MSC proliferation and induce cell cycle arrest by 
targeting cyclin E 95. Likewise, miR-143 targets ERK5 (member of MAPK family), 
which itself decreases the expression of cyclin D and CDK6. This reduces cell entry into 
S phase, suggesting miR-143 to be a negative regulator of the cell cycle progression 96, 97. 
Moreover, a number of miRNAs have determined to control the differentiation into 
specific linages, such as osteoblasts 98. For example, Peng et al. demonstrated that 
miRNAs promote the osteogenic differentiation of MSCs via BMP, WNT/β-catenin 
and NOTCH signaling pathways. Among them, miR-27 promotes differentiation by 
targeting APC, which modulates the G2/M transition 98, 99. On the other hand, miR-27 
expression is shown to be downregulated upon adipocyte differentiation 100, 101. Several 
cell cycle associated genes, including ERK1/2, ERK5, TGF-β1 and KLF5 are related to 
adipocyte differentiation, which is explained by miRNA regulation 102. Notably, miR-
143, miR-448 and miR-375 have been reported as negative regulators and miR-21 as 
positive regulator of adipocyte differentiation 102. 
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Cancer Stem Cells (CSCs) 
Altered expression and molecular abnormalities of the cell-cycle-regulatory proteins, 
such as pRB, p53, CDKs, CDKIs and cyclins, play a central role in cancer initiation 
and progression 17, 103-105. Notably, it has been suggested that a class of cancer cells 
with characteristics of stem cells, so-called cancer stem cells (CSCs), are responsible 
for tumor initiation, invasion, metastasis and chemoresistance 106, 107. As discussed 
previously in this review, miRNAs have the ability to suppress apoptosis and promote 
proliferation by interplaying with the cell cycle components. Therefore, miRNAs and 
CSCs share common properties with respect to tumorigenesis. The transcriptional 
levels of several miRNAs have shown to vary between normal stem cells and CSCs 
108. Furthermore, associations between either cell cycle components including cyclins 
and transcription factors or miRNA expression and specific CSC markers have been 
investigated 109, 110. MiRNAs as regulators of CSCs have gained attention in recent years 
in multiple fields of research 107, 109, 111, 112. The associations between miRNAs expression 
and various cancers are summarized in Table 2.2. In the following paragraph, some 
of the main CSC-related miRNAs will be discussed.
The miR-17-92 cluster affects the cell cycle by targeting E2F1 and cyclin D as well 
as it cooperates with the oncogene MYC to prevent apoptosis in CSCs 113-116. Li et 
al. investigated the miR-17-92 target genes involved in the MYC suppression. They 
demonstrated that the functionalities of the miR-17-92 target genes rely on multiple 
DNA replication, cell cycle regulation, chromosome organization, RNA transcription or 
protein metabolism 56. Similarly, this miRNA cluster is shown to coordinate the timing 
of cell cycle progression by modulating expression of BMI1, PTEN, RBL2 and p21 117-121. 
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Other important regulators of CSCs are the members of the let-7 family. Evidence 
suggests that let-7 is among the most important miRNAs involved in tumor progression 
and chemoresistance 107, 122. The expression of the let-7 family is reduced in various 
types of tumor cells, including breast, head and neck squamous (HNSCC), lung, 
pancreatic, neuroblastoma cells, among others 107, 109, 123, 124. Accordingly, decreased 
expression of let-7 has resulted in overexpression of oncogenes MYC, RAS, HMGA2 
and BLIMP1 91, 122, 125. Furthermore, members of the let-7 family have been recognized 
as negative regulators of PTEN that inactivate the PI3K/AKT/MTOR pathway. The let-
7 family has also shown to be involved in suppressing the epithelial-to-mesenchymal 
transition (EMT), which is related to metastasis and chemoresistance and therefore 
a characteristic of CSCs 107, 122. Multiple genes involved in cell cycle progression are 
suggested to be targets for the let-7 family. The latter include cyclin D, cyclin A, CDK1, 
CDK2, CDK4, CDK6, CDK8 and CDC25A 91, 122, 125. Also, it has been shown that the 
RNA binding protein LIN28 inhibits let-7 by stimulating cellular proliferation via 
cyclin D, CDK2 and CDC25A and thereby contribute to the maintenance of stemness 
characteristics of CSCs 46, 126. LIN28 has been recognized as an oncogene, as it promotes 
tumor progression by repressing let-7 122. Previous studies based on let-7 expression 
and tumor progression display that ectopic expression of let-7 was sufficient enough 
to inhibit proliferation and clonal expansion in vitro and tumor recurrence in prostate 
cancer cells in vivo 117. 
The next miRNA family, consisting of miR-34a, b, and c, is well-studied regarding to cell 
cycle progression and its expression is downregulated in several types of cancer cells 
including lung adenocarcinomas, colon cancer and liver cancer (HCC) 127-132. MiR-34a 
induces both G1/S cell cycle arrest and cell senescence 127. Reduced expression of miR-
34 has been associated with enhanced levels of BCL2 and NOTCH, which are target 
genes for tumor suppressor gene p53 107, 111, 127. Similarity, miR-34 promotes apoptosis 
via Caspase 3, and therefore increases sensitivity for anti-cancer treatment 111. By 
regulating CDK6, cyclin D1 and E2F, miR-34 negatively affects cell cycle progression in 
colon cancer cells 107, 130, 131. In addition, miR-34 represses pluripotency genes inclusive 
of NANOG, SOX2 and MYC 111. Thus, overexpression of this miRNA family may cause 
an accumulated percentage of cells in the G0/G1 phase and significantly reduces the 
population of cells in the S phase.
MiR-31 has also shown to be inversely correlated with metastasis, since high expression 
in liver cancer is linked with a poor prognosis in patients. Kim et al. showed that 
ectopic expression of miR-31 evokes an overexpression of CDK2 and HDAC2 133. They 
have demonstrated that through abnormal expression of HDAC2, negative cell cycle 
regulators p16/INK4A, p19/INK4D and p21/Cip1 are induced. 
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Furthermore, an oncogenic role has been reported for the miR-15a/16 family in chronic 
lymphocytic leukemia (CLL), pituitary adenomas, and gastric cancer 134, 135. On the other 
hand, this miRNA family has shown to act as a tumor suppressor in a subset of B cell 
lymphoma, where deletion of this miRNA family in a subset of B cell lymphomas resulted 
in chronic lymphocytic leukemia in mice 136. In fact, miR-15a and miR-16 display an anti-
proliferative potential in this type of cancer stem cell by silencing BCL2 and activating the 
intrinsic apoptosis pathway 137, 138. In addition, some studies revealed the miR-15a/16 family 
as regulator of various cyclins, including cyclins D1 and D2 and cyclin E1, and pRb 125, 139, 140. 
An additional miRNA that has been suggested as an oncomiR, through targeting multiple 
signaling pathways, is miR-21 33. Upregulation of this miRNA has an oncogenic potential 
in a wide range of tumors including lung, breast, pancreatic, brain and colon cancers, 
through downregulation  of p21 and tumor suppressor genes PTEN and PDCD4 33, 141-143. 
MiR-26a has also mentioned to be a negative regulator of cancer cell proliferation by 
targeting cyclins D2 and E2, and CDK6. It has been established that overexpression of 
miR-26a results in cell cycle arrest in human liver cancer cells in vitro 144, 145. 
Concluding remarks and future prospects 
A growing body of evidence has addressed the potential role of miRNAs in cell cycle 
regulation of stem cells. In light of recent discoveries about the role miRNAs in self-
renewal, proliferation and differentiation, it is crucial to unravel the complex mechanisms 
and molecular interactions within this field of research. In this review, we outlined the most 
established miRNAs involved in the cell cycle progression of stem cells. We highlighted 
several clusters and single miRNAs that may control self-renewal and maintenance of the 
pluripotency status in ESCs. These include but are not limited to ESCC miRNAs (let-7, miR-
290-295, miR-302, miR-17-92, miR-106b-25 and miR-106a-363), which are functionally 
upregulated to suppress negative regulators and to enhance pluripotent transcription 
factors such as NANOG and MYC in an epigenetic manner 45. 
Furthermore, specific profiles of miRNA expression in distinct somatic stem cell 
lineages are linked with developmental control by keeping several multipotent stem 
cells (e.g. HSCs) in a quiescent state. Previous research based on Dicer-knockout and 
Dgcr8-deficient mice have elucidated that miRNAs are expressed temporally and 
spatially among somatic stem cells and precursor cells 37. It is crucial for somatic stem 
cells like HSCs to keep a balance between quiescent state and proliferating state. To 
accomplish that, a complex network of miRNAs exists that inhibit positive cell cycle 
regulators such as cyclins, as well as miRNAs modulating anti-apoptotic properties. 
This review set out to summarize distinct miRNAs involved in differentiation of several 
somatic stem cells. Complex interactions between miRNAs, transcription factors and 
cell cycle-mediated components may control the gene expression upon differentiation 
of multipotent stem cells into progenitor cells and mature cells. 
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It is clear that abnormalities in the cell cycle are related to tumorigenesis and previous 
studies have highlighted the significant importance of miRNAs in the regulation of CSCs 
108. Since CSC features are linked to metastasis, invasion and therapeutic resistance, it 
is of main clinical relevance to unravel the interactive properties between CSC-related 
miRNAs and cell cycle components. From the data available so far it appears that there 
is a great overlapping role between ESCC miRNAs that are expressed in both ESCs 
and CSCs. However, a subset of miRNAs is characterized as tumor suppressor genes 
as they are expressed regarding anti-proliferating features by targeting oncogenic 
pathways including MYC. Those miRNAs, including let-7, miR-34, miR-31 and miR-
17-92 family, are of major interest since they are associated with a good prognosis in 
cancer patients. Future research should focus on targeting the CSC-related miRNAs 
involved in oncogenic pathways since they will provide a more effective approach 
to exterminate CSCs. Subsequently, a miRNA based method for cancer treatment is 
highly target driven as it interferes with specific abnormalities in the cell cycle within 
the tumor microenvironment. 
Collectively, this review marks several noteworthy insights into the cell cycle regulation 
of stem cells by miRNAs. Understanding the tightly regulated molecular networks in 
which miRNAs are interacting, will greatly enhance our knowledge in the development 
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Background: Fatty liver disease (FLD) is the most common cause of liver dysfunction 
in developed countries. There is a great interest in developing clinically valid and 
minimally-invasive biomarkers to enhance early diagnosis of FLD. The aim was to 
investigate the potential of circulatory microRNAs (miRNAs) as biomarkers of FLD at 
the population level.
Methods: Plasma levels of 2083 miRNAs were measured by RNA-sequencing in 
1,999 participants from the prospective population-based Rotterdam Study cohort. 
The Hounsfield Unit (HU) attenuation of liver was measured using non-enhanced 
computed tomography (CT-scan). Logistic and linear regression models adjusting for 
potential confounders were used to examine the association of circulatory miRNAs 
with liver enzymes (n=1,991) and CT-based FLD (n=954). Moreover, the association 
of miRNAs with hepatic steatosis and liver fibrosis were assessed longitudinally in 
individuals who underwent abdominal ultrasound (n=1,211) and transient elastography 
(n=777) after a median follow-up of >6 years.
Findings: Cross-sectional analysis showed 61 miRNAs significantly associated with 
serum Gamma-glutamyl transferase and/or Alkaline phosphatase levels (Bonferroni-
corrected p-value<8.46×10-5). Moreover, 17 miRNAs were significantly associated with 
CT-based FLD (p-value<8.46×10-5), 14 of them were associated with liver enzymes. 
Longitudinal analysis showed that four of the 14 miRNAs (miR-193a-5p, miR-122-
5p, miR-378d, and miR-187-3p) were significantly associated with hepatic steatosis 
(p-value<3.57×10-3) and three (miR-193a-5p, miR-122-5p and miR-193b-3p) were 
nominally associated with liver fibrosis (p-value<0.05). Nine of the 14 identified 
miRNAs were involved in pathways underlying liver diseases.
Interpretation: This study indicates that plasma levels of several miRNAs can be 
used as biomarkers of FLD, laying the groundwork for future clinical applications.
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Introduction
Fatty liver disease (FLD), is the most common cause of liver dysfunction in developed 
countries, that is also increasing in developing countries 1, is defined as an excess 
accumulation of fat in hepatocytes 2. Specifically, non-alcoholic fatty liver disease 
(NAFLD) is characterized by fat accumulation in hepatocytes not due to excess alcohol 
consumption 3. The disorder covers a broad spectrum of underlying conditions, ranging 
from simple fatty liver to inflammation, which can progress to fibrosis, cirrhosis and 
even liver cancer 4. FLD is strongly associated with obesity, hypertension, dyslipidemia 
and insulin resistance, regarded as hepatic manifestation of the metabolic syndrome 
5. Currently, liver biopsy is the gold standard for diagnosing and staging of FLD, 
but its application is limited by the invasive nature, risk of complications and high 
cost 6. Various imaging modalities, such as computed tomography (CT) scan and 
ultrasound, have also been used for detecting the presence or quantifying the severity 
of liver fat noninvasively 7. However, the limited diagnostic accuracy of detecting 
mild degree hepatic steatosis with CT and ultrasound is an issue that should be taken 
into consideration 7. Transient elastography is non-invasive technique that uses both 
ultrasound and low-frequency elastic waves to qualify liver fibrosis. However, recent 
research suggests that steatosis may influence its diagnostic performance 8. Controlled 
attenuation parameter (CAP) is an ultrasound-based diagnostic method and added 
to transient elastography enables simultaneous assessment of steatosis and fibrosis 9, 
but the clinical application of CAP is limited by influences of covariates 10. Therefore, 
the development of clinically valid and minimally-invasive methods are required to 
enhance early diagnosis of FLD.
MicroRNAs (miRNAs) are small non-coding RNA molecules of 20–25 nucleotides in 
length that regulate gene expression at the post-transcriptional level 11. Recently, the 
interest in miRNAs has increased tremendously because they offer new insights into 
disease mechanisms and have a great potential to be used in the clinic as diagnostic 
biomarkers and/or even therapeutic targets 12, 13. In line with this, numerous studies 
have reported increased levels of circulating miR-122 in liver diseases with different 
etiologies and suggested this miRNA as a potential biomarker and target of therapy in 
liver dysfunction 14, 15. Although extensive research has explored the role of miRNAs in 
the pathophysiology of liver diseases, little is known about the potential of circulatory 
miRNAs as FLD biomarker in the population level. Moreover, the available studies 
have mainly used qPCR-based methods and limited to small number of miRNAs and 
sample sizes 16, 17.
The aim of this study was to systematically investigate the association of circulating 
miRNAs in plasma with FLD in a population-based setting. To achieve this aim, we 
conducted regression models to identify miRNAs that are associated with FLD and 
liver enzymes at the baseline in the Rotterdam Study cohort. Moreover, we performed 
124
CHAPTER 5
subsequent analyses to check whether the identified miRNAs are linked to the risk 
of hepatic steatosis or liver fibrosis after follow-up and are involved in the known 
pathways underlying liver diseases.
Materials and methods
Study population
This study was embedded within the framework of the Rotterdam Study (RS), a 
prospective cohort study of individuals aged ≥45 years living in the Ommoord district 
of Rotterdam, the Netherlands. The objectives and design of the Rotterdam Study have 
been described in detail elsewhere 18. In 1989, the first cohort of study participants 
(RS-I) comprised 7983 persons aged 55 years or over. In 2000, the second cohort (RS-
II) was extended to include an additional 3011 participants who moved into the study 
district or had become 55 years of age. A further extension of the Rotterdam Study 
cohort (RS-III) formed in 2006 and include 3932 participants living in the research 
area and aged 45 years and older. Follow-up examinations were scheduled periodically, 
approximately every 3-5 years. All participants in the study provided written inform 
consent to participate and to obtain information from their treating physicians.
For this study, we used the expression profiles of circulating miRNA in plasma, 
collected between 2002 and 2005, from a random subset (n=1,000) of the fourth visit 
of the first cohort (RS-I-4) and a random subset (n=999) of the second visit of the 
second cohort (RS-II-2). Among them, 1,991 participants had serum Gamma-glutamyl 
transferase (GGT) and Alkaline phosphatase (ALP) levels available at baseline that 
were included to investigate the association of miRNAs with liver enzymes. Moreover, 
954 participants who underwent CT-scan from June 2003 to February 2006 were 
included for investigating the associations of miRNAs with FLD in a cross-sectional 
setting (Figure 5.1). 
For the longitudinal analysis, 1,999 participants at the baseline were followed-
up >6 years, until the fifth visit of the first cohort (RS-I-5) and the third visit of the 
second cohort (RS-II-3). Among these, 1,211 participants who underwent abdominal 
ultrasound between January 2009 and June 2014 were included to investigate the 
association of miRNAs with hepatic steatosis (424 cases). Of these, 1,147 participants 
were included to investigate the association of miRNAs with NAFLD (321 cases) and 
alcoholic FLD (76 cases). Moreover, out of the 1,999 individuals, 777 participants 
who underwent transient elatography were included to investigate the association of 
miRNAs with liver fibrosis (33 cases). A more detailed flow chart for the selection of 
study participants is shown in Figure 5.1.
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Figure 5.1. An overview of the study to identify circulatory miRNAs associated with FLD. Cross-
sectional studies at baseline were performed in participants from RS-I-4 and RS-II-2 with liver enzymes and 
CT-scan data available. Longitudinal studies were performed in participants from RS-I-5 and RS-II-3 who 
underwent abdominal ultrasound or transient elastography. Abbreviations: miRNAs, microRNAs; GGT, 
Gamma-glutamyl transferase; ALP, Alkaline phosphatase; FLD, fatty liver disease; RS, Rotterdam Study; RS-
I-4, the fourth visit of the first cohort; RS-II-2, the second visit of the second cohort; RS-I-5, the fifth visit of 
the first cohort; RS-II-3, the third visit of the second cohort; CT, computed tomography; NAFLD, non-alcoholic 
fatty liver disease; AFLD, alcoholic fatty liver disease; LSM, liver stiffness measurement.
MiRNA expression profiling
Plasma levels of cell-free miRNAs were determined using the HTG EdgeSeq miRNA 
Whole Transcriptome Assay (WTA), which measures the expression of 2083 human 
mature miRNAs. The WTA characterizes miRNA expression patterns, and measures 
the expression of 13 housekeeping genes, that allows flexibility in data normalization 
and analysis. Plasma samples, for two re-measurements that generally is sufficient to 
obtain a valid result for all samples, were sent to HTG Molecular Diagnostics (AZ, USA) 
for sequencing. Each sample was tagged individually with molecular barcodes, tagged 
samples were pooled and sequenced on an Illumina NextSeq 500 sequencer (Illumina, 
San Diego, CA, USA). Quantification of miRNA expression was based on counts per million 
(CPM). The log2 transformation of CPM was used as standardization and adjustment for 
total reads within each sample. The miRNAs with log2 CPM< 1.0 were considered as not 
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expressed in the samples. Of the 2083 miRNAs, 591 miRNAs were expressed at good levels 
in plasma. These 591 well-expressed miRNAs are those with >50% values above Lower 
Limit of Quantification (LLOQ). The LLOQ level is based on a monotonic decreasing spline 
curve fit between the means and standard deviations of all miRNAs.
Assessment of liver fat with CT scan
As part of a larger project on the assessment of vascular calcification, ECG-gated, 
cardiac, non-enhanced CT scanning on a 16-slice (n=251) or 64-slice (n=703) multi-
detector CT scanner (Somatom Sensation 16 or 64, Siemens, Forchheim, Germany). 
Imaging parameters of the scans are described in detail elsewhere 19.
Using this cardiac scans, we evaluated the liver density (attenuation) using a 
standardized procedure. First, we placed three circular regions of interest (ROIs) in 
the liver and calculated the mean liver attenuation (LA) within these regions 20. These 
ROIs are delineated throughout the imaged liver tissue (including both the left and 
right liver lobes) are carefully chosen to include only liver tissue, and avoiding the large 
blood vessels, cysts, or focal lesions. Next, we calculated the mean Hounsfield unit 
(HU) value from these three measurements as a marker of total amount of liver fat, 
which is a reliable proxy for the mean LA value of the whole liver 20. All measurements 
were done using Philips iSite Enterprise software (Royal Philips Electronics N.V. 
2006) and described in detail elsewhere 21.
The CT diagnosis of liver fat is made by measuring mean LA in HU or the difference 
between the liver and spleen 20. As the amount of liver fat increases, the measured 
LA decreases, that means low LA was equal to high risk of fatty liver. However, in the 
present study fatty liver disease was defined as mean LA< 40 HU 22.
Assessment of hepatic steatosis and liver fibrosis 
Hepatic steatosis was assessed by using abdominal ultrasound, which was carried 
out by a certified and skilled technician (Pavel Taimr) on Hitachi HI VISION 900 23. 
Images were stored digitally and re-assessed by a single hepatologist with more than 
ten years of experience in ultrasonography. Diagnosis of steatosis was determined 
dichotomously as presence of a hyperechogenic liver parenchyma according to the 
protocol by Hamaguchi et al 24.
Moreover, liver fibrosis was assessed using transient elastography (FibroScan®, 
EchoSens, Paris, France). Applied implementation of this examination has been 
described in detail previously 25. Liver stiffness measurement (LSM) was performed 
by a single certified and experienced operator, who obtained 10 serial measurements 
using either the M or XL-probe dependent on the thickness of the subcutaneous fat 
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layer 23. Moreover, LSM interquartile range/median LSM >0.3 kilopascals (kPa) and 
LSM ≥7.1 kPa were regarded as poorly reliable 26. In the present study, LSM ≥9.0 kPa 
was used as a cutoff suggesting clinically relevant liver fibrosis 8.
Assessment of covariates and liver enzymes
Information on smoking behavior, medication use and blood sampling, was obtained 
during home interviews 18. Height and weight were measured, and the body mass index 
(BMI) [(weight in kg)/(height in m)2] was calculated. Waist circumferences was measured 
at the level midway between the lower rib margin and the iliac crest with the participant 
in a standing position. Smoking status was categorized into never, current or former and 
were classified (yes/no), for ever-smokers were regarded as current and former smokers 
combined. Alcohol consumption was assessed in grams of ethanol per day and were 
classified (yes/no). Excessive alcohol consumption was defined as alcohol intake >30 g/day 
for men and >20 g/day for women 23. Hypertension was defined as a systolic blood pressure 
(BP) ≥140mmHg or a diastolic BP ≥90 mmHg or the use of BP-lowering drugs prescribed 
for hypertension 27. Diabetes mellitus was defined according to recent WHO guidelines 28 as 
fasting blood glucose ≥7.0 mmol/L or non-fasting blood glucose between ≥11.1 mmol/L or 
the use of antidiabetic medication. From the blood samples, concentrations high-density 
lipoprotein (HDL) cholesterol were determined using enzymatic procedures 29. Serum 
GGT and ALP levels were determined within 2 weeks using a Merck Diagnostica kit on an 
Elan Autoanalyzer (Merc, Darmstadt, Germany). According to local cutoffs, elevation of 
GGT was defined as >34 U/L for women and >49 U/L for men, and elevation of ALP was 
defined as >97 U/L for women and >114 U/L for men 30.
Statistical analysis
Continuous variables are reported as mean ± standard deviation (SD) unless stated 
otherwise and categorical variables were presented as sample sizes and percentages. 
To obtain a normal distribution, skewed variables (serum HDL cholesterol, GGT and 
ALP) were log transformed. In addition, the amount of liver fat (A) had a left skewed 
and we used exponential transformed values (B) using the formula [B=A3.5/10000] 21.
Multivariable linear and logistic regression models were used to investigate the 
association between miRNA levels and CT-based FLD (with the HU continues and 
dichotomous data). The multivariable linear regression models were used to check 
the association of miRNA levels with serum GGT and ALP levels. Beta, standard 
error (SE), p-value were reported. The Bonferroni-corrected p-value threshold was 
calculated based on the number of tested miRNAs (0.05/591=8.46×10-5). In basic 
model (model 1), we adjusted the analysis for age and sex. The multivariable model 
(model 2), was additionally adjusted for waist circumference, ever smoking, alcohol 
consumption, hypertension, diabetes mellitus and serum HDL cholesterol. Because 
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the missing values were likely to be missing at random and for avoidance of loss in 
efficiency, missing values on covariates (ranging from 0.1% to 1.7%) were imputed 
using a multiple imputation technique (N=5 imputations). All analyses were done 
using SPSS statistical software (SPSS, version 25; IBM Corp, Armonk) and R software 
version 3.5.2 (The R Foundation for Statistical Computing, Vienna, Austria).
Sensitivity analyses were performed by adjusting for more variables. Model 3 was built by 
adding GGT and ALP to model 2. In model 4, we further adjusted for potential intermediator 
factors including in the model 2, use of lipid-lowering medication, use of bile and liver 
medications. In model 5, we adjusted for all potential intermediator factors (including 
model 2, GGT, ALP, use of lipid-lowering medication, use of bile and liver medications).
Furthermore, multivariable logistic regression models were used to investigate 
longitudinally the association of the plasma levels of the identified miRNAs with 
prevalence of hepatic steatosis and liver fibrosis after a median follow-up of 6.4 years 
[interquartile range (IQR): 5.9-7.0 years]. The Bonferroni correction was used to set 
the significance threshold.
Two databases, the Human miRNA tissue atlas (https://ccb-web.cs.uni-saarland.de/
tissueatlas )31 and Human miRNA expression profiles (https://guanfiles.dcmb.med.
umich.edu/mirmine/ index.html), were used to check whether the identified miRNAs 
are expressed in the liver. We also searched the literature 32-35 and several web tools 
(e.g., miR2Diease and GWAS catalog) to see whether the identified miRNAs are 
associated with liver function and diseases.
Results
At baseline, 954 participants who had miRNA expression data and CT-based liver fat 
measurement were included to test the association of miRNAs and FLD. The mean age 
of the study population was 68.8±6.7 years, and 46.6% were male. The mean LA in the 
population was 61.6 HU (IQR: 55.4-65.6 HU). Among the study participants, 14.8% 
were diagnosed with cancer, but none of them was diagnosed with liver cancer. At 
follow-up, 1,211 participants who had underwent abdominal ultrasound were included 
to test the association of miRNAs and hepatic steatosis. The man age of the study 
population was 76.3±6.5 years, and 42.4% were male. Lifestyle, clinical and biochemical 
characteristics of all study participants are presented in Table 5.1. Comparison of 
characteristics between healthy controls and FLD patients based on CT-scan and 
ultrasound data (in baseline and follow-up study) are shown in Supplementary Table 
5..1. The participants with FLD have significantly higher BMI, waist circumference and 
alcohol consumption than healthy controls. In addition, compare to healthy controls, 
individuals with FLD have significantly lower serum HDL cholesterol. 
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Age, years 68.8±6.7 76.3±6.5
Male, n (%) 445 (46.6) 513 (42.4)
Body mass index , kg/m2 27.9±4.0 27.5±4.1
Waist circumference, cm 94.4±11.7 93.2±12.0
Hypertension, n (%) 709 (74.3) 1,047 (86.5)
Blood-pressure-lowering medication, 
n (%)
385 (40.4) 644 (53.2)
Smoking status, n (%)
Ever 677 (71.0) 791 (65.3)
Current 130 (13.6) 116 (9.6)
Former 547 (57.4) 675 (55.7)
Diabetes mellitus, n (%) 123 (12.9) 156 (12.9)
Use of lipid-lowering medication, 
n (%)
246 (25.8) 372 (30.7)
Alcohol intake, grams/day 8.6 (1.4-20.0) 8.6 (1.6-8.6)
Mean liver attenuation, HU 61.6 (55.4-65.6) −
Serum HDL cholesterol, mmol/L 1.4 (1.2-1.7) 1.4 (1.2-1.7)
GGT level, U/L 26.0 (18.0-39.0) 24.0 (17.0-34.2)
ALP level, U/L 77.0 (66.0-91.0) 68.0 (57.0-80.0)
Cancer, n (%) 141 (14.8) −
Liver cancer, n (%) 0 (0) −
Fatty liver, n (%) 47 (4.93) 424 (35)
The table shows characteristics of 954 participants with CT-scan data at baseline and 1,211 participants with 
ultrasound data at follow-up. Values are represented as mean (±standard deviation), sample sizes (percentage), 
or median (inter-quartile range) for characteristics with skewed distributions. Abbreviations: BP: blood 




In the linear regression analysis with liver enzymes, 37 miRNAs were significantly 
associated with serum GGT levels and 29 miRNAs with serum ALP levels, at the 
Bonferroni-corrected p-value< 8.46×10-5 (0.05/591 well-expressed miRNAs) 
(Supplementary Table 5.2 and Supplementary Table 5.3, respectively). 
Volcano plot showing differently expressed miRNAs in relation to GGT and ALP levels 
is depicted in Figure 5.2A-B. 
Figure 5.2. Volcano plots showing correlation between plasma levels of miRNAs and GGT (A), 
ALP (B), and continuous Hounsfield Unit values (C). The red dots indicate miRNAs significantly 
associated at Bonferroni-corrected p-value< 8.46×10-5. The gray dots indicate miRNAs with no significant 
association. The name of miRNAs that were significantly associated with liver enzymes and the continuous 
Hounsfield Unit values are mentioned in the Figure 2C. Abbreviations: miRNAs, microRNAs; GGT, Gamma-
glutamyl transferase; ALP, Alkaline phosphatase.
Using a linear regression analysis of the continuous HU values, in the multivariable 
model 2, we found 15 miRNAs to be significantly associated at Bonferroni-corrected 
p-value< 8.46×10-5 (Supplementary Table 5.4). Volcano plot showing differently 
expressed miRNAs in relation to the continuous HU values is depicted in Figure 
5.2C. In addition, in a logistic regression model testing the association of miRNA levels 
with the dichotomous HU values assessing FLD (mean LA ≤ or >40), 6 miRNAs were 
significantly associated (p-value< 8.46×10-5) (Figure 5.3). In model 3, further adjusting 
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for GGT and ALP changed slightly the associations and with less miRNAs significant 
associated, but 2 out of the 17 and 6 out of 17 miRNAs remained significant using 
dichotomous and continuous Hounsfield Unit values, respectively (p-value< 8.46×10-5) 
(Supplementary Table 5.5 and Supplementary Table 5.6). Additional adjustment 
for use of lipid-lowering medication, use of bile and liver medications (model 4) did not 
change the observed associations between miRNAs and FLD (Supplementary Table 
5.5 and Supplementary Table 5.6). In model 5, we added GGT, ALP, use of serum 
lipid reducing agents, use of bile and liver medications to model 2, the associations of 
miRNAs with FLD were similar to model 3, the same miRNAs remained significant 
(Supplementary Table 5.5 and Supplementary Table 5.6). 
Collectively, our cross-sectional studies with the baseline data revealed 61 unique 
miRNAs associated with liver enzymes (GGT and/or ALP) and 17 unique miRNAs 
associated with CT-based FLD (continuous or dichotomous HU values). Of these, 14 
miRNAs were common in both lists that were selected for further analyses (Table 5.2).
Figure 5.3. Comparison between expression levels of the top 10 miRNAs in patients with fatty 
liver disease and healthy controls. Of these 10 miRNAs, 6 of them (miR-193a-5p, miR-378a-3p, miR-
422a, miR-378d, miR-320d and miR-378e) were significantly associated with fatty liver disease at Bonferroni-
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The longitudinal analysis was performed for the 14 miRNAs by using ultrasound and 
FibroScan data. Using a logistic regression in the multivariable model 2, we found 
significant association between four of the 14 miRNAs (miR-193a-5p, miR-122-5p, 
miR-378d, and miR-187-3p) with hepatic steatosis at Bonferroni-corrected p-value< 
3.57×10-3 (0.05/14 miRNAs) (Table 5.3). Moreover, we found significant association 
of miR-122-5p and miR-187-3p with NAFLD (p-value< 3.57×10-3), and miR-3937 was 
nominally (p-value< 0.05) associated with alcoholic FLD (Supplementary 5.7). 
Using FibroScan data and in a multivariable logistic regression model, we found miR-
193a-5p (p-value= 5.58×10-3, β= 1.11), miR-122-5p (p-value=0.0147, β= 0.45) and miR-
193b-3p (p-value= 0.0102, β= 1.19) were to be nominally associated with liver fibrosis 
(Table 5.3). 
Table 5.3. Longitudinal study of the 14 identified miRNAs with hepatic steatosis and liver fibrosis




Beta SE p-value Beta SE p-value
miR-193a-5p 0.54 0.16 2.02×10-10 1.11 0.40 5.58×10-03
miR-4484 0.21 0.10 4.65×10-02 0.41 0.28 1.37×10-01
miR-1306-5p -0.33 0.28 2.36×10-01 -1.16 -0.73 1.14×10-01
miR-378a-3p 0.37 0.21 8.19×10-02 1.23 0.64 5.67×10-02
miR-6803-5p 0.13 0.15 3.79×10-01 0.70 0.41 8.42×10-02
miR-6870-3p -0.22 0.14 1.18×10-01 0.07 0.45 8.80×10-01
miR-3937 -0.13 0.09 1.44×10-01 -0.18 0.26 4.87×10-01
miR-122-5p 0.33 0.08 6.06×10-05 0.45 0.18 1.47×10-02
miR-422a 0.37 0.18 4.12×10-02 0.96 0.54 7.61×10-02
miR-378d 0.54 0.17 1.65×10-03 0.73 0.53 1.69×10-01
miR-187-3p -1.01 0.34 2.76×10-03 -0.42 0.98 6.68×10-01
miR-6809-5p -0.55 0.24 2.49×10-02 -0.66 -0.76 3.83×10-01
miR-193b-3p 0.22 0.15 1.42×10-01 1.19 0.46 1.02×10-02
miR-378e 0.50 0.18 7.25×10-03 0.94 0.60 1.14×10-01
Model 2: adjusted for age, sex, waist circumference, ever smoking, alcohol consumption, hypertension, 
diabetes mellitus and serum HDL cholesterol. The table is sorted based on the association of 14 miRNAs with 
the continues Hounsfield Unit values in the cross-sectional study. The p-values surpassing the Bonferroni-
corrected threshold of p-value< 3.57×10-3 (0.05/14 miRNAs) are bold and nominal associations with p-value 
<0.05 are underlined. Abbreviations: miRNA, microRNA; SE, standard error.
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Additionally, we searched the Human miRNA tissue atlas and the miRmine database 
to see whether the 14 miRNAs associated with FLD in plasma are also expressed in the 
liver that are shown in Supplementary Table 5.8. Among them, miR-122-5p is a 
specifically expressed miRNA with the tissue specificity index (TSI) of 0.97 and highly 
expressed in the liver. Then, we sought to find whether the 14 identified miRNAs are 
reported in previous studies to be associated with liver function or/and diseases. A 
summary of evidence for associations between 9 of these miRNAs and liver diseases 
are shown in Supplementary Table 5.9. Finally, we extracted SNPs annotated to the 
16 identified miRNAs and checked their associations with FLD and liver enzymes using 
summary statistics data from pervious GWAS 34, 35. There were 63 SNPs related to miR-
193a-5p, miR-378d and miR-193b-3p, none of them showed significant association 
after correcting the p-value for multiple testing.
Discussion
In this study, we investigated the association between circulating miRNAs and liver 
enzymes in a population-based setting and found 61 unique miRNAs to be associated 
with serum GGT or ALP levels. Moreover, we found plasma levels of 17 miRNAs to be 
associated with CT-based FLD, 14 of these were also associated with the liver enzymes. 
Higher plasma levels of three and lower plasma level of one of these 14 miRNAs were 
significantly associated with hepatic steatosis after >6 years follow-up. These findings 
indicate that plasma levels of miRNAs can be considered as potential biomarkers of 
FLD and hepatic steatosis in the general population.
Several studies have demonstrated the potential of miRNAs to be used as biomarkers 
for liver diseases 36-38. However, previous studies have conducted for subset of miRNAs, 
using qPCR-based methods, or on the modest sample sizes. While our study is embedded 
within the Rotterdam Study with much larger sample size, based on RNA-sequencing 
method, conducted genome-wide profiling of almost all important cell-free miRNAs, 
and adjusted for a broad range of potential confounders, such as waist circumference, 
smoking status, alcohol consumption, hypertension and diabetes mellitus, which 
have been overlooked in most of previous studies 36, 39. Such a large-scale population-
based study with long term follow-up data provided a more statistical power to detect 
multiple significant associations. Compared to microarray or qPCR-based profiling 
techniques, the cell-free RNA-seq analysis can provide higher sensitivity to measure 
miRNAs expression levels over a wide dynamic range and with ability to identify novel 
miRNAs 40. Additionally, due to the high stability of cell-free miRNAs in body fluids 
and accessibility of plasma compared with the target tissue, the identified miRNAs can 
be considered as potential easy-to-use biomarkers in clinical routine 41.
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Previous studies on human or mouse model have demonstrated particularly miR-122-
5p as potential biomarkers and therapeutic target for liver diseases 39, 42, 43. In line with 
previous studies, we found that the higher plasma miR-122-5p level is significantly 
associated with FLD and liver enzymes also in a population-based setting. In addition 
to the well-established liver-associated miR-122, we found evidence in previous studies 
for 8 of the other identified miRNAs in our study to be associated with liver diseases, 
indicating the importance of these miRNAs in pathways underlying liver function and 
diseases. In particular, the expression of miR-193a-5p, which is one of our top miRNAs 
associated with FLD and hepatic steatosis, is reported to be upregulated in HCC tissues 
44, whereas miR-193a-5p can distinguish HCC from other non-HCC individuals 43 and 
inhibited HCC development through targeting SPOCK1 45. Similarly, miR-422a was 
related to NAFLD 46, miR-378d 47 miR-187-3p 48, miR-6809-5p 49 and miR-4484 50 
were associated with HCC. Moreover, miR-193b-3p which were significantly associated 
with FLD and nominally associated with liver fibrosis in our study, have been verified 
previously to be involved in the pathogenesis of liver fibrosis in vitro 51. Finally, the 
members of miR-378 family, in particular miR-378a-3p that has been also proposed to 
have a therapeutic potential for liver fibrosis 52.
Our results showed a minimal of the use of serum lipid reducing agents, use of bile and 
liver medications on the observed associations between miRNAs and FLD. We observed 
slightly change in the associations between miRNAs and FLD by adding GGT and ALP to 
the model. This difference may indicate that liver enzymes have more stronger links to 
FLD compared to medication use. Also, we did not find significant association between 
SNPs related to the identified miRNAs and FLD in the summary statistics from previous 
GWAS, but we need to take into consideration the sample sizes of available GWAS of 
liver diseases. To date, the GWAS on liver diseases are mainly from two studies 34, 35, 
Nakamura et al. conducted a study to identify susceptibility loci for primary biliary 
cirrhosis, a GWAS in 963 Japanese individuals and in a subsequent replication study 
including 1,402 other Japanese individuals. The sample sizes of this study is limited and 
the analysis conducted in Asia population, while our study was conducted in European 
population, and miRNAs expression might exhibits population differences 53. In 
addition, Namjou et al. conducted a GWAS using both adult and pediatric participants 
(1,106 NAFLD cases and 8,571 controls) from electronic medical records to identify 
genetic contributions to NAFLD. As the cohorts in that GWAS study represent many 
geographic area in USA, other ancestry groups are under-represented in the electronic 
medical records. Thus, it is possible that future trans-ethnic GWAS with larger samples 
sizes find association between some of the identified miRNAs and FLD.
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Our study has some limitations that should be considered. First, in the cross-sectional 
observational study the ability to assess causality or temporality is limited. We therefore 
assessed additionally the associations of the identified miRNAs as biomarkers for 
diagnosis hepatic steatosis after follow-up. Future studies are still needed to confirm our 
findings in longitudinal settings considering the incidence date, longer follow-up time 
and in different age groups. Second, we defined the mean LA< 40 HU as FLD and found 
47 cases out of 954 individuals (5%), which is lower than the excepted prevalence of FLD 
in the general population. A liver-to-spleen ratio< 1.0 is comparable to using a mean 
LA cut off ≤ 51 HU for diagnosis of mild liver fat 54. However, previous studies have 
demonstrated different cut-offs, mainly a cut-off value of 40 HU on non-enhanced CT 
as the most clinically indicator for moderate-to severe steatosis 20, 22. In our study, the 
cut-off value is 40 HU for FLD, it is relatively strict than using the mean LA≤ 51 HU, 
which increases the certainty of identifying participants with true FLD and also results 
in a lower prevalence. Therefore, we performed cross-sectional analysis at baseline 
with the continuous HU values and liver enzymes as well. The majority (14 out of 17) 
of the identified miRNAs with CT-scan data showed significant association with liver 
enzyme, indicating the robustness of our results. Yet, compare to the liver biopsy as 
the gold standard, but invasive method, to measure FLD, CT-based liver fat has limited 
diagnostic accuracy of detecting mild degree hepatic steatosis. Therefore, there might 
be some known or unknown causes for low density of the liver on CT scan. Also, there 
might be some inconsistency between CT-scans and ultrasound data for diagnosing FLD 
and hepatic steatosis. In an optimal setting, one should use the repeated measurement 
of liver fat by a similar diagnostic method for longitudinal analysis.
In conclusion, we found that plasma levels of several miRNAs were significantly 
associated with FLD and hepatic steatosis that can be considered as plasma disease 
biomarkers in this population-based study. Future research need to be conducted even 
with more sample sizes and longer follow-up times in order to confirm the potential 
of the identified miRNAs as biomarkers for early diagnosis and progression of FLD 
and also to uncover underlying molecular mechanisms by which these miRNAs may 
control liver fat.
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Supplementary Table 5.2. 37 miRNAs significantly associated with GGT in model 2
miRNA ID Beta  SE p-value
miR-122-5p 0.14 0.01 2.39E-116
miR-194-5p 0.19 0.01 8.77E-79
miR-192-5p 0.16 0.01 6.25E-65
miR-193a-5p 0.14 0.01 6.15E-29
miR-148a-3p 0.11 0.01 2.56E-22
miR-193b-3p 0.11 0.01 2.01E-21
miR-100-5p 0.11 0.01 1.50E-18
miR-99a-5p 0.12 0.01 1.09E-15
miR-125b-5p 0.09 0.01 8.31E-11
miR-34a-5p 0.06 0.01 3.78E-10
miR-378a-3p 0.09 0.02 8.45E-08
miR-6870-3p -0.06 0.01 9.04E-08
miR-4433b-5p -0.08 0.01 1.33E-07
miR-4655-3p -0.11 0.02 3.39E-07
miR-378d 0.06 0.01 5.55E-07
miR-6809-5p -0.08 0.02 1.45E-06
miR-3937 -0.03 0.01 1.90E-06
miR-187-3p -0.11 0.02 3.78E-06
miR-378g 0.08 0.02 4.42E-06
miR-6775-3p -0.11 0.03 7.80E-06
miR-3140-5p -0.10 0.02 9.03E-06
miR-6780b-5p 0.04 0.01 9.09E-06
miR-4257 -0.08 0.02 9.28E-06
miR-422a 0.06 0.01 9.71E-06
miR-6165 -0.04 0.01 1.18E-05
miR-1225-5p -0.11 0.03 1.26E-05
miR-2115-5p -0.10 0.02 1.29E-05
miR-212-3p -0.09 0.02 1.52E-05
miR-6870-5p 0.04 0.01 2.35E-05
miR-6794-3p -0.10 0.02 2.45E-05
miR-7851-3p 0.04 0.01 2.90E-05
miR-378e 0.06 0.01 3.13E-05
miR-4484 0.03 0.01 4.02E-05
miR-6803-5p 0.05 0.01 6.31E-05
miR-1306-5p -0.09 0.02 6.45E-05
miR-548d-5p 0.04 0.01 7.64E-05
miR-1299 0.04 0.01 7.83E-05
The table shows 37 miRNAs that are significantly associated with GGT in Model 2. The significant threshold 
is the Bonferroni-corrected p-value of 8.46E-05 (0.05/591 miRNAs). Model 2: adjusted for age, sex, waist 
circumference, ever smoking, alcohol consumption, hypertension, diabetes mellitus and serum HDL 




Supplementary Table 5.3. 29 miRNAs significantly associated with ALP in model 2
 miRNA ID Beta SE p-value
miR-3674 0.03 0.005 1.32E-07
miR-126-5p -0.03 0.005 1.46E-07
miR-4463 0.03 0.006 2.64E-07
miR-4459 0.03 0.007 5.07E-07
miR-566 0.02 0.005 1.41E-06
miR-126-3p -0.03 0.006 1.57E-06
miR-6799-5p 0.03 0.006 1.69E-06
miR-1304-3p 0.03 0.007 5.21E-06
miR-139-5p -0.04 0.008 6.75E-06
miR-3135a 0.02 0.006 9.46E-06
miR-1273a 0.02 0.004 1.06E-05
miR-4257 -0.03 0.008 1.25E-05
miR-1273c 0.02 0.005 1.26E-05
miR-1254 0.02 0.005 1.41E-05
miR-195-5p -0.03 0.007 1.42E-05
miR-1255b-2-3p 0.02 0.004 1.44E-05
miR-1273e 0.02 0.004 1.55E-05
miR-5585-3p 0.02 0.004 1.77E-05
miR-1299 0.02 0.005 2.05E-05
miR-1285-5p 0.02 0.004 2.58E-05
miR-7851-3p 0.02 0.005 2.72E-05
miR-1303 0.02 0.005 2.86E-05
miR-1273g-5p 0.02 0.004 3.06E-05
miR-1914-5p 0.03 0.006 3.10E-05
miR-548d-5p 0.02 0.005 3.72E-05
miR-4478 0.02 0.006 6.30E-05
miR-10b-5p -0.03 0.007 6.57E-05
miR-4512 0.02 0.004 7.21E-05
miR-6870-3p -0.02 0.005 8.00E-05
The table shows 29 miRNAs that are significantly associated with ALP in model 2. The significant threshold is the 
Bonferroni-corrected p-value of 8.46E-05 (0.05/591 miRNAs). Model 2: adjusted for age, sex, waist circumference, 
ever smoking, alcohol consumption, hypertension, diabetes mellitus and serum HDL cholesterol).Abbreviations: 
miRNA, microRNA;  ALP, Alkaline phosphatase ; SE, standard error; HDL, high-density lipoprotein. 
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Supplementary Table 5.4. 15 miRNAs significantly associated with fatty liver disease (continuous 
Hounsfield Unit values)
MiRNA ID Beta SE p-value
miR-193a-5p -35.88 5.11 4.26E-12
miR-4484 -20.04 3.67 6.02E-08
miR-1306-5p 55.59 10.42 1.21E-07
miR-6803-5p -27.96 5.34 2.01E-07
miR-6870-3p 25.79 5.04 3.87E-07
miR-3937 15.02 3.00 6.59E-07
miR-378a-3p -34.61 7.23 1.95E-06
miR-378d -26.00 5.70 5.87E-06
miR-122-5p -12.74 2.84 8.05E-06
miR-187-3p 48.67 11.12 1.33E-05
miR-6809-5p 34.03 7.85 1.61E-05
miR-193b-3p -23.17 5.50 2.77E-05
miR-4713-3p 16.96 4.03 2.80E-05
miR-34b-3p 30.06 7.48 6.27E-05
miR-422a -25.07 6.22 6.09E-05
Model 2: adjusted for age, sex, waist circumference, ever smoking, alcohol consumption, hypertension, 
diabetes mellitus and HDL cholesterol. The significant threshold is the Bonferroni-corrected p-value of 8.46E-




Supplementary Table 5.5. Additional adjustments for liver enzymes and medication use in the 
association between 17 identified miRNAs and FLD (using dichotomous Hounsfield Unit values)
miRNA ID Model 3 Model 4 Model 5
Beta SE p-value Beta SE p-value Beta SE p-value
miR-193a-5p 1.58 0.30 1.43E-07 1.86 0.29 1.77E-10 1.59 0.29 5.59E-08
miR-4484 0.58 0.22 9.98E-03 0.72 0.22 8.80E-04 0.57 0.22 1.05E-02
miR-1306-5p -0.11 0.63 8.64E-01 -0.63 0.60 2.90E-01 -0.01 0.63 9.82E-01
miR-378a-3p 2.05 0.47 1.17E-05 2.35 0.45 2.06E-07 2.10 0.46 5.77E-06
miR-6803-5p 0.51 0.34 1.29E-01 0.72 0.32 2.43E-02 0.47 0.33 1.61E-01
miR-6870-3p -0.46 0.26 7.90E-02 -0.59 0.24 1.64E-02 -0.43 0.26 9.90E-02
miR-3937 -0.43 0.18 1.87E-02 -0.57 0.17 1.14E-03 -0.41 0.18 2.50E-02
miR-122-5p 0.24 0.17 1.54E-01 0.54 0.14 1.49E-04 0.27 0.17 1.07E-01
miR-422a 1.73 0.46 1.94E-04 2.02 0.46 9.31E-06 1.76 0.46 1.34E-04
miR-378d 1.50 0.41 2.84E-04 1.75 0.40 1.21E-05 1.54 0.41 1.60E-04
miR-187-3p -1.25 0.64 4.93E-02 -1.36 0.59 1.98E-02 -1.15 0.62 6.54E-02
miR-6809-5p -0.63 0.43 1.38E-01 -0.76 0.38 4.47E-02 -0.60 0.42 1.56E-01
miR-193b-3p 0.56 0.35 1.08E-01 1.02 0.34 2.47E-03 0.63 0.34 6.72E-02
miR-4713-3p -0.46 0.24 5.28E-02 -0.60 0.22 6.11E-03 -0.42 0.23 7.41E-02
miR-320d 1.11 0.29 1.55E-04 1.16 0.28 3.20E-05 1.13 0.29 1.16E-04
miR-34b-3p -0.45 0.46 3.25E-01 -0.80 0.45 7.67E-02 -0.45 0.46 3.30E-01
miR-378e 1.41 0.43 1.02E-03 1.64 0.41 7.43E-05 1.45 0.43 6.63E-04
The table is sorted based on Bonferroni-corrected p-value association of miRNAs with FLD based on Hounsfield 
Unit values in model 2. The significant threshold is the Bonferroni-corrected p-value of 8.46E-05 (0.05/591 
miRNAs). MiRNAs passing the thresholds are shown in bold. Model 2: adjusted for age, sex, waist circumference, 
ever smoking, alcohol consumption, hypertension, diabetes mellitus and HDL cholesterol. Model 3: model 2, 
+ additionally adjusted for GGT and ALP.  Model 4: model 2, + additionally adjusted for use of lipid-lowering 
medication, use of bile and liver medications. Model 5: model 2, + additionally adjusted for GGT, ALP, use of 
lipid-lowering medication, use of bile and liver medications. Abbreviations: miRNA, microRNA; FLD, fatty liver 
disease; GGT, Gamma-glutamyl transferase; ALP, Alkaline phosphatase; SE, standard error.
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Supplementary Table 5.6. Additional adjustments for liver enzymes and medication use in the 
association between 17 identified miRNAs and FLD (using continuous Hounsfield Unit values)
miRNA ID Model 3 Model 4 Model 5
Beta SE p-value Beta SE p-value Beta SE p-value
miR-193a-5p -25.28 5.21 1.45E-06 -36.09 5.11 3.26E-12 -25.34 5.21 1.35E-06
miR-4484 -18.01 3.56 4.90E-07 -20.12 3.67 5.34E-08 -18.08 3.55 4.36E-07
miR-1306-5p 45.15 10.20 1.07E-05 56.74 10.45 7.26E-08 46.65 10.21 5.54E-06
miR-378a-3p -25.69 7.10 3.16E-04 -34.64 7.23 1.92E-06 -25.51 7.10 3.45E-04
miR-6803-5p -21.59 5.24 4.17E-05 -28.04 5.35 1.97E-07 -21.73 5.24 3.70E-05
miR-6870-3p 20.80 4.94 2.83E-05 26.01 5.05 3.12E-07 20.94 4.94 2.49E-05
miR-3937 11.80 2.95 6.81E-05 15.32 3.03 5.13E-07 12.25 2.97 4.04E-05
miR-122-5p -1.62 3.12 6.05E-01 -12.82 2.84 7.05E-06 -1.58 3.12 6.13E-01
miR-422a -18.16 6.07 2.85E-03 -25.22 6.22 5.50E-05 -18.23 6.06 2.72E-03
miR-378d -19.32 5.60 5.92E-04 -26.00 5.71 6.03E-06 -18.96 5.61 7.64E-04
miR-187-3p 40.87 10.83 1.71E-04 49.31 11.14 1.07E-05 41.84 10.83 1.19E-04
miR-6809-5p 28.14 7.63 2.38E-04 34.45 7.87 1.34E-05 28.82 7.63 1.70E-04
miR-193b-3p -12.91 5.50 1.92E-02 -23.26 5.50 2.59E-05 -12.92 5.49 1.89E-02
miR-4713-3p 13.56 3.93 5.81E-04 17.40 4.06 2.02E-05 14.28 3.95 3.14E-04
miR-320d -12.38 4.89 1.15E-02 -14.57 5.03 3.87E-03 -12.60 4.89 1.01E-02
miR-34b-3p 23.99 7.25 9.83E-04 30.15 7.49 6.11E-05 24.21 7.25 8.78E-04
miR-378e -15.58 6.17 1.17E-02 -21.72 6.33 6.29E-04 -15.49 6.18 1.23E-02
The table is sorted based on Bonferroni-corrected p-value association of miRNAs with FLD based on Hounsfield 
Unit values in model 2. The significant threshold is the Bonferroni-corrected p-value of 8.46E-05 (0.05/591 
miRNAs). MiRNAs passing the thresholds are shown in bold. Model 2: adjusted for age, sex, waist circumference, 
ever smoking, alcohol consumption, hypertension, diabetes mellitus and HDL cholesterol. Model 3: model 2, 
+ additionally adjusted for GGT and ALP.  Model 4: model 2, + additionally adjusted for use of lipid-lowering 
medication, use of bile and liver medications. Model 5: model 2, + additionally adjusted for GGT, ALP, use of 
lipid-lowering medication, use of bile and liver medications. Abbreviations: miRNA, microRNA; FLD, fatty liver 
disease; GGT, Gamma-glutamyl transferase; ALP, Alkaline phosphatase; SE, standard error.
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Supplementary Table 5.7. The expression of 14 identified miRNAs in the liver and relevant 
tissues
miRNA ID Database Tissue specifity index  Liver
miR-193a-5p TissueAtlas 0.61 42.94
miR-4484 TissueAtlas 0.57 159.15
miR-1306-5p miRmine − 3.30
miR-378a-3p TissueAtlas 0.97 444.41
miR-6803-5p miRmine − 0.00
miR-6870-3p miRmine − 0.00
miR-3937 TissueAtlas 0.58 316.39
miR-122-5p TissueAtlas 0.97 4468.79
miR-422a TissueAtlas 0.62 52.80
miR-378d TissueAtlas 0.98 68.44
miR-187-3p miRmine − 7.40
miR-6809-5p miRmine − 0.00
miR-193b-3p TissueAtlas 0.86 62.19
miR-378e TissueAtlas 0.92 22.18
TissueAtlas database: Human miRNA tissue atlas database [1] (https://ccb-web.cs.uni-saarland.de/
tissueatlas). miRmine database: Human miRNA expression database (https://guanfiles.dcmb.med.umich.
edu/mirmine/index.html ). The table shows the expression level of 14 identified miRNAs in the liver .  Tissue 
specifity index range from 0 to 1 with the score of 0 corresponding to ubiquitously expressed miRNAs and 
a score of 1 for miRNAs that are expressed in a single tissue. The threshold originally proposed for defining 
housekeeping and specifically expressed miRNAs of tissue specifity index <0.15 and >0.85. Abbreviations: 
miRNA, microRNA; FLD, fatty liver disease; HDL: high-density lipoprotein.
References
[1] Ludwig N, Leidinger P, Becker K, et al. Distribution of miRNA expression across human tissues. 
Nucleic Acids Res 2016;44(8):3865-77
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Supplementary Table 5.8. miRNA associated with NAFLD and AFLD based on logistic regression 
models using ultrasound data in model 2
MiRNA ID NAFLD AFLD
Model 2 Model 2
Beta SE p-value Beta SE p-value
miR-193a-5p 0.30 0.17 7.10E-02 0.55 0.40 1.69E-01
miR-4484 0.15 0.11 1.86E-01 0.45 0.28 1.08E-01
miR-1306-5p -0.30 0.33 3.53E-01 -1.41 0.76 6.21E-02
miR-378a-3p 0.17 0.23 4.59E-01 0.13 0.58 8.28E-01
miR-6803-5p 0.10 0.16 5.63E-01 0.64 0.41 1.12E-01
miR-6870-3p -0.33 0.15 2.89E-02 0.08 0.43 8.49E-01
miR-3937 -0.07 0.10 4.69E-01 -0.59 0.23 9.75E-03
miR-122-5p 0.30 0.09 8.56E-04 0.27 0.19 1.52E-01
miR-422a 0.39 0.20 4.98E-02 -0.25 0.43 5.63E-01
miR-378d 0.34 0.19 6.74E-02 0.21 0.45 6.38E-01
miR-187-3p -1.14 0.37 1.86E-03 -1.18 0.97 2.24E-01
miR-6809-5p -0.46 0.27 8.31E-02 -1.21 0.66 6.72E-02
miR-193b-3p 0.16 0.17 3.48E-01 0.08 0.33 8.03E-01
miR-378e 0.51 0.21 1.43E-02 -0.24 0.41 5.62E-01
Model 2: Additionally adjusted for waist circumference, ever smoking, hypertension, diabetes mellitus and 
HDL cholesterol.  The significant threshold is the Bonferroni-corrected p-value of 3.57E-03 (0.05/14 miRNAs). 
The miRNAs significantly associated with NAFLD in model 2 are bold. The miRNAs nominally (p-value< 0.05) 
associated with AFLD in model 2 are blod. Abbreviations: miRNA, microRNA;  NAFLD, non-alcoholic fatty 
liver disease; AFLD, alcoholic fatty liver disease;SE, standard error; HDL, high-density lipoprotein.
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Background: MicroRNAs (miRNAs) are non-coding RNA molecules that regulate 
gene expression. Extensive research has explored the role of miRNAs in the risk for 
type 2 diabetes (T2D) and coronary heart disease (CHD) using single-omics data, but 
much less by leveraging population-based omics data. Here we aimed to conduct a 
multi-omics analysis to identify miRNAs associated with cardiometabolic risk factors 
and diseases. 
Methods: First, we used publicly available summary statistics from large-scale 
genome-wide association studies to find genetic variants in miRNA-related sequences 
associated with various cardiometabolic traits, including lipid and obesity-related 
traits, glycemic indices, blood pressure, and disease prevalence of T2D and CHD. 
Then, we used DNA methylation and miRNA expression data from participants of 
the Rotterdam Study to further investigate the link between associated miRNAs and 
cardiometabolic traits. 
Findings: After correcting for multiple testing, 180 genetic variants annotated to 
67 independent miRNAs were associated with the studied traits. Alterations in DNA 
methylation levels of CpG sites annotated to 38 of these miRNAs were associated with 
the same trait(s). Moreover, we found that plasma expression levels of 8 of the 67 
identified miRNAs were also associated with the same trait. Integrating the results of 
different omics data showed miR-10b-5p, miR-148a-3p, miR-125b-5p and miR-100-
5p to be strongly linked to lipid traits. 
Interpretation: Collectively, our multi-omics analysis revealed multiple miRNAs 
that could be considered as potential biomarkers for early diagnosis and progression 
of cardiometabolic diseases.  
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Introduction
Type 2 diabetes mellitus (T2D) is a complex metabolic disease that is characterized by 
insulin resistance and impairment of insulin secretion, which leads to hyperglycemia. 
The presence of T2D leads to a two- to four-fold increase risk of developing coronary 
heart disease (CHD) 1, which is among the leading causes of morbidity and mortality 
worldwide 2. Many risk factors are identified as mediators of these diseases, including 
hypertension, dyslipidemia, central adiposity and elevated blood glucose, which are 
together known as cardiometabolic traits 3. Despite substantial advances in diagnosis 
and widely prescribed drugs for these diseases, their rate continue to increase 
worldwide, emphasizing the need for deeper insights into underlying mechanisms and 
innovative therapeutic strategies. Cardiometabolic traits and diseases have underlying 
genetic components and many loci have been discovered through large-scale genome- 
and epigenome-wide association studies 4, 5. However, most of the identified genetic 
variants do not affect protein sequences, but are thought to affect gene regulation. One 
of the potential regulatory mechanisms involved might be microRNAs (miRNAs). 
MiRNAs represent a class of small non-coding RNAs, which function as post-
transcriptional regulators of gene expression via targeting the 3’ untranslated region 
of target transcripts 6. Over the past years, miRNAs have emerged as key regulators of 
biological processes underlying T2D and CHD. In this context, aberrant expression 
and function of miRNAs, such as miR-33, miR-208, miR-133 and miR-124, have 
been shown to be associated with lipid metabolism, insulin secretion, myocardial 
infarction and T2D 7-9. Most of the disease-associated miRNAs have been discovered in 
cells originated from tissue of interest in small number of samples or animal studies. 
But advances in high-throughput technologies make it possible to study miRNAs in 
a population-based manner. In particular cell-derived vesicles, known as exosomes, 
release miRNAs in the blood stream that are very stable and can be used as biomarkers 
for disease 10.
Similar to other regulatory RNA molecules, the function and expression of miRNAs 
can be affected by genetic variants. Single-nucleotide polymorphisms (SNPs) can occur 
at various stages of the miRNA biogenesis including precursor- and mature miRNA 
sequences 11 as well as within regulatory elements, such as promoter regions 12. Also, 
DNA methylation can control transcription, which have been reported to be associated 
with the expression level of miRNAs 13. In this context, epigenome-wide association 
studies (EWAS) have shown that altered DNA methylation within miRNA promoters 
is associated with miRNAs expression levels and therewith modify disease risk 14. 
However, previous studies are mainly based on single omics data or small sample size 
15, 16. As each type of omics data provides associations that can be useful for detecting 
development or progression of disease, integrating different omics layers can limit 
passive correlations and provide a more comprehensive view of the disease biology.
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In this study, we applied a multi-omics approach to identify miRNAs associated with 
cardiometabolic traits. First, we identified genetic variants in miRNA sequences and 
their potential regulatory regions associated with different cardiometabolic risk factors 
and diseases using genetic association data from the available genome-wide association 
studies (GWAS). We then integrated population-based DNA methylation and miRNA 
expression data from the Rotterdam Study to link omics layers, strengthening the 
association of the identified miRNAs with cardiometabolic traits. We envision that the 
identified miRNAs could be considered as potential biomarkers for early diagnosis of 
cardiometabolic diseases. 
Material and Methods
A graphical overview of the multi-omics approach used in this study is illustrated in 
Figure 6.1.
Figure 6.1. Overview of the multi-omics layers used in this study.    
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Genetic association study
Retrieval of SNPs in miRNA-related regions
The primary transcripts of miRNAs for the processing to mature miRNAs are 
approximately 3-4kb in length 17. We collected the genomic position of all human 
miRNAs employing the miRBase database (v21) 18, ProMiR II 19 and FANTOM5 12. 
Using dbSNP database 20, we extracted 18,545 SNPs located in +/-2kb of the precursor 
miRNA sequences (pre-miRNA) of 1,554 known miRNAs. Of these, 2,420 SNPs are 
located in pre- and mature sequences of miRNAs. Genetic variants have been found 
to alter miRNA expression and are known as miRNA expression quantitative trait loci 
(miR-eQTLs). To this end, we included 5,528 miR-eQTLs that change the expression of 
221 mature miRNA using data from the Framingham Heart Study (FHS) 21 and from the 
Ottawa Hospital Bariatric Centre 22. The FHS focused on cis-miR-eQTLs, of which the 
majority was located 300-500kb away from their target miRNA. Nikpay et al. (2019) 
investigated both cis-miR-eQTLs and trans-miR-eQTLs, however, they reported 
similar to the FHS that most cis-miR-eQTLs were distal regulators of the miRNAs. 
There were 83 miR-eQTLs overlapping with the SNPs in +/-2kb of the precursor 
miRNA sequence. Altogether, 23,990 unique SNPs were included in our analysis. 
The genomic location of miRNAs can be discriminated among intergenic and 
intragenic. Roughly half of the known miRNAs are found to be transcribed from 
intergenic regions of the genome, suggesting that these miRNAs are transcribed under 
independent control of regulatory elements 23. The intragenic miRNAs are embedded 
within sequences of protein-coding genes, including intronic and exonic regions. If 
the intragenic miRNA and its host gene share the same promoter, the miRNA is likely 
to be co-expressed with the host gene 24. Here, the genomic location of the identified 
miRNAs was obtained using miRIAD 25. 
Genome-wide association studies of cardiometabolic traits 
Cardiometabolic risk factors and diseases in this study were classified into four specific 
trait groups based on their shared pathophysiology and underlying pathways. These 
include i) Anthropometric traits: body mass index (BMI), waist to hip ratio (WHR) and 
waist circumference (WC); ii) Glycemic traits: fasting glucose (FG), glucose 2 hours 
(G2H), fasting insulin (FI), proinsulin (Pro-Ins), hemoglobin A1c (HbA1c), homeostatic 
model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-β) and 
type 2 diabetes mellitus (T2D); iii) Lipid traits: low-density lipoprotein (LDL), high-
density lipoprotein (HDL), total serum cholesterol (TC) and triglycerides (TG); and iv) 
Cardiovascular traits: coronary artery disease (CAD), diastolic (DBP) and systolic blood 
pressure (SBP). To test the association of miRNA-related SNPs with cardiometabolic 
traits we used publicly available GWAS summary statistics. A description of GWAS 
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meta-analysis data and corresponding consortia used in this study is provided in 
Supplementary Table 6.1. To obtain the number of independent SNPs, we used the 
linkage disequilibrium (LD) based SNP pruning in PLINK (http://pngu.mgh.harvard.
edu/~purcell/plink/), in which we excluded the SNPs with R2 > 0.7. Bonferroni 
correction was used to adjust for multiple testing based on the number of independent 
SNPs available in the GWAS data (HapMap or 1000G project imputed data). 
Prioritization of miRNA-related SNPs associated with 
cardiometabolic traits 
For miRNA-related SNPs significantly associated with cardiometabolic traits, we 
performed in silico analysis to prioritize the SNPs that are more likely to be functional 
in their corresponding loci based on the following criteria: i) association between 
the miRNA-related SNP and the cardiometabolic trait, ii) association between the 
miRNA-related SNP and the expression level of miRNA/miRNA hosting gene, and iii) 
expression of the miRNA in tissues relevant to cardiometabolic traits. In this regard, 
regional association plots were generated (using LocusZoom web tool, Version 1.1) to 
visualize the physical position and evaluate the association of the cardiometabolic traits 
with the miRNA-related SNP and its proxy SNPs (R2 > 0.8) in the corresponding locus: 
(i) To explore whether the SNP is associated with the expression of related miRNA or 
miRNA hosting genes in relevant tissues (e.g., adipose tissue, liver, pancreas, muscle 
and blood), we used eQTL data from GTEx Portal (https://www. gtexportal.org/
home/), (ii) We used two online databases; miRmine and Human miRNA tissue atlas 
26, 27 to test where a miRNA is expressed in tissues relevant to cardiometabolic traits 
(e.g., adipose tissue, liver, pancreas, muscle, and blood), (iii) The Vienna RNAfold 
algorithm was used to check miRNA secondary structure and free energy changes with 
wild-type and mutant alleles of SNPs located in miRNA sequences 28. 
Determination of methylation quantitative trait loci  
(me-QTLs)
To determine if the identified SNPs have an effect on the methylation levels of CpG 
sites (me-QTLs), we used data of a recent me-QTL study performed in five cohorts, 
including the RS, with a total of 3,841 individuals 29. We incorporated both cis-me-
QTLs and trans-me-QTLs. Where cis-me-QTLs were defined as the effect of SNPs on 
the methylation levels of a CpG sites no further than 250kb apart, trans-me-QTLs were 
defined as the effect of distal SNPs on the CpG methylation levels. Details on the me-
QTL mapping are described elsewhere 29. We tested if the cardiometabolic-associated 
SNPs found in the current study were identified as me-QTLs.     
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DNA methylation analysis in the Rotterdam 
Study
The Rotterdam Study (RS) is a large prospective population-based cohort study 
conducted among middle-aged and elderly people in the suburb Ommoord in 
Rotterdam, the Netherlands. In 1989, 7,983 inhabitants aged 55 and older were recruited 
in the first cohort (RS-I) (78% of 10,215 invitees). In 2000, the RS was extended with 
a second cohort of 3,011 participants that moved to Ommoord or turned 55 years old 
(RS-II). In 2006, the third cohort (RS-III) was initiated in which inhabitants aged 45-
54 years were invited and included 3,932 participants. A detailed description of RS 
can be found elsewhere 30. In the current study, we used DNA methylation data from 
a random subset (n=717) of the third visit of RS-II (RS-II-3) and second visit of RS-III 
(RS-III-2) and a random subset (n=721) of the first visit of RS-III (RS-III-1). There was 
no overlap in participants. The RS has been approved by the institutional review board 
(Medical Ethics Committee) of the Erasmus Medical Center and by the review board of 
The Netherlands Ministry of Health, Welfare and Sports. All participants gave written 
consent before participation in the study. Participant characteristics are presented in 
Supplementary Table 6.2. 
DNA was extracted from whole peripheral blood using standardized salting out 
methods, of which 500ng was bisulfite treated using the Zymo EZ-96 DNA methylation 
kit (Zymo Research, Irvine, CA, USA). Bisulfite converted DNA was hybridized 
to the Illumina Human 450K array (Illumina, San Diego, CA, USA), according to 
manufacturer’s protocol. Data preprocessing was performed using an R programming 
pipeline based on the pipeline developed by Touleimat and Tost 31. The genome 
coordinates provided by Illumina (GRCh37/hg19) were used to identify independent 
loci. We extracted 12,939 unique CpGs located in +/-2kb of the pre-miRNA sequences 
using the Illumina450K array annotation file as provided by Illumina 32. Among these, 
12,617 CpGs were located in the regulatory region of 1,269 miRNAs and 450 CpGs were 
located in the pre- and mature sequence of 391 miRNAs. We tested the association 
of these CpGs with different cardiometabolic traits using linear mixed models. Data 
collection on these traits in the RS is described in Supplementary Methods. The 
models were adjusted for age, gender, current smoking, blood cell counts (monocytes, 
granulocytes, lymphocytes) as fixed effects and technical covariates as random effects. 
Models were further adjusted for covariates per group as follows: i) for Anthropometric 
traits we adjusted WC and WHR for BMI, ii) for Glycemic traits we adjusted for BMI and 
diabetic medication, iii) for Lipid traits we adjusted for BMI and lipid medication, and 
iv) for Cardiovascular traits we adjusted for BMI, blood pressure lowering medication 
and lipid medication. A candidate-based approach was used to sought overlap between 
identified miRNAs. A nominal p-value of <0.05 was found to be significant.  
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Determination of miR-eQTMs 
To identify association between the methylation level of CpGs and the expression of 
miRNAs (miR-eQTMs), we used miR-eQTM data from a recent study 13. The latter 
study analyzed associations of expression levels of 283 miRNAs with methylation of 
CpGs from 3,565 individuals, in which they identified 227 miR-eQTMs at FDR<0.01. 
We tested if any of the cardiometabolic-associated CpGs in the current study was 
among the identified miR-eQTM 13. 
MiRNA expression profiling in the Rotterdam Study
We performed miRNA expression analysis in 2,000 RS participants, including a 
random subset (n=1,000) of the fourth visit of RS-I (RS-I-4) and a random subset 
(n=1,000) of the second visit of RS-II (RS-II-2). Plasma miRNA levels were determined 
using the HTG EdgeSeq miRNA Whole Transcriptome Assay (WTA), which measures 
the expression of 2,083 mature human miRNAs (HTG Molecular Diagnostics, Tuscon, 
AZ, USA) and using the Illumina NextSeq 500 sequencer (Illumina, San Diego, 
CA, USA). The WTA characterizes miRNA expression patterns, and measures the 
expression of 13 housekeeping genes, that allows flexibility in data normalization 
and analysis. Quantification of miRNA expression was based on counts per million 
(CPM). Log2 transformation of CPM was used as standardization and adjustment for 
total reads within each sample. MiRNAs with Log2 CPM <1.0 were indicated as not 
expressed in the samples. The lower limit of quantification (LLOQ) was used to select 
well-expressed miRNAs. The LLOQ level was based on a monotonic decreasing spline 
curve fit between the means and standard deviations of all miRNAs. In our definition 
well-expressed miRNA levels in plasma were those with >50% values above LLOQ. Out 
of the 2,083 measured miRNAs, 591 miRNAs were expressed at good levels in plasma. 
The miRNAs significantly associated with cardiometabolic traits, in the genetic 
association studies, were tested for the association of their plasma expression levels 
with the same cardiometabolic trait(s). Linear models were used to test the association 
between available continuous traits in the RS (incl. BMI, WC, WHR, FG, HDL, TC, SBD 
and DBP) and miRNA expression. Additionally, we used binomial models to test the 
association between disease prevalence (incl. T2D and CHD) and miRNA expression. 
We used the cardiometabolic traits as dependent variable and plasma miRNAs level 
as explanatory variable, adjusting for age, gender and current smoking. Models were 
further adjusted for covariates per group as follows: i) for Anthropometric traits 
we adjusted WC and WHR for BMI, ii) for Glycemic traits we adjusted for BMI and 
diabetic medication, iii) for Lipid traits we adjusted for BMI and lipid medication, and 
iv) for Cardiovascular traits we adjusted for BMI, blood pressure lowering medication 
and lipid medication. A candidate-based approach was used to sought overlap between 
identified miRNAs. A nominal p-value of <0.05 was found to be significant.
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In addition, we extracted strongly validated target genes, defined as being validated 
by western blot and/or luciferase reporter assay, of the identified miRNAs from the 
miRTarBase database 33. Next, we extracted SNPs in these target genes and tested 
their associations with cardiometabolic traits using summary statistics of previously 
mentioned GWAS data.
Results
Association of miRNA-SNPs with cardiometabolic traits and diseases 
Out of 23,990 miRNA-related SNPs, 2,358 independent SNPs were present in the 
GWAS data based on HapMap and 8,652 independent SNPs were present in the 
1000G project. Bonferroni correction was used to set the significance threshold, at 
p-value <2.12×10-5 (0.05/2,358) for GWAS with HapMap imputed data and p-value 
<5.78×10-6 (0.05/8,652) for GWAS with 1000 Genomes project imputed data. Of these, 
180 SNPs annotated to 67 miRNAs passed the significance threshold to be associated 
with at least one cardiometabolic trait (Table 6.1). Out of the 180 identified SNPs, 
89 SNPs were located in +/-2kb of 57 primary miRNA transcripts (Supplementary 
Table 6.3) and 92 SNPs were among the previously reported miR-eQTLs of 15 mature 
miRNAs (Supplementary Table 6.4). Manhattan plots illustrated in Figure 6.2 
present the miRNA-annotated genetic variants associated with lipid traits and the 
prevalence of T2D and CHD. Table 6.2 shows the top miRNA-related SNPs associated 
with cardiometabolic traits, which were annotated to 20 miRNAs.
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Figure 6.2. Manhattan plots showing the association of miRNA-SNPs with T2D, CAD and lipid 
traits. The association miRNA-related SNPs and cardiometabolic traits were examined using the publicly 
available GWAS data. We reported the most significantly associated miRNA of each SNP loci. The horizontal 
red line indicates the study significance threshold. (A) Manhattan plot showing the association of miRNA-
SNPs with T2D in which 12 SNPs in 8 miRNAs passed the significant threshold. (B) Manhattan plot showing 
the association of miRNA-SNPs with CAD in which 13 SNPs in 9 miRNAs passed the significance threshold. 
(C) Manhattan plot showing the association of miRNA-SNPs with lipid traits in which 107 SNPs in 36 miRNAs 
passed the significant threshold. When SNPs were present in more traits, the most associated SNP was plotted.
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Table 6.1. Description of GWAS of cardiometabolic traits and associated miRNA SNPs









Body-mass index GIANT48 9 0 9 7
Waist to hip ratio GIANT49 2 1 1 4
Waist circumference GIANT49 10 0 1 8
 
Glycemic traits
Glucose fasting MAGIC50 3 0 1 4
Glucose after 2h MAGIC51 0 0 0 0
Insulin fasting MAGIC50 1 0 2 2
Proinsulin MAGIC52 3 0 4 3
HbA1c MAGIC53 1 0 15 4
HOMA-IR MAGIC54 0 0 0 0
HOMA-β MAGIC54 0 0 0 0
Type 2 diabetes DIAGRAM55 12 0 1 8
 
Lipid traits
LDL GLGC56 22 1 20 11
HDL GLGC56 12 1 23 9
Total cholesterol GLGC56 26 1 40 13





10 0 2 4
DBP ICBP58 3 0 - 2
SBP ICBP58 2 0 - 2
Shown are SNPs located within +/-2kb of primary miRNA transcripts, pre- and mature miRNA sequences, 
miRNA-eQTL SNPs). 
* Number of SNPs that passed the significance threshold (p-value <2.12x10-5 for SNPs imputed with HapMap 
and p-value <5.78x10-6 for SNPs imputed with 1000G)
† Number of independent loci.
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In order to prioritize miRNA-related SNPs based on potential functionality in relation 
to the associated cardiometabolic traits, we created regional association plots to 
visualize the LD of miRNA SNP with the top SNP in the corresponding locus (Figure 
6.3). We found three top SNPs in their loci, including rs7117842 associated with TC 
(p=2.48×10-15, β=0.029) and located ~512kb upstream of miR-100-5p/miR-125b-5p 
(Figure 6.3A), rs1997243 associated with TC (p=2.72×10-10, β=0.033) and located 
~21kB upstream of miR-339-3p (Figure 6.3B), and rs7607369 associated with BMI 
(p=1.10×10-7, β=-0.016) and located ~11.7kb upstream of miR-26b-5p (Figure 6.3C). 
These three SNPs were previously identified as miR-eQTLs that change the expression 
levels of related miRNAs in blood 21. In addition, rs4722551 located ~2kb upstream of 
miR-148a shows the strongest association with LDL (p=3.95×10-14, β=0.039) on the 
Chr7p15.2 locus (Figure 6.3D).
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shown in the legend. Genes are illustrated below. The associated miRNA is illustrated with a red box. (A) 
Regional plot showing the association of rs7117842 located ~512kb upstream of miR-100-5p/125b-5p with TC, 
LDL and HDL on the Chr11q24.1 locus. (B) Regional plot showing the association of rs1997243 located ~21kB 
upstream of the primary transcript of miR-339-3p with TC and HDL on the Chr7p22.3 locus. (C) Regional 
plot showing the association of rs7607369 located ~11.7kb upstream of the primary transcript of miR-26b-5p 
with BMI and TG on the Chr2q35 locus. (D) Regional plot showing the association of rs472551 located ~2kb 
upstream of the primary transcript of miR-148a with LDL, TG and TC on the Chr7p15.2 locus.
Moreover, rs174561 has previously been reported by 22 to change the expression of 
miR-1908-5p. We found this SNP, located in the coding sequence of miR-1908-5p, 
to be associated with lipid traits (LDL, HDL,TC and TG), and rs11614913, located in 
the coding sequence of miR-196a2-3p, to be associated with WHR. These two variants 
have previously been reported to be associated with lipid traits and WHR and have 
been suggested to change the miRNA structure and expression 34. We also found a 
suggestive association between rs58834075, located in the pre-miR-656 sequence 
(T>C, Chr14:101066756) and T2D (p=6.30×10-5, β= -0.170). The miRNA secondary 
structure and free energy changes of both wild-type and mutant alleles of these three 
SNPs (rs174561, rs11614913 and rs58834075) are illustrated in Supplementary 
Figure 6.1. 
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Identification of methylation quantitative trait loci (me-QTLs)
We identified 29 cis-me-QTL effects for 47 independent CpGs at FDR< 0.05 (49 SNP-
CpG pairs). Among these, we found 14 cis-me-QTLs that were associated with both the 
expression level of 8 miRNAs and the methylation level of 26 CpGs (Supplementary 
Table 6.5). In total there were 7 cis-me-QTLs (for 8 CpGs) that were associated with 
a cardiometabolic trait in the current study (Table 6.3). Furthermore, 4 trans-me-
QTL effects for 21 independent CpGs were found at FDR<0.05 (27 SNP-CpG pairs) 
(Supplementary Table 6.5). Two out of the four trans-me-QTL were miR-
eQTL SNPs (rs174548 for miR-1908-5p and rs1997243 for miR-339-3p). None of 
the associated CpGs in trans were found in the current study to be associated with 
cardiometabolic traits. 
Table 6.3. Identified me-QTLs with cardiometabolic-associated CpGs











miR-611 rs174538 cg16150798 Cis - FG, LDL, HDL, TG, TC WC
miR-588 rs9388486 cg20229609 Cis - T2D SBP, DBP
miR-1908-5p rs174548 cg03921599 Cis √ FG, HbA1c, LDL, 
HDL, TG, TC
LDL, TC
miR-199a-1 rs3786719 cg02907064 Cis - LDL, TC LDL
miR-6745 rs901750 cg00724111 Cis - HDL FI, SBP, DBP
miR-8073 rs3809346 cg22382805 Cis - CAD FI
miR-653, 
miR-489
rs2528521 cg06934092 Cis - BMI FG, FI, TC
miR-8073 rs3809346 cg19700260 Cis - CAD DBP
Shown are 7 me-QTLs associated with methylation levels of 8 cardiometabolic-associated CpG sites. 
* miR-eQTL SNP is associated to change the expression of miRNA level  
† SNP and CpG are located not further away than 250kb 
165
Multi-omics analysis reveals microRNAs associated with cardiometabolic traits 
6
Testing DNA methylation and expression of miRNAs 
associated with cardiometabolic traits  
To access the relationship between miRNAs and cardiometabolic traits in other 
omics layers, we performed a candidate-based test to check whether the 67 identified 
miRNAs, with SNPs associated with cardiometabolic traits, show also association 
between DNA methylation and miRNA expression with cardiometabolic traits. 
Using DNA methylation data from 1,438 RS participants, we found 278 CpG sites 
annotated to 64 out of the 67 miRNAs, to be associated with any cardiometabolic 
trait (Supplementary Table 6.6). By integrating our DNA methylation results with 
the GWAS data, we observed an overlap of 38 miRNAs (79 CpGs) that had both a 
SNP and a CpG associated with the same trait (Supplementary Table 6.7). The 
CpG site showing the most significant association was cg15616915 which is located in 
the regulatory region of miR-26b and is positively associated with TG (p=1.59×10-4 
, β=0.009). We found 16 cardiometabolic-associated CpGs that are annotated to 
more than one miRNA. For example, cg03722243 associated with BMI (p=1.55×10-3, 
β=0.001) is annotated to miR-489 and miR-653, which are clustered on chromosome 
7. In addition, cg15334028 associated with WC, HDL, LDL and TG is annotated to 
three miRNAs (miR-638, miR-6793 and miR-4748) on chromosome 19. 
We identified two CpGs that are associated with the expression level of miRNAs (miR-
eQTM) at FDR<0.01. The most significant cis-miR-eQTM, cg26363555 has been reported 
to be negatively associated with both miR-125b-5p (~2kb downstream) and miR-100-5p 
(~50kb upstream) expression levels 13. The CpG cg26363555 was positively associated 
with FG (β=0.012) and DBP (β=2.00x10-4) and negatively associated with HDL (β=-
0.004) in the RS. In addition, cg03891346 has been reported to be negatively associated 
with the expression level of miR-100-5p (~53kb downstream) 13. This CpG, which is also 
annotated to MIR125B1, was positively associated with WC (β=5.00x10-4) in the RS. 
Next, we tested whether the 67 identified miRNAs show differential expression in 
plasma in relation to the associated cardiometabolic trait(s). Of the 67 miRNAs, we 
could only test the association of 28 mature miRNAs that were well-expressed in 
plasma and of which the phenotype of interest was available in the RS. Of these, plasma 
levels of 22 miRNAs were nominally associated with at least one cardiometabolic 
traits (Supplementary Table 6.8). Furthermore, out of the 67 miRNAs, we found 
12 differently expressed mature miRNAs to be associated with the same trait (Table 
6.4). Plasma levels of miR-126-3p, miR-126-5p, miR-10b-5p, miR-148a-3p, miR-
199a-1-3p, miR-199a-1-5p, miR-125b-5p and miR-100-5p were positively associated 
with serum TC levels. In contrast, miR-6886 was negatively associated with serum 
TC levels. A negative association between miR-126-5p and miR-126-3p and CHD was 
found. Furthermore, we observed a negative association between miR-4681 levels and 
WC. An overview of the number of associated miRNAs using different omics data is 
illustrated in Figure 6.4. 
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Table 6.4. Plasma expression levels of miRNAs associated with cardiometabolic traits 
miRNA β-coefficient P value Associated trait
miR-126-3p 0.379 1.09x10-14 TC†
miR-10b-5p 0.352 3.30x10-11 TC†
miR-126-5p 0.258 3.75x10-11 TC†
miR-148a-3p 0.189 8.01x10-06 TC†
miR-199a-1-3p 0.171 3.38x10-05 TC†
miR-125b-5p 0.159 2.43x10-03 TC†
miR-100-5p 0.141 3.15x10-03 TC†
miR-6886-3p -0.083 9.49x10-03 TC†
miR-126-5p -0.365 1.24x10-02 CHD‡
miR-4681 -0.440 2.13x10-02 WC*
miR-199a-1-5p 0.074 3.38x10-02 TC†
miR-126-3p -0.385 3.54x10-02 CHD‡
Model 1: adjusted for: age, gender, current smoking   
* Model 1 + BMI  
† Model 1 + BMI, lipid medication  
‡ Model 1 + BMI, blood pressure lowering medication, lipid medication
Figure 6.4. Overview of miRNAs associated with cardiometabolic traits by integrating three 
omics layers.     
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Furthermore, out of 22 miRNAs that were associated with at least one cardiometabolic 
trait, we found validated target genes for 14 miRNAs. We tested the association 
between these target genes and cardiometabolic traits using summary statistics GWAS 
data. After correcting for multiple testing, based on the number of tested SNPs in the 
target genes of a miRNA, we found 24 unique target genes for 9 of the 14 miRNAs to be 
associated with cardiometabolic traits (Supplementary Table 6.9). 
Finally, we sought overlapping miRNAs that were associated with the same 
cardiometabolic trait in the three different omics analyses (Supplementary Table 
6.10). Since not all related phenotypes were available within the RS and not all miRNAs 
were expressed, we tested 64 miRNAs that had DNA methylation sites and 22 mature 
miRNAs that were available for miRNA expression analyses using the RS. We found 
five miRNAs, including miR-10b-5p, miR-148a-3p, miR-100-5p, miR-125b-5p and 
miR-6886 that had at least one CpG and of which the expression was also associated 
with the same cardiometabolic trait. After prioritization based on the suggested criteria 
for potential functionality, miR-10b-5p, miR-148a-3p, miR-125b-5p and miR-100-5p 
were highlighted as the most likely miRNAs involved in the pathogenesis of risk factors 
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Discussion
In this study, we integrated different population-based omics data (including 
genetics, epigenetics and miRNA expression) to identify miRNAs associated with 
cardiometabolic traits. Genetic variants related to 67 miRNAs were associated with the 
studied traits. Alterations in DNA methylation of CpG sites annotated to 38 of these 
miRNAs and plasma expression levels of 8 of them were also associated with the same 
trait. In principle, the association between a miRNA and trait of interest in more than 
two layers of omics may strengthen its potential to play a role in the disease underlying 
mechanisms. In this context, we sought to identify overlap between miRNAs that 
were associated with the same cardiometabolic trait across different approaches. This 
integration analysis revealed the correlation between four miRNAs (miR-10b-5p, miR-
148a-3p, miR-125b-5p and miR-100-5p) and lipid traits. 
MiR-10b-5p is a highly conserved miRNA across multiple species and is located 
inside the homeobox D cluster on chromosome 2. A recent study showed a mediating 
role for miR-10b between obesity and primary breast cancer 35. Moreover, previous 
research in mice found a negative regulatory role of miR-10b on cholesterol efflux via 
targeting the ATP binding cassette transporter gene (ABCA1) 36. MiR-10b has been also 
shown to be involved in the progression of atherosclerosis, which is a major cause of 
cardiovascular disease 37. We found a genetic variant (rs532436;A>G) annotated to the 
Alpha 1-3-N-acetylgalactosaminyltransferase (ABO) gene to be positively associated 
with LDL, TC, CAD and T2D. The ABO gene has been linked to cholesterol absorption 
and cardiovascular disease 38. Rs532436, located on chromosome 9, has been reported 
as trans-miR-eQTL for miR-10b-5p 22. In this study, we further showed that a CpG site 
(cg25820279) annotated to Homeobox D3 (HOXD3), is located in the regulatory region of 
miR-10b and is associated with total cholesterol levels in serum. In addition, the expression 
level of miR-10b-5p in plasma showed a positive association with total cholesterol levels, 
which further support the crucial role of miR-10b-5p in lipid metabolism.
MiR-148a-3p has been shown to control the LDL uptake and cholesterol efflux through 
affecting the expression of low-density lipoprotein receptor (LDLR) 39. Moreover, in 
vivo studies in mouse models have confirmed that miR-148a-3p is upregulated in 
adipogenesis and highly expressed in liver tissue 40. We found rs4722551, located 
~2kb upstream of miR-148a, associated with LDL, TC and TG. It has been suggested 
previously that a large part of regulatory elements such as promoter regions are 
located within +/-2kb of pre-miRNAs 17. Rs4722551 has previously been reported to 
be positively associated with serum lipid levels via cis-miR-eQTL in liver tissue 41. Our 
findings may shed light on the mechanism that associates the rs4722551 risk allele 
(T>C) with an increased miR-148a-3p expression, which is subsequently associated 
with higher serum cholesterol levels. Furthermore, our results showed a CpG site 
(cg18188200) in the regulatory region of miR-148a to be associated with LDL, TC 
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and TG and demonstrated that the plasma expression level of miR-148a-3p is also 
associated with total serum cholesterol levels. These data are in line with the findings 
from previous studies reporting a functional role for miR-148a-3p in lipid metabolism 
confirmed by various in vivo and in vitro validation experiments 39, 41. 
We found strong associations of rs7117842, located ~512kb upstream of miR-100-
5p/125b-5p, with TC, LDL and HDL, suggesting these two miRNAs to play a role in 
lipid metabolism. The SNP has been previously shown to be negatively associated 
with the expression levels of miR-100-5p and miR-125b-5p in blood 21. In our 
analysis, plasma expression levels of miR-100-5p and miR-125b-5p are positively 
associated with TC. These findings could be interpreted in a way that carrying the 
risk allele of rs7117842 (T>C) is associated with decreased expression of miR-100-
5p/125b-5p, which is associated with a reduced increase of total serum cholesterol 
levels. In addition, cg26363555, located in the promoter region of miR-125b-5p, was 
previously reported to act as miR-eQTM by changing the expression levels of both 
miR-100-5p and miR-125b-5p 13. We found cg26363555 associated with HDL in the 
RS. In addition, cg03891346 annotated to MIR125B1 was reported to be associated 
with the expression level of miR-100-5p 13. Our DNA methylation analysis results 
showed the association between cg03891346 and waist circumference in the RS. Our 
findings are partly in line with previous research investigating the role of miR-125b-
5p on adipogenesis where it is observed that miR-125b-5p downregulates the anti-
adipogenic gene MMP11 in human, indicating that miR-125b-5p via MMP11 positively 
regulate adipogenesis 42. Conversely, the same study demonstrated a direct effect of 
reduction in fat accumulation through overexpression of miR-125b-5p 42. In addition 
to the role of miR-125b-5p on lipid metabolism in human, its regulatory role has been 
investigated in other organisms including zebrafish and mice. Over-expression of miR-
125b in zebrafish is linked to lipid metabolism in brain, heart and liver tissue 43. This 
study observed that overexpression of miR-125b inhibits osteoblastic differentiation 
and promotes fat synthesis. Moreover, the expression of miR-125b is activated by 
estrogen via ERα in vitro and in vivo in mice, in which they demonstrated that miR-
125b can limit fat accumulation in liver tissue 44. These contradictory findings may 
implicate that miR-125b-5p plays an important role in lipid metabolism via a complex 
molecular cascade. However, the role of miR-100-5p in regard to lipid metabolism and 
cardiovascular disease yet to be further investigated. Since miR-100-5p and miR-125b-
5p are located in the same locus on chromosome 11, it could be possible that miR-125b-
5p is the driving miRNA in relation to the associated lipid traits. Future research is 
warranted to confirm the regulatory role of miR-100-5p in lipid metabolism. 
The main strengths of this study include the use of robust data from the large-
scale GWAS studies and multi-omics implementation of a large sample size in the 
Rotterdam Study, which indicates with more confidence that miRNAs are involved 
in the pathophysiology of cardiometabolic diseases. Our study, however, does not 
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come without limitations. First, our study design is based on associations rather than 
causations, therefore this approach does not prove that the identified miRNAs play 
a causal role in the studied traits. To test for causal inferences between miRNAs and 
disease risk, future studies should test mediating effects and incorporate functional 
follow-up experiments. Furthermore, our study design was based on a cross-sectional 
approach, which means that individuals included in this study were not free of CHD 
or T2D. In regard to test whether the identified miRNAs are associated with the risk of 
developing disease, future longitudinal studies are warranted. Another limited factor 
is that we were unable to link all identified miRNAs with epigenetic and expression 
analyses in the RS, since not all phenotypic data were available for each trait of interest 
nor were all miRNAs well-expressed in plasma. In addition, different sub cohorts of 
the RS were used for DNA methylation and miRNA expression analysis due to the 
availability of data. DNA methylation and miRNA signatures are dynamic over 
time and could have yield in confounding results. The challenge of this multi-omics 
approach includes the intra-individual variation and thereby lack of generalizability 
between datasets. However, the sub cohorts of RS-II and RS-III are extensions of the 
RS-I cohort. Previous epigenetic (DNA methylation) studies using the RS data showed 
that the results are replicated after additional adjustment for sub cohort 45-47. This may 
indicate that the intra-individual differences between variables in these RS sub cohorts 
have not significantly affected by exposing to different environmental factors. Yet in 
an optimal setting one should apply the multi-omics analysis in the same individuals 
and the same timeframe. Furthermore, we used whole blood to determine DNA 
methylation and plasma to check expression levels of miRNAs, which are not the most 
relevant tissue for cardiometabolic traits. This could have resulted in overlooking some 
of the miRNAs, but the found associations are comparable because both analyses were 
performed in the same tissue. In an optimal setting one should examine the observed 
associations using next-generation sequencing covering all miRNAs in target tissues 
(e.g. adipose tissue, heart, pancreas and liver). Such infrastructure is not yet available 
in large epidemiologic studies with validated clinical data. However, for the use of 
miRNAs as targets for early diagnosis or progression of T2D and CHD, blood might be 
a very good test tissue since it is a non-invasive method for biomarker measurements in 
clinical diagnosis. In addition, regarding potential missed cardiometabolic-associated 
SNPs, our study could have benefited from denser genotyping methods including 1000 




In this study, we systematically examined the association of miRNAs with 
cardiometabolic risk factors and diseases using population-based genetic, DNA 
methylation and miRNA expression data. By integrating these omics data we found 
several cardiometabolic- associated miRNAs, such as miR-10b-5p, miR-148a-3p, miR-
125b-5p and miR-100-5p involved in lipid metabolism, that can be viewed as potential 
biomarkers for early diagnosis or progression of T2D and CHD. Future experimental 
studies are warranted to elucidate pathways underlying the link between these miRNAs 
and cardiometabolic risk factors such as dyslipidemia, central adiposity and elevated 
blood glucose levels. 
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Supplementary Figure 6.1. Predicted secondary structure of miRNA wild type and variant. 
Location of the SNP is demonstrated by an arrow. The red part shows the mature sequence and the blue 
part shows the rest of the pre-miR. The corresponding minimum free energy (MFE) is illustrated with the 
thermodynamic ensemble ΔG. A, Secondary structure of miR- 196a2-3p wildtype and variant (rs11614913) 
located in mature miRNA sequence. MFE changes by -4.6kcal/mol. B, Secondary structure of miR-656 
wildtype and variant (rs58834075) located in precursor miRNA sequence. MFE changes by -0.6kcal/mol. C, 
Secondary structure of miR-1908-5p wildtype and variant (rs174561) located in precursor miRNA sequence. 
MFE changes by +3.2kcal/mol.
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Supplementary Table 6.2. Participant characteristics of the Rotterdam Study for DNA 








 (RS-II-3 & RS-
III-2)
 (RS-III-1)  (RS-I-4 &  
RS-II-2)
N 717 721 1999
Female 413 (57.6%) 391 (54.2%) 1141 (57.1%) <0.001
Age (years) 67.5 (5.93) 59.8 (8.16) 71.6 (7.58) <0.001
BMI (kg/m2) 27.7 (4.12) 27.6 (4.63) 27.7 (4.11)
Waist circumference 94.4 (12.00) 93.75 (12.92) 93.6 (11.98)
WHR  0.9 (0.09) 0.9 (0.08) 0.9 (0.09)
Current smoking (yes) 76 (10.6%) 193 (26.8%) 288 (14.4%)
Triglycerides (mmol/L) 1.5 (0.79) 1.5 (0.88) NA
HDL-cholesterol (mmol/L) 1.5 (0.44) 1.4 (0.41) 1.4 (0.39) <0.001
LDL-cholesterol (mmol/L) 3.7 (0.94) 3.9 (1.00) NA <0.001
Total cholesterol (mmol/L) 5.5 (1.02) 5.6 (1.07) 5.6 (0.99) 0.004
Lipid lowering medication (yes) 225 (31.4%) 191 (26.5%) 450 (22.5%) <0.001
Systolic blood pressure 144.8 (21.91) 134.2 (19.76) 148.2 (20.82)
Diastolic blood pressure 84.4 (11.66) 82.8 (11.38) 79.6 (10.84)
Coronary heart disease 28 (3.9%) 46 (6.4%) 214 (10.7%) <0.001
Anti-hypertensive medication 
(yes)
310 (43.2%) 217 (30.1%) 880 (44.0%) <0.001
Glucose (mmol/L) 5.7 (1.11) 5.6 (1.04) 5.8 (1.09) 0.001
Insulin (pmol/L) 82.6 (48.26) 96.0 (63.04) NA <0.001
Prevalence type 2 diabetes 96 (13.4%) 74 (10.3%) 278 (13.9%) 0.04
Anti-diabetic medication 59 (8.2%) 39 (5.4%) 132 (6.6%)
Values are presented as mean ±(SD) or N (%).  
*Differences between groups were addressed using ANOVA in the case variables were available among three 
groups, Student’s T-tests in the case variables were available in two groups. 
NA: Not  Available
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Background: MicroRNAs (miRNAs) are post-transcriptionally regulators of gene 
expression that can be released extracellularly upon pathophysiological processes. By 
complementary binding of target transcripts, miRNAs can modulate the expression 
of an abundance of genes. Increasing evidence recognize miRNAs as promising 
biomarkers for complex traits, including cardiovascular disease and stroke. We 
conducted a longitudinal study to determine the association between circulatory 
miRNAs and incident stroke in a population-based setting. 
Methods: Next-generation sequencing was used to measure expression levels of 2,083 
miRNAs in plasma samples, collected between 2002 and 2005, from 1,914 stroke-
free participants of the Rotterdam Study. Participants were assessed for incident 
stroke through continuous monitoring of medical records until January 1st 2016. 
Cox proportional hazards regression models adjusted for age, sex and vascular risk 
factors were used to investigate the association between the levels of 591 miRNAs well-
expressed in plasma and incident stroke. Furthermore, stroke-subtype analysis was 
performed to assess the link between identified miRNAs and ischemic, hemorrhagic 
and unspecified stroke. Subsequently, post-hoc analyses were conducted to gain 
insight into the association between putative target genes of miRNAs and stroke. 
Findings: Of 1,914 participants (mean age 71.5 years±7.6; 57.7% women), 138 
were diagnosed with incident stroke during a mean follow-up of 9.7±3.2 years. After 
adjusting for potential confounders, we found plasma levels of three miRNAs to be 
associated with incident stroke (false discovery rate-adjusted P-value<0.05). These 
include miR-6124 (hazard ratio (HR) 1.66, 95%CI 1.31-2.09), miR-5196-5p (HR 1.90, 
95%CI 1.39-2.61) and miR-4292 (HR 2.65, 95%CI 1.62-4.34). In-silico analysis of the 
miRNA putative target genes showed associations of variants in several target genes 
with stroke. 
Interpretation: This study indicates that plasma levels of three miRNAs are 
associated with the risk of stroke, proposing them as potential biomarkers for early 
detecting of the disease. 
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Introduction 
Although environmental and vascular risk factors are well-known to be involved in the 
pathology of stroke, genetic factors also contribute to the risk of developing ischemic 
and hemorrhagic stroke 1-5. It has been previously shown that not only coding genes, in 
particular loci such as 12q24.2 and ABO, account for a proportion of the heritable risk, 
but also non-coding regions of the genome, such as microRNAs (miRNAs), can play a 
role in the pathophysiology of stroke 6. A better understanding of the role of miRNAs in 
the development of stroke and their potential as biomarkers in the diagnosis of disease 
could lead to early detection of individuals with high risk profiles.
MiRNAs are small RNA molecules of approximately 22 nucleotides that regulate 
post-transcriptionally gene expression through complementary binding of target 
transcripts. They can potentially target hundreds-to thousands genes and are involved 
in various molecular pathways 7. In addition to their ability to modulate cellular 
processes in both disease and non-disease states, miRNAs are released from cells into 
body fluids, such as plasma 8. These circulatory miRNAs are very stable in plasma, 
due to their packaging into membranous vesicles including exosomes, and are thereby 
potentially clinically relevant as biomarkers for diseases 9. Previous studies have linked 
changes in plasma miRNA levels with cardiovascular disease and stroke 10-16. Most of 
the stroke-associated miRNAs have been identified cross-sectionally in patient cohorts 
with acute-stroke, leaving it uncertain whether the identified miRNAs are related to 
the risk of developing stroke. Prospective cohorts could overcome this limitation. 
Indeed, a recent longitudinal study with a modest sample size (n=51 cases) found the 
association between plasma levels of miR-656-3p and miR-941 and incident stroke 
with a mean follow-up time of 2.5±1.6 years 17. However, longitudinal studies with a 
relatively long follow-up period are limited. In the current study, we determined the 
association between circulatory miRNAs and the risk of all stroke and its subtypes in a 
prospective-population based study with almost 10 years follow-up. Subsequently, we 
performed post-hoc analyses of the miRNA putative target genes to gain insight into 





This study was conducted within the Rotterdam Study, a large prospective population-
based cohort among participants aged ≥45 years in the suburb Ommoord in Rotterdam, 
the Netherlands. In 1990, 7,983 inhabitants aged 55 years or older were recruited to 
participate in the first cohort of the Rotterdam Study (RS-I) (78% response rate of 
10,215 invitees). In 2000, the Rotterdam Study was extended by 3,011 participants 
that moved to Ommoord or turned 55 years old (RS-II). A detailed description of the 
Rotterdam Study can be found elsewhere 18. In the current study, miRNA expression 
profiling (n=2,000) was performed in a random subset (n=1,000) of the fourth visit of 
RS-I (RS-I-4) and a random subset (n=1,000) of the second visit of RS-II (RS-II-2). 
These visits of the Rotterdam Study were performed between 2002 and 2005, and 
with follow-up visits every 4-5 years. From 2,000 participants with miRNA data, we 
excluded participants with prevalent stroke (n=83) and individuals with no informed 
consent for follow-up (n=2). Furthermore, one participant was excluded because of 
missing data for all miRNAs. For more information regarding the inclusion criteria, 
see Figure 7.1. 
Figure 7.1. Flowchart of the study participants. RS, Rotterdam Study.
185
Circulatory microRNAs as potential biomarkers for stroke risk 
7
Informed Consent and Ethics Approval
The Rotterdam Study has been approved by the medical ethics committee at the 
Erasmus University of Rotterdam and the Ministry of Health, Welfare and Sport of 
the Netherlands. The study is implemented in the Population Studies Act: Rotterdam 
Study (Wet Bevolkingsonderzoek ERGO). All participants included in the current 
study provided written informed consent for participation and for researchers to 
access medical information from their personal physicians. 
Measurements on circulatory miRNAs 
Blood samples were collected in EDTA treated containers and centrifuged. Plasma was 
then aliquoted and frozen at -80°C according to standard procedures. Subsequently, 
plasma miRNA levels were determined using the HTG EdgeSeq miRNA Whole 
Transcriptome Assay, which measures the expression of 2,083 mature human 
miRNAs (HTG Molecular Diagnostics, Tuscon, AZ, USA) and using the Illumina 
NextSeq 500 sequencer (Illumina, San Diego, CA, USA). The Whole Transcriptome 
Assay characterizes miRNA expression patterns and measures the expression of 
13 housekeeping genes, allowing flexibility in data normalization and analysis. 
Quantification of miRNA expression was based on counts per million (CPM). Log2 
transformation of CPM was used as standardization and adjusted for total reads 
within each sample. The lower limit of quantification (LLOQ) was used to select well-
expressed miRNAs. The LLOQ level was based on a monotonic decreasing spline curve 
fit between the means and standard deviations of all miRNAs. In our definition well-
expressed miRNA levels in plasma were those with >50% values above LLOQ. This 
includes a set of 591 miRNAs that were used for association analysis. 
Assessment of stroke 
Stroke was defined according to the World Health Organization definition as a 
syndrome of rapidly developing clinical signs of focal or global disturbance of cerebral 
function, with symptoms lasting 24 hours or longer or leading to death, with no 
apparent cause other than of vascular origin 19, 20. We assessed the prevalence of stroke 
at baseline during interview and verified it using medical records. After enrollment, 
participants were continuously monitored for incident stroke by linking the study 
database to files of general practitioners. Records of nursing homes and records from 
general practitioners of the participants who moved out of the study district were also 
checked. Additional information, such as clinical notes and neuroimaging reports, 
were obtained from hospital records. 
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Stroke patients were further classified as ischemic or hemorrhagic based on 
neuroimaging reports. If neuroimaging was lacking, a stroke was classified as 
unspecified. This classification corresponds with ICD-10 codes I61, I63 and I64. 
Potential stroke patients were reviewed by research physicians and verified in a 
consensus panel led by an experienced stroke neurologist. 
The follow-up for incident stroke was conducted until January 1st, 2016. Participants 
were followed from study entry until stroke, death, last health status update when they 
were known to be stroke-free, or January 1st, 2016, whichever came first. Follow-up 
was complete for 92.9% of potential person-years.
Assessment on covariates
Information on age, sex and smoking status (current/former/never) was obtained 
from questionnaires. Body-mass index (BMI) was calculated based on weight in 
kilograms divided by the height in meters squared. Blood samples of participants were 
obtained during the visit to the research center. Using automatic enzymatic method, 
levels of high-density lipoprotein (HDL) and total cholesterol were measured in serum 
(mmol/L). Systolic and diastolic blood pressure were measured (mm Hg) in a seating 
position after a 5 minute rest period on the right upper arm of the participant using a 
random-zero sphygmomanometer. Prevalent diabetes mellitus type 2 was identified 
according to the World Health Organization criteria: fasting glucose levels of ≥7.0 
mmol/L, non-fasting glucose levels ≥11.1 mmol/L, or the use of glucose lowering 
medication. Prevalent coronary heart disease was defined when the participant suffered 
a myocardial infarction or underwent a coronary artery bypass grafting or percutaneous 
coronary revascularization procedure. Prevalent atrial fibrillation was assessed using 
a 10 seconds 12-lead electrocardiogram and medical records. Information regarding 
the use of lipid lowering medication, blood pressure lowering medication and glucose 
lowering medication was obtained from pharmacy records and home interviews. All 
covariates included for statistical analysis were obtained at baseline examination. 
Statistical analysis 
We used Cox proportional hazards regression to determine hazard ratios (HR) with 
95% confidence intervals for the association between miRNA expression and stroke 
risk. Hazard ratios were reported per each additional unit of log2 CPM of miRNA 
expression. Models were adjusted for age, sex and cohort. Additionally, we adjusted for 
smoking, BMI, HDL, total cholesterol, systolic blood pressure, diastolic blood pressure, 
prevalent diabetes mellitus type 2, prevalent coronary heart disease, prevalent atrial 
fibrillation, lipid lowering medication and blood pressure lowering medication. To 
reduce the false positive results, the Benjamini-Hochberg (BH) procedure was used 
to adjust the p-values into false discovery rate (FDR) 21. In this study, a FDR-corrected 
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p-value <0.05 (5%) was set as significance threshold. Subsequently, we analyzed the 
association between the expression of the identified miRNAs and risk of ischemic, 
hemorrhagic and unspecified stroke separately. To avoid the risk of overfitting, we 
adjusted models for the association between miRNA expression and hemorrhagic and 
unspecified stroke only for age, sex and cohort. To reduce the possible bias induced by 
missing values, multiple imputation on confounders was performed based on outcome 
and included covariates for predictors of missing data. Values were imputed with a 
maximum iteration number of 10 (n=25 imputations) using the Markov Chain Monte 
Carlo method, R package “mice”. Areas under the curve (AUC) for time-dependent 
receiver operating characteristics (ROC) at 10-years were calculated for the vascular 
risk factor model (covariates included in model 2) and the vascular risk factor model 
complemented by the identified miRNAs. The AUC were calculated using the Kaplan-
Meier method, R package “survivalROC”. Furthermore, the identified miRNAs were 
categorized in ‘high- or low expressed’ based on their median expression values and 
cumulative hazard graphs were generated. Additionally, we performed a permutation 
test to check the enrichment of the identified miRNAs in the association with stroke 
compared to sets of randomly selected miRNAs. Analyses were performed using R 
version 3.6.1 (The R foundation for Statistical Computing, Vienna, Austria).
Post-hoc genetic analyses
To test whether the stroke-associated miRNAs are potentially involved in the pathways 
underlying disease, we performed in silico analysis on their putative target genes. Three 
commonly used miRNA target prediction databases, TargetScan (v7.2) 22, miRTarBase 
23 and miRDB 24, were used to retrieve putative target genes of the stroke-associated 
miRNAs. Then, we extracted single-nucleotide polymorphisms (SNPs) in these target 
genes. Moreover, we extracted SNPs located in +/-2kb of the precursor sequences of 
the associated miRNAs 25. Subsequently, we performed a look-up to test whether the 
SNPs located in target genes and in +/-2kb of the miRNA precursor sequences are 
associated with stroke by using the summary statistics of a previous genome-wide 
association study (GWAS) on stroke 3. Target genes were considered significantly 
associated with stroke based on FDR<0.1 (10%). 
Furthermore, we sought to explore whether the identified miRNAs are expressed in the 
brain, a relevant tissue for stroke. We also retrieved the miRNA host genes as proxy for 
the identified miRNAs to check their expression in the brain using the Human Protein 
Atlas (https://www.proteinatlas.org/) 26. The rationale for this analysis is that the 
genomic location of miRNAs can be discriminated among intergenic and intragenic. 
The intragenic miRNAs and their host genes may share the same promoter, and these 
miRNA are likely to be co-expressed with their host genes 27. The genomic location of 




The baseline characteristics of the 1,914 Rotterdam Study participants used for this 
study are presented in Table 7.1. The individuals that were diagnosed with incident 
stroke were on average slightly older compared to non-cases (74.6 years vs. 71.2 years). 
Table 7.1. Baseline characteristics of the Rotterdam Study participants of this study
Characteristic Incident stroke  
N=138
No incident stroke 
N=1776
P value 
Age, years 74.6 ± 7.5 71.2 ± 7.5 <0.001
Female, n(%) 76 (55.1%) 1029 (57.9%) 0.51
Body mass index, kg/m2 27.6 ± 3.4 27.6 ± 4.2 0.87
Systolic blood pressure, mmHg 156.5 ± 23.0 147.5 ± 20.6 <0.001
Diastolic blood pressure, mmHg 80.6 ± 12.2 79.4 ± 10.8 0.25
Total serum cholesterol, mmol/L 5.5 ± 1.1 5.7 ± 1.0 0.13
High-density lipoprotein, mmol/L 1.4 ± 0.4 1.5 ± 0.4 0.5
C-reactive protein, mg/L 3.9 ± 6.5 3.0 ± 6.3 0.11
Smoking 0.35
              current, n(%) 20 (14.5%) 260 (14.6%)
              former, n(%) 83 (60.1%) 966 (54.4%)
             never, n(%) 35 (25.4%) 550 (31.0%)
Prevalent diabetes mellitus type 2, n(%) 26 (18.8%) 217 (12.2%) <0.05
Prevalent coronary heart disease, n(%) 22 (15.9%) 172 (9.7%) <0.05
Prevalent atrial fibrillation, n(%) 8 (5.8%) 79 (4.4%) 0.46
Prevalent heart failure, n(%) 13 (9.4%) 77 (4.3%) <0.01
Chronic kidney disease, n(%) 3 (2.2%) 22 (1.2%) 0.34
Any Internal carotid artery plaque, n(%) 89 (64.5%) 913 (51.4%) <0.01
Any Internal carotid artery stenosis, n(%) 16 (11.6%) 89 (5.0%) <0.01
Blood pressure lowering medication, n(%) 77 (55.8%) 737 (41.5%) <0.01
Lipid lowering medication, n(%) 29 (21.0%) 385 (21.7%) 0.86
Anti-coagulant medication, n(%) 50 (36.3%) 348 (19.6%) <0.001
Anti-platelet medication, n(%) 7 (5.1%) 93 (5.2%) 0.93
Variables are presented as mean ± SD, or number (%). Missing values were imputed. Number of missing values 
for final study population: 8 (0.4%) for systolic blood pressure, 8 (0.4%) for diastolic blood pressure, 12 (0.6%) 
for blood pressure lowering medication, 12 (0.6%) for lipid lowering medication, 26 (1.4%) for coronary heart 
disease, 28 (1.5%) for smoking, 37 (1.9%) for body-mass index and 75 (3.9%) for diabetes mellitus type 2. 
Differences between incident stroke cases and non-cases were examined by T-test for continuous variables and 
Chi-square test for categorical variables.  
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During a mean follow-up of 9.7 years (± 3.2), 138 individuals were diagnosed with 
incident stroke. Of these, 96 were ischemic, 19 were hemorrhagic and 23 cases were 
unspecified. The results of the association between miRNA levels in plasma and the 
incidence of stroke are presented in Table 7.2. We found significant associations 
between the expression levels of three miRNAs and risk of stroke, miR-6124 (HR 
1.66, 95%CI 1.31-2.09, P-value= 2.00×10-5), miR-5196-5p (HR 1.90, 95%CI 1.39-2.61, 
P-value= 6.07×10-5), and miR-4292 (HR 2.65, 95%CI 1.62-4.34, P-value= 1.09×10-4). 
In total, 39 miRNAs were at least nominally associated (P-value<0.05) with incident 
stroke (Supplemental Table 7.1). The distribution of plasma expression levels of 
the three identified miRNAs in the study population are illustrated in Figure 7.2. The 
AUC for the time-dependent ROC at 10 years was 0.735 for the vascular risk factor 
model and 0.761 for the model complemented by miR-6124, miR-5196-5p and miR-
4292 (Figure 7.3). Analyses by stroke subtype showed associations of miR-6124, 
miR-5196-5p and miR-4292 with both ischemic and hemorrhagic stroke. However, 
the number of hemorrhagic cases was small (n=19), which resulted in a wide 95% 
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Figure 7.2. Scatter plots of the distribution of log2 expression values of the three identified miRNAs in the 
study participants. Stars indicate cases (incident stroke) and dots indicate non-cases.
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Figure 7.3. Time-dependent ROC curve analysis at 10 years. The lower line indicate a ROC curve of the 
vascular risk factor model with an AUC of 0.735. The upper line indicate a ROC of the vascular risk factor model 
combined with the plasma values of miR-6214, miR-5196-5p and miR-4292, with an AUC of 0.761.   
To assess the impact of relative expression of the identified miRNAs on 10-year stroke 
risk, we categorized the expression values based on the median value of each miRNA 
into two categories, including low and high. See Supplemental Table 7.2 for the 
baseline characteristics split by the median expression values of the three miRNAs. 
We found that high expression levels of miR-6124 (median normalized value >10.01) 
and miR-5196-5p (median normalized value >8.09) were also significantly associated 
with higher cumulative hazard of stroke (Figure 7.4). A combination of the high 
values of miR-6124, miR-5196-5p and miR-4292 is represented in 23.7% of the study 
participants and was associated with a higher cumulative hazard for the risk of stroke 
(P-value= 4.20×10-4). 
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Figure 7.4. Cumulative hazard curves of log2 CPM expression of the three identified miRNAs and the risk of 
incident stroke. The upper curves indicate a high expression level and the lower curves indicate a low expression 
level based on the log2 median values of individual miRNAs. P value indicates difference between the two 
curves. Y-axis indicates cumulative hazard. X-axis indicates time scale in years. A. Cumulative hazard on 
incident stroke between high and low expression levels of miR-6124. B. Cumulative hazard on incident stroke 
between high and low expression levels of miR-5196-5p. C. Cumulative hazard on incident stroke between 
high and low expression levels of miR-4292. D. Cumulative hazard on incident stroke between high and low 
expression levels of miR-6124, miR-5196-5p and miR-4292.
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Next, we retrieved the predicted target genes of miR-6124, miR-5196-5p and miR-4929 
from the online miRNA target prediction databases. We focused on the target genes 
overlapping in at least two out of the three databases. This resulted in 1,633 target 
genes for miR-6124, 821 target genes for miR-5196-5p and 384 target genes for miR-
4292. We extracted SNPs in these target genes and tested their associations with risk of 
stroke using summary statistic from a recent GWAS on stroke 3. Based on FDR<0.1, we 
found variants in 10 unique target genes to be associated with stroke (Supplemental 
Table 7.3). Among these, nine were putative target genes of miR-6124 (CASZ1, 
COL15A1, HDAC9, NRP2, RERE, SH3PXD2A, SLC4A8, STXBP5, ZFHX3), one was 
target gene of miR-5196-5p (SH3PXD2A), and three were target genes of miR-4292 
(CASZ1, FURIN, STXBP5). Furthermore, we found that rs79684932 (T>C), located 
on chromosome 19, ~15.9kb upstream of the transcription start site of miR-5196 is 
nominally associated with stroke in the GWAS data (P-value= 1.20×10-2, Beta= -0.065) 
3. This SNP was also reported to be associated with the expression of CD22, the host 
gene of miR-5196, in whole blood 29. 
Finally, we sought to explore whether the three identified miRNAs are expressed in 
the brain. We did not find any reports regarding the brain expression levels of the 
identified miRNAs in literature. Alternatively, we explored the expression in brain of 
the miRNA host genes as proxy for the identified miRNAs. Two of the three identified 
miRNAs (miR-6124 and miR-4292) were reported to be embedded within an intron of 
the protein-coding genes (MICAL2 and RABL6) in a sense orientation 28. Moreover, 
miR-5196-5p is located in the exonic region of CD22. All three host genes are expressed 
in brain tissue, of which MICAL2 has been reported to be expressed at relatively high 
levels in the brain according to the Human Protein Atlas (https://www.proteinatlas.
org/) 26. Out of the 10 stroke-associated target genes, expression levels of 8 genes were 
detected in the brain (HDAC9, FURIN, NRP2, RERE, SH3PXD2A, SLC4A8, STXBP5, 
ZFHX3), of which SLC4A8 has been reported to be expressed at relatively high levels 
in the brain 26. 
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Discussion 
In this longitudinal study, we found that higher plasma levels of three miRNAs (miR-
6124, miR-5196-5p and miR-4292) were significantly associated with stroke risk at the 
population level, suggesting them as potential plasma biomarkers for the disease. In 
addition, we identified several putative target genes of these miRNAs to be associated with 
stroke using GWAS data. These observations may suggest that the identified miRNAs are 
also involved in the pathophysiology of stroke that warrant further investigations. 
The findings of this study that circulatory miRNAs are associated with incident stroke 
is consistent with a previous longitudinal study 17. In their longitudinal study on ~2,700 
participants from the Framingham Heart Study (FHS), Mick et al. found plasma levels 
of miR-656-3p and miR-941 to be associated with incident stroke (n=51 cases) 17. This 
may confirm that miRNAs are relevant as biomarkers for stroke risk in the general 
population. But the major differences between Mick et al. and the current study 
include the methodology and data normalization. Therefore, the number of available 
miRNAs measured by qPCR in the FHS (301 miRNAs) and next-generation sequencing 
in the current study (591 miRNAs) do not have to overlap completely between studies. 
Notably, the expression levels of miR-6124, miR-5196-5p and miR-4292 were not 
included in the study of Mick et al., and similarly, miR-656-3p and miR-941 were not 
among the 591 well-expressed miRNAs included in the current study. An independent 
study from the FHS observed no significant differences of 257 blood-derived miRNA 
levels between incident stroke cases (n=80) and non-stroke participants 30. In a similar 
study Salinas et al. linked the levels of miR-574-3p to prevalent stroke 30. However, the 
follow-up time of previous studies was considerably shorter than the current study (3.2 
and 2.5 years vs. 9.7 years). Given the relatively small effect of a single miRNA, changes 
in expression levels are likely to be more impactful over a longer period of time. This 
may explain why Salinas et al. found no association between miRNA expression levels 
and incident stroke 30. In addition, a different study population is likely to reflect a 
different miRNA abundance. The FHS participants were 5.2 years younger than the 
participants of the RS, and age is shown to be highly associated with both miRNA 
expression and stroke risk 1, 31.
A notable observation of previous studies regards the difference in miRNA detection 
between different types of extracellular biofluids such as, serum, plasma, urine and 
saliva, but also between extracellular and cellular fluids, like whole blood 8, 32. Most 
previous studies have measured miRNA expression in whole blood 11, 15, 30. Although, 
blood is an easy accessible tissue, blood biomarkers are more likely to reflect blood-
based features than phenomena caused by disease. 33. In particular, cell-derived 
vesicles, known as exosomes release miRNAs into extracellular fluids, which can be 
linked to different pathological conditions. We measured cell free miRNA levels in 
plasma, which is therefore unbiased compared to miRNAs levels in whole blood. 
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MiRNAs can affect the expression of protein-coding genes by complementary binding 
of their target sequences. Alteration in expression of stroke-associated genes can 
influence the disease pathophysiology. We found that the three identified miRNAs 
can potentially target 10 genes that are associated with stroke using the GWAS data 3. 
Among these, 8 genes are expressed in the brain 26. Furthermore, the three identified-
miRNAs are located in intergenic regions of coding genes and are therefore likely to 
be expressed together with their host genes in the brain 27. For instance, miR-6124 is 
located in the intronic region of MICAL2, which has been reported to be expressed 
at relatively high levels in brain tissue 26. To our knowledge, MICAL2 has not been 
previously linked to stroke in human. However, Hou et al. demonstrated that Mical2 
is involved in the endothelial and vascular mechanisms that are disturbed with an 
ischemic stroke in mice 34. In addition, according Malik et al. some of the identified 
putative target genes are related to vascular traits, such as blood pressure (CASZ1, 
FURIN), coronary artery disease (HDAC9) and atrial fibrillation (ZFHX3) 3. The latter 
gene, ZFHX3, is associated with cardioembolic stroke, which accounts for a significant 
proportion of ischemic strokes 3. However, it is beyond the scope of this study to 
elaborate on the pathophysiologic implications of putative target genes. Future studies 
are needed to experimentally confirm the regulatory interaction between the identified 
miRNAs and target genes and their relation to stroke subtypes. 
Furthermore, we observed differences in the association between the median expression 
levels of the three identified miRNAs and various stroke risk factors (Supplemental 
Table 7.2). While miR-6124 and miR-5196-5p are associated with nearly all stroke 
risk factors, miR-4292 shows only a nominal association with HDL and BMI. This may 
indicate that the two former miRNAs play a role in the causal pathways of stroke. MiR-
4292, unlike miR-6124 and miR-5196-5p, might be involved differently in stroke, but 
is still useful as a predictive biomarker of the disease. Future studies are needed to 
identify the molecular mechanisms by which these miRNAs promote stroke. 
Our study has limitations that need to be considered for interpretation of the results. 
The pathology of ischemic and hemorrhagic stroke is different, and for risk stratification 
purposes, it is important to know whether a biomarker is specific for a subtype. With 
our study design, we were able to elaborate on the associations between some miRNAs 
and stroke subtypes. However, the number of cases of hemorrhagic stroke was small 
(n=19) and with a wide 95% confidence interval; future studies with larger samples 
are needed to provide more certainty. In addition, we used the brain-tissue expression 
levels of the host genes as proxy for the identified miRNAs. Since most tissue-specific 
expression levels are obtained via qPCR methods, no information was available on the 
RNA sequencing-measured expression levels of the identified miRNAs in brain tissue. 
Strengths of our study include the prospective design, almost 10 years of follow-up 
and the ability to measure virtually all known miRNAs to date with a highly specific 
and sensitive method. The ideal biomarker is easy assessable, non-invasive, cost-
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effective, disease-specific and can be detected before the onset of the disease. To this 
end, plasma-derived miRNAs are favorable for biomarker discovery and unbiased 
compared to blood-derived miRNAs that might reflect blood-specific features. 
Summary
This study indicates that higher plasma levels of miR-6124, miR-5196-5p and miR-
4292 are associated with the risk of stroke in the general population. The elevated levels 
of these miRNAs may reflect the risk of stroke and therefore could serve as plasma 
biomarkers for early diagnosis of the disease. Future studies with even more samples 
and experimental validation are warranted to replicate and verify the potential of the 
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Supplemental Table 7.1. MiRNAs nominally associated with incident stroke 
miRNA HR Std.Error P value P value 
adjusted 
miR-6124 1,66 0,12 2,00E-05 1,18E-02 
miR-5196-5p 1,90 0,16 6,07E-05 1,79E-02 
miR-4292 2,65 0,25 1,09E-04 2,15E-02 
miR-4534 1,97 0,19 4,50E-04 6,65E-02 
miR-6870-5p 1,47 0,12 1,15E-03 1,36E-01 
miR-7111-5p 1,54 0,14 1,85E-03 1,68E-01 
miR-6728-3p 0,57 0,19 2,31E-03 1,68E-01 
miR-3940-5p 1,48 0,13 2,39E-03 1,68E-01 
miR-4676-3p 1,78 0,19 2,56E-03 1,68E-01 
miR-3141 1,64 0,17 3,07E-03 1,78E-01 
miR-7150 1,70 0,18 3,31E-03 1,78E-01 
miR-3648 1,55 0,16 5,25E-03 2,59E-01 
miR-92b-3p 0,60 0,18 6,05E-03 2,75E-01 
miR-6798-5p 1,36 0,12 8,45E-03 3,48E-01 
miR-4478 1,59 0,18 9,42E-03 3,48E-01 
miR-1915-3p 1,52 0,16 1,03E-02 3,48E-01 
miR-4449 1,39 0,13 1,03E-02 3,48E-01 
miR-374b-5p 0,56 0,22 1,06E-02 3,48E-01 
miR-126-3p 0,60 0,21 1,21E-02 3,67E-01 
miR-5703 1,50 0,16 1,24E-02 3,67E-01 
miR-30a-3p 0,70 0,15 1,35E-02 3,80E-01 
miR-16-5p 0,60 0,21 1,43E-02 3,84E-01 
miR-345-5p 0,55 0,25 1,70E-02 4,36E-01 
miR-765 1,52 0,18 1,79E-02 4,42E-01 
miR-6873-3p 0,76 0,12 2,00E-02 4,63E-01 
miR-6127 1,45 0,16 2,04E-02 4,63E-01 
miR-374b-3p 0,55 0,26 2,12E-02 4,63E-01 
miR-6778-5p 1,70 0,23 2,24E-02 4,67E-01 
miR-4459 1,64 0,22 2,29E-02 4,67E-01 
miR-4784 1,88 0,28 2,57E-02 5,05E-01 
miR-30e-3p 0,50 0,33 3,09E-02 5,89E-01 
miR-133a-3p 0,79 0,11 3,50E-02 6,47E-01 
miR-4430 1,39 0,16 3,64E-02 6,47E-01 
miR-532-3p 0,82 0,10 3,72E-02 6,47E-01 
miR-3620-3p 0,74 0,14 3,84E-02 6,48E-01 
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miRNA HR Std.Error P value P value 
adjusted 
miR-205-5p 0,85 0,08 4,29E-02 7,04E-01 
miR-1275 1,47 0,19 4,53E-02 7,06E-01 
miR-3937 0,82 0,10 4,61E-02 7,06E-01 
miR-4745-3p 0,65 0,22 4,66E-02 7,06E-01 
Association between plasma miRNA levels and incident stroke. Models are adjusted for: age, sex, cohort, 
smoking, BMI, HDL, total cholesterol, systolic blood pressure, diastolic blood pressure, prevalent diabetes 
mellitus type 2, prevalent coronary heart disease, prevalent atrial fibrillation, lipid lowering medication and 
blood pressure lowering medication
Additional supplementary material for this chapter can be found 










In this thesis, I investigated the potential role of miRNAs as regulators and biomarkers 
of aging and age-related diseases. I have made efforts in improving the understanding 
about the biological functions of miRNAs in both cellular developmental and 
pathological mechanisms of these complex diseases. This epidemiological approach 
made it possible to characterize circulatory miRNAs at the population level within 
the Rotterdam Study. To this end, I have identified differential miRNA expression 
patterns for individuals with underlying conditions towards metabolic and vascular 
diseases. This thesis makes a small contribution to unleashing the potential of miRNAs 
as diagnostic and prognostic biomarkers, as well as to better understanding of their 
role in functional mechanisms in complex systems. Although I have not fully been 
able to investigate the molecular mechanisms and complex interplay of genetics, DNA 
methylation, metabolites and miRNA expression, the work presented in this thesis is 
a preview towards the important contribution of miRNAs in human biology. In this 
chapter, the main findings, research challenges, clinical relevance and future directions 
are discussed.
Main findings
Aging is a change in an organism that leads to an increased risk of tissue dysfunction, 
diseases and death1,2. As we tend to define aging in a chronological manner, this may 
not be true. Individuals with the same chronological age could differ in terms of age-
associated functional decline. A proposed cause of biological aging involves epigenetics, 
in which the established epigenetic role in embryonic development is increasingly seen 
as relevant to later life stages3. To this end, epigenetic markers such as DNA methylation 
are associated with cellular dysfunction that lead to accelerative aging4. A common 
phenomenon of cellular aging is the increase in size and the reduced ability to divide5. In 
Part I, I described the role of miRNAs in aging. I highlighted several miRNAs in chapter 
2 that regulate cell cycle initiation and progression of stem cells and have impact on the 
grow and divide phases (G1 and S-phase in respective) of various cell types, in particular 
miR-290-295, miR-302, miR-17-92, miR-106b-25 and miR-106a-363. The reported 
findings of chapter 3 indicated that miR-19b, a member of the miR-17-92 cluster, is 
the leading identified age-associated miRNA. Additionally members of the miR-17-92 
cluster, such as miR-19a (number 4), miR-17 (number 8) and miR-92a (number 12) were 
also presented among the top age-associated miRNAs, suggesting that the miR-17-92 
cluster plays an important role in aging. Through a systematically assessment of plasma-
derived miRNA age signature I noted a correlation with chronological age (r=0.60). 
Although this correlation is very moderate compared to the DNA methylation age 
(r=0.97) described by Horvath in 20136, a relationship exists. I found that miRNA age 




risk of all-cause mortality with 9%. This finding is consistent with a previous study that 
found whole-blood derived miRNA-delta age to be associated with all-cause mortality 
with 10% per each year increase7. 
Increased age is a major risk factor for complex diseases including, neurodegeneration 
and cardiovascular diseases. In chapters 4, 5 and 8, I discussed several miRNAs that 
were differently expressed between participants diagnosed with disease compared to 
healthy participants. The expression levels of identified miRNAs, such as miR-4798-3p 
for atrial fibrillation, miR-193a-5p and miR-122-5p for fatty liver disease, and miR-139-
5p for type 2 diabetes, explain some of the susceptibility to the disease. In addition, these 
miRNAs may explain some etiological aspects of the disease. For example, the identified 
association of miR-4798-3p with prevalent atrial fibrillation was only significant among 
men, suggesting that miR-4798-3p may play a role in the not yet fully understood sex 
difference in atrial fibrillation8. In the post-hoc target gene analyzes, I shed light on the 
underlying disease pathways of the identified miRNAs. For example, in chapter 4, I 
highlighted the link between miR-139-5p and BLC2 gene, which has been validated 
previously by in vitro experiments9. Previous studies have linked BLC2 to glucose 
metabolism, suggesting that there may be a mediating role for miR-139-5p in glucose 
metabolism10. Another example is described in chapter 7, where I found miR-6124, 
miR-5196-5p and miR-4292 to be associated with the risk of stroke. Of the 10 target 
genes of the stroke-associated miRNAs, 8 genes have been reported to be expressed 
in the brain, which is a predominant tissue for stroke11. In addition, a previous stroke 
GWAS reported that some of the identified target genes of the stroke-associated miRNAs 
are related to vascular features, such as blood pressure and coronary artery disease12. 
While future research is needed to elucidate the link between identified miRNAs and 
stroke, this indicates a promising pathophysiological role for miRNAs.
In chapter 4 and 7, I found that expression levels of certain miRNAs were associated 
with an increased risk of developing type 2 diabetes and stroke in respective. Because 
the miRNAs were quantified before the onset of disease, the associated miRNAs may 
give important information about the pathophysiology of diseases. During a follow-
up period of almost 10 years, I identified positive relationships between four miRNAs 
(miR-99a-5p, miR-29a-3p, miR-122-5p and miR-125b-5p) and incident diabetes. 
These findings can contribute to an early detection of type 2 diabetes. On the other 
hand, I found miR-4664-3p associated with incident diabetes in a negative direction, 
suggesting a protective effect of miRNA in disease onset. Although functional studies 
are needed to confirm this protective effect in vivo, over-expression of miR-4664-3p 
could be beneficial to prevent type 2 diabetes. In chapter 7, I identified three miRNAs 
(miR-6124, miR-5196-5p and miR-4292) associated with stroke risk. A similar 
longitudinal study on indecent stroke found plasma levels of miR-656-3p and miR-941 
associated with stroke, confirming that miRNAs are useful as indicators for stroke risk 
in the general population13. Stroke is classified into ischemic stroke and hemorrhagic 
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stroke. Since the pathophysiology of ischemic strokes differs from hemorrhagic stroke, 
it is relevant to gain knowledge about the role of miRNAs in underlying processes. 
Interestingly, I showed that, unlike miR-4292, miR-6124 and miR-5196-5p were 
associated with coronary artery disease, heart failure, and carotid plaques in a cross-
sectional analysis. This could indicate that miR-6124 and miR-5196-5p are involved 
in pathophysiological processes underlying stroke that are different from miR-4292. 
The realization that complex diseases, such as cardiometabolic disorders, are better 
not investigated by means of one exposure and one outcome, has led us to integrate 
multiple data in this thesis. The information that can be gathered in each of the omics 
layers (e.g., genomics, epigenomics, metabolomics) improves our understanding of the 
disease14. To this end, I found four miRNAs (miR-10b-5p, miR-148a-3p, miR-125b-5p 
and miR-100-5p) associated with lipid traits in three omics layers (genetic variation, 
DNA methylation, miRNA expression) in chapter 6. While an observed association 
in only one omics layer should not rule out a possible causal effect for a miRNA, 
significant associations in all layers make this more likely. Moreover, in chapter 4, I 
show that some genetic variants associated with the miRNA expression, miR-eQTLs, 
are also associated with diabetes-related metabolites15. This suggests an interaction 
between miRNAs and metabolites in which they together affect type 2 diabetes.
The battle between etiology and prediction, how 
can microRNAs cross this line?
Epidemiology makes a distinction between prediction research and etiological research. 
In terms of prediction research, the probability of having (diagnostic) or developing 
(prognostic) an event can be estimated. The main purpose here is risk assessment 
irrespective of underlying causes. On the other hand, etiological research provides 
insight into the cause and origin of observations, and does not predict the outcome. 
Based on their nature, miRNAs can be linked to the underlying mechanisms of diseases. 
The ability to bind complementarily to gene transcripts and thereby affect gene 
expression is one aspect that makes miRNAs unmistakably related to pathophysiological 
conditions. Nevertheless, the observed effects of miRNAs on repressing translation 
of gene transcripts are discovered inside a cell. Considering miRNAs are released 
from the cells into the bloodstream upon pathophysiological processes, quantifying 
extracellular miRNAs may reflect certain states of the body, suggesting the potential 
of miRNAs as disease biomarkers16,17. With these motivations, miRNAs hold promise 
for both prediction and etiological research. In contrast to etiological research, where 
one has to correct for possible confounding, in prediction research all that matters is 
the accuracy of the predictive biomarker. From that perspective, it does not matter 
whether the identified miRNAs are causal or non-causal for the disease in question. 




disease A can play a (causal) role in disease B by suppressing the translation of target 
transcripts in tissues relevant to disease B. While miRNAs can cross the line between 
etiology and prediction based on their nature, I think researchers should be careful 
about including both prediction and etiological research areas. Most importantly, the 
research question must be leading in the choice of modeling. 
In this thesis, I investigated the prediction ability of the miRNAs by answering the 
following: are certain miRNAs differentially expressed in plasma of patients versus 
non-patients and can therefore serve as diagnostic or even prognostic biomarkers 
of the disease? Then, I investigated whether the identified miRNAs are potentially 
causally related to the pathophysiology of disease of interest by studying the genomic 
region of the miRNAs and their potential downstream target genes and pathways using 
in silico analysis.
Is a microRNA a good biomarker?
A biomarker has been defined as biological marker that is objectively measured and 
evaluated as indicator of normal biological processes, pathological processes, or 
pharmacological responses to therapeutic interventions18,19. Since the main purpose of 
using a biomarker is to evaluate status (‘how’) and not to collect information about the 
cause of status (‘why'), biomarker research belongs to prediction research. Some criteria 
describing an ideal biomarker include: (I) non-invasively detectable from accessible 
sources such as blood or urine, (II) high sensitivity, and (III) high specificity for the disease.
While this concept is still in its early stages, miRNAs have characteristics that make 
these small non-coding RNAs as potential promising biomarkers for complex diseases. 
Figure 9.1 illustrates a steady increasing number of publications on miRNAs as 
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Figure 9.1. Number of publications  miRNAs biomarkers from 2002 till 2020 (PubMed).
Especially, some aspects that makes circulatory miRNAs in body fluids interesting for 
biomarker discovery is their stability even under extreme conditions (e.g. long term 
storage and freezing)20. This is due to the protective effect of extracellular vesicles that 
protect the cargo against degradation of, for example, RNAse. These lipid bilayer-
delimited particles, such as exosomes or microvesicles, are released from a cell21,22. 
They carry among others proteins, lipids and miRNAs and facilitate the intercellular 
communication23. These extracellular vesicles, and with them miRNAs, are easy to 
detect in body fluids such as blood, urine and saliva, allowing us to tick the first criteria 
as ideal biomarker. But the main challenge is to what extent can circulatory miRNAs 
be specific disease indicators? 
It has been established that miRNAs can function as pleiotropic modulators24. An 
example in this thesis is the observed effects of miR-122-5p and miR-193a-5p that were 
found to be associated with both type 2 diabetes and fatty liver disease. Given that type 
2 diabetes and fatty liver disease are both metabolic diseases, these miRNAs may be 
specific for shared characteristics and common obesity pathways. Another possibility 
is that the same miRNA has a different function in different phenotypes. For example, 
previous studies have shown that miR-181b was highly expressed in bladder cancer25 
whereas it was found to be down-regulated in prostate cancer26, suggesting that the 
function of miR-181b is different across different tissues. Notably, the use of circulatory 
miRNAs does not provide information about the origin of tissue. A previous study has 
demonstrated that the vast majority (~83%) of the mature miRNAs in human were 




proportion (~14%) was found to be tissue specific, including miR-1-3p which was 
highly expressed in muscle and myocardium tissue27. This latter study has determined 
the abundance of 1997 mature miRNAs in 61 tissues of different organs from two 
subjects collected post mortem. Unfortunately, little information is currently available 
about the miRNA expression in different tissues for relatively novel miRNAs (e.g. four 
digits), such as miR-6124 and miR-5196-5p I identified in chapter 7. To circumvent 
this issue, one approach is to test if the host gene was expressed in the tissue of interest. 
However, using the host gene expression as proxy for the miRNA is only informative 
if the miRNA is located in the exonic- or intronic region and likely to be co-expressed 
with the host gene28. For instance, I found that the stroke-associated miR-5195-5p in 
chapter 7 was embedded in the exonic region CD22 gene, which was reported to be 
expressed in brain tissue11,29. Another example is the diabetes-associated miR-139-5p 
in chapter 4 that was embedded in the intronic region of PDE2A29. Previous research 
has demonstrated that PDE2A was expressed in endothelial cells in liver and pancreas 
tissue11. Moreover, a dysfunction of endothelial cells is known to be related to type 2 
diabetes30. This might suggest that higher levels of miR-139-5p in the circulation are 
a result of the cellular damage to endothelial cells caused by type 2 diabetes. But this 
scenario should be still validated by testing the levels of miRNAs in the target tissues.
In this thesis, I aimed to shed light on miRNAs as prognostic biomarkers. Using cross-
validation in chapter 3, I tested the ability of a miRNA-age signature to predict 
mortality. This miRNA-age signature was built by 291 miRNAs. In this study I found 
that miRNA-age could predict mortality in the validation set. Given that the magnitude 
of the effect estimates of individual miRNAs on age was small, ranging from 0.003-
0.04, a large sample size of a multiple-miRNA signature is needed for use as an age-
related biomarker. This is in line with the receiver operator characteristics analysis in 
chapter 7, in which I demonstrated a moderate improvement in stroke prediction 
by adding identified miRNAs to a general vascular risk factor model (ROC vascular= 
0.735 versus ROC vascular+miRNAs= 0.761).
Novel statistical methods help to identify miRNAs involved in disease 
etiology 
Causal relationships are important in etiological research, but extremely difficult to 
prove in observational studies, using cohort data such as the Rotterdam Study31, as 
well as in clinical trials. The miRNAs that I have found to be associated with disease 
prevalence in chapter 4, 5 and 8 can either reflect the cause or effect of the disease 
and therefore excluded from cause- and effect relationship. Although the longitudinal 
analyzes performed in chapters 4 and 7 provide a temporal framework indicating 
that exposure (miRNA expression) precedes outcome (type 2 diabetes and stroke), 
these studies are still subject to (unmeasured) confounding and systemic errors. In 
recent years, a popular method used in epidemiological research to examine the causal 
238
CHAPTER 9
eff ect of an exposure on the outcome is Mendelian randomization (MR)32,33. This 
approach is based on the second law of Mendel; the law of independent assortment, 
which states the allele of one gene separates independently of an allele of other gene. 
This method uses genetic variants as instrumental variable for the exposure. Since 
genetic variants are randomly inherited, Mendelian randomization is an approach that 
is free from confounding and reverse causality and can therefore diff erentiate between 
a true causal and non-causal exposure. Yet, valid instrumental variables must meet 
three assumptions (Figure 9.2) 34: 
I. The genetic instrument must associate with the exposure 
II. The genetic instrument must infl uence the outcome only through the exposure
III. The genetic instrument must not associate with measured or unmeasured 
confounders   
Figure 9.2. Schemetic presentation of the MR method. 
In chapter 4, I identifi ed a causal eff ect of miR-139-5p on type 2 diabetes using 
Mendelian randomization. I used 22 genetic variants for miR-139-5p that were 
valid according to the MR three assumptions. However, I was not always able to 
identify valid genetic tools for miRNAs and therefore unable to perform Mendelian 
randomization testing the causal inference between the identifi ed miRNAs and several 
traits. Nevertheless, this does not exclude the potential causal role of the identifi ed 
miRNAs in the pathophysiology of disease. In this context, an important component 




the association between genetic variants in miRNA target genes and the disease of 
interest, I was able to provide some evidence for a possible mediating effect between 
the identified miRNAs and disease. 
The lack of generalization
In this thesis I provide an overview of miRNAs, that emerged as small emperors of 
physiological conditions. These findings form the basis of an epidemiological approach 
to the utility of miRNAs that can serve as accessible biomarkers as well as potential drug 
targets. While I have marked several miRNAs as biomarkers for metabolic disorders 
and cardiovascular disease, the clinical implications of miRNAs still have a long way to 
go. In particular, the lack of external validity is a big challenge that has led to miRNAs 
remaining in the research phase as biomarkers. The non-standardized quantification 
and normalization of miRNA expression data are important factors why the thus far 
identified miRNA biomarkers do not take off the ground.    
Quantification of miRNAs
The increasing interest in discovering miRNAs for complex traits has led to better 
miRNA quantification platforms. In particular, the EdgeSeq array, which has been used 
in several chapters of this thesis, is a next-generation high-throughput technology 
that is able to measure 2083 mature miRNAs and is reported to quantify with a high 
accuracy, sensitivity and specificity. Although this EdgeSeq method is still little used in 
epidemiological studies, it has been shown to detect novel miRNAs with the least bias 
detection.35 Aside from the above benefits, the EdgeSeq method is relatively expensive 
and time consuming, and therefore not often used in similar studies of comparable 
sample size. In addition, one of the reasons why the relatively novel miRNAs (e.g. miR-
6124, miR-5196-5p, miR-4292, miR-4798-3p) were not identified in previous miRNA 
studies using a RT-qPCR tool is probably due to limited available assays. Future 
studies that have the ability to use a high-throughput technology like EdgeSeq, should 
overcome this limitation.  
Normalization of miRNAs 
In the studies included in this thesis, I used a set of miRNAs that was according the 
normalization method defined as well-expressed miRNAs. The benefit of using well-
expressed miRNAs instead of all measured miRNAs is that I could minimize false-
positive findings (type 1 error). This type of error is likely to increase when there is a 
relative large contribution of accidental outliers compared to the overall effect. The 
normalization method used in this thesis is based on a monotonic decreasing spline 
curve fit between the means and standard deviations of all miRNAs. This excludes 
miRNAs with standard deviations that exceed the means and have low expression 
levels. Using a lower limit of quantification (LLOQ), which is based on the lowest 
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concentration of the measured miRNAs that can be accurately quantified, a threshold 
for defining well-expressed miRNAs was established. In the definition well-expressed 
miRNA levels in plasma, were those with >50% values above LLOQ. Out of the 2083 
measured miRNAs, a set of 591 miRNAs was qualified as well-expressed and used 
as exposure variables in the studies conducted in this thesis. As this normalization 
approach is not standardized across studies, I performed a series of sensitivity analyses 
in chapter 3 to test if normalization is likely to be a source of discrepancy between 
studies. I reported that the top hits of associated miRNAs were nearly identical 
between different cut-offs, from 50% (n=591 miRNAs) to 25% (n=687 miRNAs) and 
0% (n=2083 miRNAs) expression values  above LLOQ, indicating that normalization is 
probably not the main reason for the inability to replicate the findings.
The independency of miRNAs and how to correct for that 
In the association analyses conducted in this thesis, I tested more than one hypothesis 
simultaneously. If I do not take into account this multitude of tests, there is a good 
chance that some of the true null hypothesis will be rejected by chance alone. For 
example, if I test 50 hypotheses simultaneously, the probability that at least one true 
null hypothesis will be rejected is 92% (1-0.9550 = 0.92). By focusing on a particular 
hypothesis like I did partly in chapter 6, the nominal cutoff of P value <0.05 is well-
accepted. In the event that 591 miRNAs are tested simultaneously, as I have done in 
the majority of this thesis, I have to take into account this multitude of tests. There 
are multiple ways to correct for multiple testing, each with their pros and cons. The 
Bonferroni correction sets the significant cutoff at 0.05/number of independent tests. 
This means that for testing 591 miRNAs, the significant threshold will be 8.46x10-5. 
Chapters 3, 5 and 6 are examples where I have used the Bonferroni correction. 
While this method is well established in epidemiological research, the correction is 
usually a bit too conservative, especially for miRNAs. For example, in chapter 2, I 
discussed several miRNAs that are clustered in the genome. It is very likely that these 
miRNAs share the same promoter and therefore transcribed at the same time, which 
is often reflected in miRNA expression profiles26. While this is not always the case as 
with families, such as the miR-499 family, whose members have different expression 
patterns in different tissues27, it may raise the question of how independent miRNAs 
are from each other? As a counter-argument to the dependence on miRNAs, I look 
at the biological function of the miRNAs. The ability of highly “correlated" miRNAs, 
including -3p/-5p miRNAs to repress gene transcripts could be different. Because of 
having different seed sequences, the miRNAs could bind to different target transcripts. 
For example, according to TargetScan7.236, there are 365 putative target genes for 
miR-150-5p, while for miR-150-3p there are 2570, leading to them targeting different 




Another widely used method to correct for multiple testing is the false discovery rate 
(FDR). This approach is based on the proportion of false positives among all significant 
results. By allowing a false positive threshold of 5%, the adjusted P value must be less 
than 0.05 (FDR <0.05). I used this method in chapters 4 and 7 of this thesis. The main 
difference between the Bonferroni and FDR is that the Bonferroni penalizes all P values 
equally while the FDR penalties the P values  according to their rank. Nevertheless, 
both Bonferroni and FDR correction are accepted methods in epidemiological studies. 
In addition, in chapter 8, I found that among the 591 miRNAs, 142 were independent 
based on the methodology described by Li & Ji in 200537. By correcting for the 
independent miRNAs, I used 3.52x10-4 (0.05/142) as significant threshold. Although 
this is significantly less stringent compared to the previously mentioned 8.46x10-5 
threshold, this method is widely used in genetic research. Elastic net regularization 
is a method used to deal with correlation of high-dimensional data (high number of 
rows and columns) that I used in chapter 3. High-dimensional datasets are prone 
to noise and uncertainties. The elastic net regularization regression combines two 
penalties methods, lasso (L1) and ridge (L2)38. Lasso regression takes into account 
the magnitudes of the coefficient, resulting in that the effect of some miRNAs can be 
completely neglected. An advantage is that lasso regression helps in miRNA selection. 
In the ridge regression, the coefficient of each miRNA is equally penalized, which is 
useful when there is collinearity between miRNAs, but not for miRNA selection. In the 
elastic net the penalty value (alpha value) can range between 0 and 1, in which an alpha 
of 0 corresponds to ridge and alpha of 1 to lasso. In chapter 3, I reported an alpha 
parameter of 0.90, indicating that the L1 (lasso) penalization is predominant. 
What does the future hold for miRNAs?
From bench to bedside: microRNA-based therapy 
As this chapter is being written, a global pandemic is underway that is having an extreme 
impact on society. The coronavirus outbreak has infected millions of people and the 
severity of the COVID-19 infection caused is linked to older and obese individuals, which 
are major risk factors for cardiovascular diseases39,40. This once again shows the burden 
of this vulnerable population and the importance of risk management. The fight against 
the coronavirus has taken RNA-based vaccinology into gear. Biotech companies Pfizer / 
BioNTech and Moderna have developed RNA-based vaccines with over 90% efficiency41. 
Continuously evolving RNA therapies and vaccines underscore the exciting future for 
this RNA-based drug. Similarly, during the last 20 years of miRNA research in humans, 
multiple pharmaceutical and biotech companies have addressed the therapeutic potential 
of miRNAs42-46. In this context, miRNA mimics can be used to increase the expression of 
miRNAs that exhibit a protective effect on the disease45,47. For example, in theory miRNA 
mimicry of miR-4664-3p could be beneficial for type 2 diabetes. In addition, miRNA 
inhibitors, known as anti-miRs, may suppress the expression or function of miRNAs 
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associated with a deleterious effect on the disease48. In the field of cardiovascular disease, 
several anti-miRs have been developed, including anti-miR-21 which reverses cardiac 
remodeling and anti-miR-92a which promotes blood vessel growth49,50. One of the major 
challenges in miRNA-based therapeutics is the off-target effect in tissues other than the 
tissue of interest51. For instance, when miRNAs are expressed in a non-tissue specific 
manner, manipulation of a specific miRNA can affect target genes in different tissues, 
which can have both beneficial and deleterious consequences. In addition, most studies 
will stall in preclinical stages due to inefficient delivery, toxicity and pharmacokinetics52. 
Nonetheless, a success story of anti-miR therapies is that of miR-122 for the treatment 
of hepatitis C virus46. Clearly, we still have a long way to go to manifest miRNA therapies 
in clinical practice. Nevertheless, the biological function of miRNAs during disease and 
the success of anti-miR-122 showing evidence for safe and efficient miRNA therapy hold 
great promise for miRNA as drug targets in the future.
Your personal microRNA makeup
In the coming years, medical research will increasingly focus on personalized medicine. 
The ultimate goal is to provide an optimal presentation of a person's health status that 
can illustrate and predict the impact of modifiable factors on aging and disease. To this 
end, the diagnosis and treatment will be tailored for each individual and adverse side 
effects will be minimized based on their genetic makeup. Multiple effort in genomics 
has already contributed to risk profiles that can be applied to support clinical decision 
making. More recently, the importance of factors that can change over the course 
of a person's life has been recognized in optimizing individual health care. Among 
these, gene-environment interactions that can be measured in epigenomics data are 
extremely important. This thesis provides evidence on the importance of miRNAs as 
genetic fine-tuners and regulators that should be considered as a key element in such 
personalized profile. The breakthrough of personalized medicine will with all certainty 
benefit humankind, but will also bring challenges. One of these challenges regards the 
large and complex datasets that require innovative tools such as artificial intelligence. 
Moreover, we face ethical and moral issues such as discrimination by healthcare 
companies, but also the burden of truth. Looking beyond the current limitations, 





1. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related 
disease: from mechanisms to therapy. Nat Med 2015; 21(12): 1424-35.
2. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: Linking Aging to Chronic Disease. Cell 2014; 
159(4): 709-13.
3. Sen P, Shah PP, Nativio R, Berger SL. Epigenetic Mechanisms of Longevity and Aging. Cell 2016; 
166(4): 822-39.
4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell 2013; 
153(6): 1194-217.
5. Yang J, Dungrawala H, Hua H, et al. Cell size and growth rate are major determinants of replicative 
lifespan. Cell Cycle 2011; 10(1): 144-55.
6. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013; 14(10): R115.
7. Huan T, Chen G, Liu C, et al. Age-associated microRNA expression in human peripheral blood is 
associated with all-cause mortality and age-related traits. Aging Cell 2018; 17(1): e12687.
8. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in 
women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016; 
13(6): 321-32.
9. Huang H-Y, Lin Y-C-D, Li J, et al. miRTarBase 2020: updates to the experimentally validated 
microRNA–target interaction database. Nucleic Acids Research 2019; 48(D1): D148-D54.
10. Gurzov EN, Eizirik DL. Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and 
dysfunction. Trends in Cell Biology 2011; 21(7): 424-31.
11. Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome. Science 
2015; 347(6220): 1260419.
12. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 
subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics 2018; 
50(4): 524-37.
13. Mick E, Shah R, Tanriverdi K, et al. Stroke and Circulating Extracellular RNAs. Stroke 2017; 
48(4): 828-34.
14. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biology 2017; 18(1): 83.
15. Lotta LA, Pietzner M, Stewart ID, et al. A cross-platform approach identifies genetic regulators of 
human metabolism and health. Nature Genetics 2021; 53(1): 54-64.
16. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for 
cancer detection. Proceedings of the National Academy of Sciences 2008; 105(30): 10513.
17. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for 
diagnosis of cancer and other diseases. Cell Res 2008; 18(10): 997-1006.
18. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions 
and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95.
19. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004; 1(2): 182-8.
20. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z. miRNA in Plasma Exosome is Stable under Different 
Storage Conditions. Molecules 2014; 19(2).
244
CHAPTER 9
21. van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: A Common Pathway for a Specialized 
Function. The Journal of Biochemistry 2006; 140(1): 13-21.
22. Doyle LM, Wang MZ. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and 
Methods for Exosome Isolation and Analysis. Cells 2019; 8(7): 727.
23. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of 
mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell 
Biology 2007; 9(6): 654-9.
24. Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. Cell 2009; 136(2): 215-33.
25. Ratert N, Meyer HA, Jung M, et al. Reference miRNAs for miRNAome analysis of urothelial 
carcinomas. PLoS One 2012; 7(6): e39309.
26. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA 
profiling in prostate carcinoma. Int J Cancer 2010; 126(5): 1166-76.
27. Ludwig N, Leidinger P, Becker K, et al. Distribution of miRNA expression across human tissues. 
Nucleic acids research 2016; 44(8): 3865-77.
28. Lutter D, Marr C, Krumsiek J, Lang EW, Theis FJ. Intronic microRNAs support their host genes by 
mediating synergistic and antagonistic regulatory effects. BMC Genomics 2010; 11(1): 224.
29. Hinske LC, França GS, Torres HA, et al. miRIAD-integrating microRNA inter- and intragenic data. 
Database (Oxford) 2014; 2014.
30. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes 
mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol 2018; 17(1): 121.
31. Ikram MA, Brusselle G, Ghanbari M, et al. Objectives, design and main findings until 2020 from 
the Rotterdam Study. European Journal of Epidemiology 2020; 35(5): 483-517.
32. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to 
understanding environmental determinants of disease? Int J Epidemiol 2003; 32(1): 1-22.
33. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in 
epidemiological studies. Human Molecular Genetics 2014; 23(R1): R89-R98.
34. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for 
the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 
2017; 36(11): 1783-802.
35. Godoy PM, Barczak AJ, DeHoff P, et al. Comparison of Reproducibility, Accuracy, Sensitivity, and 
Specificity of miRNA Quantification Platforms. Cell Reports 2019; 29(12): 4212-22.e5.
36. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian 
mRNAs. Elife 2015; 4.
37. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation 
matrix. Heredity (Edinb) 2005; 95(3): 221-7.
38. Zou H, Hastie T. Regularization and variable selection via the elastic net. Journal of the Royal 
Statistical Society: Series B (Statistical Methodology) 2005; 67(2): 301-20.
39. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective 
on the epidemiology and biological relationships. Obesity Reviews 2020; 21(11): e13128.
40. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired 
metabolic health and COVID-19. Nature Reviews Endocrinology 2021; 17(3): 135-49.
41. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 




42. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering 
novel targets and developing specific therapy. Perspect Clin Res 2016; 7(2): 68-74.
43. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer 
and other diseases. Nature Reviews Drug Discovery 2017; 16(3): 203-22.
44. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO 
Molecular Medicine 2014; 6(7): 851-64.
45. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and 
obstacles. Nature Reviews Drug Discovery 2012; 11(11): 860-72.
46. Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV Infection by Targeting MicroRNA. 
New England Journal of Medicine 2013; 368(18): 1685-94.
47. Montgomery RL, Yu G, Latimer PA, et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO 
Molecular Medicine 2014; 6(10): 1347-56.
48. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR 
oligonucleotides. Silence 2012; 3(1): 1.
49. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a Controls Angiogenesis and Functional 
Recovery of Ischemic Tissues in Mice. Science 2009; 324(5935): 1710.
50. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating 
MAP kinase signalling in fibroblasts. Nature 2008; 456(7224): 980-4.
51. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR 
oligonucleotides. Silence 2012; 3(1): 1-.
52. van Rooij E, Purcell Angela L, Levin Arthur A. Developing MicroRNA Therapeutics. Circulation 






Summary of Research findings
The studies in this thesis are related to two main research objectives. The first aim was 
to elucidate the role of miRNAs on aging. I provided an overview of miRNAs involved 
in the cell cycle progression and investigated whether miRNAs are linked to biological 
aging in an advanced population. The results related to this objective are presented 
in Part I of this thesis. The second aim was to investigate the role of miRNAs in 
diseases. I shed light on the biomarker potential of circulatory miRNAs in disease and 
investigated the functional role these miRNAs in the pathophysiology. In this section I 
conducted observational research using data from the Rotterdam Study and examined 
the interplay of multiple omics layers in a systemic biological approach. The results 
related to this objective are presented in Part II of this thesis. 
In chapter 2 I reviewed the current knowledge regarding the role of miRNAs in cell cycle 
progression of stem cells. The cell cycle is a series of events that take place in a cell to 
grow and divide. The literature included in this chapter described key miRNAs involved in 
different phases of the cell cycle, including the clusters miR-290-295, miR-302, miR-17-
92, miR-106b-25 and miR-106a-363. These phases are under control by many regulators, 
such as p21 and p53 that are responsible for cell arrest when there are defects in the cell 
cycle. I focused on embryonic stem cells, adult stem cells and cancer stem cells. 
In chapter 3 I created an miRNA-age signature based on plasma miRNA expression 
levels and tested that were associated with mortality and morbidities. I identified 291 
miRNAs to be associated with chronological age among 1,930 individuals from the 
Rotterdam Study. For this, I used elastic net regularization and cross-validation and 
showed that miRNA-age was correlated with chronological age. Based on the difference 
between miRNA-age and chronological age, I defined miRNA-delta age. Accelerated 
aging equates to a positive miRNA-delta age, while slower aging equates to a negative 
miRNA-delta age. I found that miRNA-delta age is predictive of all-cause mortality, with 
each additional miRNA-delta age year increasing the risk of all-cause mortality with 9%. 
In contrast, I did not find an association between miRNA-delta age and morbidities.
In chapter 4 I examined the association between miRNAs plasma levels and type 2 
diabetes. I observed a positive relationship between four miRNAs (miR-99a-5p, miR-
29a-3p, miR-122-5p and miR-125b-5p) and incident diabetes during follow-up. These 
findings can contribute to an early detection of individuals with high-risk profiles for 
type 2 diabetes. On the other hand, I found a miRNA (miR-4664-3p) associated with 
incident diabetes in a negative direction, suggesting a protective effect. In addition, I 
provided evidence that plasma levels of miR-139-5p and miR-193a-5p were significantly 
increased in baseline diabetic patients. I performed a GWAS on the seven identified 
miRNAs to obtain genetic variants. Based on Mendelian randomization using these 




diabetes. Downstream effects of miR-139-5p, including target genes have previously 
been reported to be involved in pathways underlying diabetes, supporting the possible 
etiological role of miR-139-5p in type 2 diabetes. 
In chapter 5 I described the association between miRNAs plasma levels and the 
prevalence of fatty liver disease. I tested the associations between miRNAs and fatty liver 
disease and liver enzymes (gamma-glutamyl transferase and alkaline phosphatase). I 
provided evidence that 61 miRNAs were associated with liver enzymes. Furthermore 17 
miRNAs were associated with fatty liver disease, of which 14 were also associated with 
liver enzymes. Among them I found miR-122-5p, which is a well-established miRNA 
in liver tissue.
In chapter 6 I described a study in which I integrated genetic data, DNA methylation data 
and miRNA expression data from the general population to investigate miRNAs associated 
with cardiometabolic traits. By GWAS using summary statistics I identified genetic variants 
annotated to 67 miRNAs associated with cardiometabolic diseases (e.g. coronary heart 
disease and type 2 diabetes) or risk factors (e.g. anthropometric traits, blood pressure traits, 
glycemic traits and lipid traits). Alterations in DNA methylation of CpG sites annotated to 
38 of these miRNAs and plasma expression levels of 8 of them were also associated with 
the same trait. Integrating the results from different omics data showed that miR-10b-5p, 
miR-148a-3p, miR-125b-5p and miR-100-5p are strongly linked traits. This study provides 
evidence that miRNAs are related to cardiometabolic traits in more than two omics layers, 
which may enhance the potential to be involved in the etiology of disease.
In chapter 7 I reported the results of the association between miRNA plasma levels 
and incident stroke. I was able to identify three circulatory miRNAs (miR-6124, miR-
5196-5p and miR-4292) associated with the risk of any type of stroke. These findings 
suggest that higher plasma levels of miR-6124, miR-5196-5p and miR-4292 are linked 
to higher risk for developing stroke. Using GWAS summary statistics I observed that 
10 of the potential miRNA target genes were associated with stroke. Among these 10 
target genes, 8 were reported to be expressed in the brain, which is a primary tissue for 
stroke. All in all, this reinforces the hypothesis that miR-6124, miR-5196-5p and miR-
4292 are not only a biomarker but are also involved in the pathology of stroke. 
In chapter 8 I reported the findings on the association between miRNAs and prevalent 
and incident atrial fibrillation in the Rotterdam Study. Since sex differences exist in the 
pathology of atrial fibrillation pathology, I stratified the analysis by sex. I identified 
lower expression levels of miR-4798-3p associated with prevalent atrial fibrillation in 
men, but not in women or the general population, indicating that miR-4798-3p may 
have a sex-specific role in atrial fibrillation. I described in this study that miR-4798-3p 
has a predicted number of more than 50 target genes it can regulate, several of which 
are related to electrical and structural remodeling of the heart known to be involved in 




De studies in dit proefschrift hebben betrekking op twee onderzoeksdoelstellingen. 
Het eerste doel was om de rol van miRNA's op veroudering op te helderen. Ik gaf een 
overzicht van miRNA's die betrokken zijn in de celcyclus en onderzocht of miRNA's 
verband houden met biologische veroudering in een gevorderde populatie. De 
resultaten met betrekking tot deze doelstelling worden gepresenteerd in het eerste 
deel van dit proefschrift. Het tweede doel was om de rol van miRNA's bij ziekten te 
onderzoeken. Ik wierp licht op het biomarkerpotentieel van circulatoire miRNA's 
bij ziekte en onderzocht de functionele rol van deze miRNA's in de pathofysiologie. 
In deze sectie heb ik observationeel onderzoek gedaan met behulp van gegevens uit 
de Rotterdam Studie en het samenspel van meerdere omics-lagen in een systemisch 
biologische benadering onderzocht. De resultaten met betrekking tot deze doelstelling 
worden gepresenteerd in het tweede deel van dit proefschrift.
In hoofdstuk 2 heb ik de huidige kennis over de rol van miRNAs in celcyclus van 
stamcellen besproken. De celcyclus is een reeks gebeurtenissen die plaatsvinden 
in een cel om te groeien en te delen. De literatuur in dit hoofdstuk beschrijft de 
belangrijkste miRNA's die betrokken zijn bij verschillende fasen van de celcyclus, 
waaronder de clusters miR-290-295, miR-302, miR-17-92, miR-106b-25 en miR-
106a-363. Deze fasen worden gecontroleerd door veel regulatoren, zoals p21 en p53, 
die verantwoordelijk zijn voor bij defecten in de celcyclus. Ik concentreerde me op 
embryonale stamcellen, volwassen stamcellen en kankerstamcellen.
In hoofdstuk 3 heb ik een miRNA-leeftijdshandtekening gemaakt op basis van 
plasma-miRNA-expressieniveaus en de associatie met mortaliteit en morbiditeit 
getest. Ik identificeerde 291 miRNA's die geassocieerd zijn met chronologische 
leeftijd onder 1,930 individuen uit de Rotterdam Studie. Hiervoor gebruikte ik elastic 
net regularization en cross- validatie en liet zien dat miRNA-leeftijd gecorreleerd 
was met chronologische leeftijd. Op basis van het verschil tussen miRNA-leeftijd 
en chronologische leeftijd, heb ik miRNA-delta-leeftijd gedefinieerd. Versnelde 
veroudering staat gelijk aan een positieve miRNA-delta-leeftijd, terwijl langzamere 
veroudering gelijk staat aan een negatieve miRNA-delta-leeftijd. Ik ontdekte dat 
miRNA-delta-leeftijd voorspellend is voor sterfte, waarbij elk extra miRNA-delta-
leeftijdsjaar het risico op sterfte door alle oorzaken met 9% verhoogt. Daarentegen 
vond ik geen verband tussen miRNA-delta-leeftijd en morbiditeit.
In hoofdstuk 4 heb ik de associatie tussen miRNAs plasma-expressieniveaus en 
type 2 diabetes onderzocht. Ik heb een positieve relatie waargenomen tussen vier 
miRNA's (miR-99a-5p, miR-29a-3p, miR-122-5p en miR-125b-5p) en incidentele 




detectie van personen met een hoog risicoprofiel voor diabetes type 2. Aan de andere 
kant vond ik een miRNA (miR-4664-3p) geassocieerd met incidentele diabetes in 
een negatieve richting, wat een beschermend effect suggereert. Bovendien leverde ik 
bewijs dat de plasma-expressieniveaus van miR-139-5p en miR-193a-5p significant 
verhoogd waren bij prevalente diabetespatiënten. Ik heb een GWAS uitgevoerd op de 
zeven geïdentificeerde miRNA's om genetische varianten te verkrijgen. Op basis van 
Mendeliaanse randomisatie met behulp van deze GWAS-samenvattende statistieken 
kon ik een causaal effect van miR-139-5p op diabetes type 2 aantonen. Eerder is 
gerapporteerd dat target genen van miR-139-5p betrokken zijn bij diabetes, wat de 
mogelijke etiologische rol van miR-139-5p bij type 2-diabetes ondersteunt.
In hoofdstuk 5 beschreef ik de associatie tussen miRNAs plasma-expressieniveaus 
en de prevalentie van leververvetting. Ik heb de associaties tussen miRNA's en 
leververvetting en leverenzymen (gamma-glutamyltransferase en alkalische fosfatase) 
getest. Ik leverde bewijs dat 61 miRNA's geassocieerd waren met leverenzymen. 
Bovendien waren 17 miRNA's geassocieerd met leververvetting, waarvan 14 ook 
geassocieerd waren met leverenzymen. Onder hen vond ik miR-122-5p, een veel 
bestudeerd miRNA in leverweefsel.
In hoofdstuk 6 beschreef ik een studie waarin ik genetische data, DNA-
methyleringsdata en miRNA-expressiedata van de algemene bevolking integreerde 
om miRNA's te onderzoeken die geassocieerd zijn met cardiometabole eigenschappen. 
Met behulp van GWAS summary statistics identificeerde ik genetische varianten die 
waren geannoteerd op 67 miRNA's en waren geassocieerd met cardiometabole ziekten 
(bijv. Coronaire hartziekte en type 2 diabetes) of risicofactoren (bijv. Antropometrische 
kenmerken, bloeddrukkenmerken, glykemische kenmerken en lipidenkenmerken). 
Ik vond veranderingen in DNA-methylatie op CpG-sites, geannoteerd op 38 van de 
eerder geïdentificeerde miRNA's die geassocieerd zijn met dezelfde cardiometabole 
eigenschap. Ook vond ik expressieniveaus van 8 van de eerder geïdentificeerde 
miRNA’s geassocieerd met dezelfde cardiometabole eigenschap. Door de resultaten 
van de drie verschillende omics-gegevens te integreren, bleek dat miR-10b-5p, miR-
148a-3p, miR-125b-5p en miR-100-5p waren geassocieerd met lipiden. Deze studie 
levert het bewijs dat miRNA's gerelateerd zijn aan cardiometabole eigenschappen in 
meer dan twee omics-lagen, wat het potentieel om betrokken te zijn bij de etiologie van 
ziekte kan vergroten.
In hoofdstuk 7 rapporteerde ik de resultaten van de associatie tussen miRNA plasma-
expressieniveaus en een beroerte. Ik was in staat om drie circulatoire miRNA's (miR-
6124, miR-5196-5p en miR-4292) te identificeren die verband houden met het risico 
op beroerte. Deze bevindingen suggereren dat hogere plasma-expressieniveaus van 
miR-6124, miR-5196-5p en miR-4292 verband houden met een hoger risico op het 
ontwikkelen van een beroerte. Met behulp van GWAS-summary statistics observeerde 
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ik dat 10 van de potentiële miRNA-target genen geassocieerd waren met een beroerte. 
Van deze 10 target genen werd eerder gemeld dat er 8 tot expressie werden gebracht 
in de hersenen, het primaire weefsel voor een beroerte. Al met al versterkt dit de 
hypothese dat miR-6124, miR-5196-5p en miR-4292 niet alleen een biomarker zijn, 
maar ook betrokken zijn bij de pathologie van een beroerte.
In hoofdstuk 8 rapporteerde ik de bevindingen over de associatie tussen miRNA's 
en prevalente en incidentele atriumfibrilleren in de Rotterdam Studie. Omdat er 
sekseverschillen bestaan  in de pathologie van atriale fibrillatiepathologie, heb ik de 
analyse gestratificeerd naar geslacht. Ik identificeerde dat lagere expressieniveaus van 
miR-4798-3p geassocieerd waren met prevalente atriale fibrillatie bij mannen, maar 
niet bij vrouwen of de algemene bevolking, wat aangeeft dat miR-4798-3p mogelijk een 
geslacht-specifieke rol heeft bij atriumfibrilleren. Ik beschreef in deze studie dat miR-
4798-3p meer dan 50 target genen heeft die het kan reguleren, waarvan er verschillende 
gerelateerd zijn aan elektrische en structurele hermodellering van het hart waarvan 
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